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The book aims to provide an overview of current knowledge regarding germ cell 
tumors.  It deals with the clinical presentations, treatment modalities, the biology 
and genetics of germ cell tumors in children and adults.  Most chapters are focused 
on testicular germ cell tumors whose incidence has been increasing in young males.  
Included are reviews on the pathogenesis, risk factors, diagnosis and treatment 
regimens applied to precursor, pre-invasive lesions as well as to seminomatous and 
non-seminomatous germ cell tumors of the testes.  In addition, a review is included 
on the diagnosis and current management options for intracranial germ cell tumors 
in children.  Authors have also contributed articles on the genetics and epigenetics of 
germ cell tumor development in humans and in the mouse model system.  This book 
will be of interest to scientists, physicians and lay readers wishing to review recent 
developments in the field of germ cell cancers.
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Preface 
In Germ Cell Tumor, leading scientists and physicians from different countries have
contributed to review the latest ideas and developments regarding the clinical
presentation, current treatment modalities and the biology and genetics of germ cell
tumors. Most authors have focused on testicular germ cell tumors which are the most
common cancers in young adult males and whose incidence has been increasing in
recent years.
The book is divided into two sections. The first section, Clinical Perspectives, discusses 
observations and current ideas regarding presentation and treatment of germ cell 
tumors in children and adults. Clinical perspectives includes a comprehensive review
by Nick Liu and co-authors regarding the pathogenesis, risk factors, diagnosis and
treatment regimens applied to intratubular germ cell neoplasia which are the 
precursor, pre-invasive lesion for testicular cancers. In Chapter 2, Paul Johnston and
Stephen Beck review current management options for the most common type of germ
cell tumors of the testes, non-seminomatous germ cell tumors. In Chapter 3, Takamitsu
Fujimaki reviews intracranial germ cell tumors, which affect mostly children, and their 
diagnosis and treatment. Additionally, Chapter 4 reviews current management
strategies for all the different histological sub-types of testicular cancers. Nikhil
Vasdev and Andrew Thorpe provide a European perspective on treatment of germ cell
tumors.  
In the second section, Scientific Perspectives, the chapters review current perspectives 
on experimental systems such as mouse models of testicular germ cell tumors and the
genetics and epigenetics of germ cell tumor development in humans and in mice.
Delphine Carouge and Joseph Nadeau provide a thorough review on mouse models of 
testicular germ cell tumors (Chapter 6). They also compare results obtained from
genetic studies of testicular cancer susceptibility in humans to that in mice. Epigenetic
dysregulation is implicated in a variety of cancers, including in testicular cancers.
Christopher Payne presents an up to date review on the epigenetic modifications 
found in normal germ cells, in the pre-invasive precursor cells and in testicular germ
cell tumors of young adults (Chapter 7). Yiermi Soini reviews the role of claudins, 
which are components of tight junctions, in germ cell tumors (Chapter 8).
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These chapters will be useful for scientists, physicians and lay readers wishing to 
review the current status of our knowledge regarding germ cell cancers. We hope that 
the chapters will serve to inspire further ideas towards increased understanding of 
development of germ cell cancers and improved treatment and management of this 
disease. I thank all the authors for their contributions. In addition, I thank Ms. Gorana 
Scerbe and Dragana Manestar for their invaluable assistance in the preparation and 
publication of this book. 
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of the Testis and Bilateral Testicular Tumors: 
Clinical Significance and Management Options 
Nick W. Liu, Michael C. Risk and Timothy A. Masterson 





Although rare, testicular cancer is the most common solid tumor in men between ages 20 
and 34, with approximately 5.5 new cases per 100,000 men reported in the United States 
each year (Howlader et al., 2011). For reasons that are still unclear, the incidence of testicular 
cancer worldwide has doubled in the past 40 years, with the most significant increases seen 
in industrialized countries in North America, Europe and Oceania (Huyghe et al., 2003). The 
vast majority of malignant testicular tumors are testicular germ cell tumors (TGCTs), which 
can be divided into two main categories: seminomas and non-seminomas. The pathogenesis 
of TGCTs has been the subject of intense interest recently due to the rising incidence (Chia et 
al., 2010). Skakkebaek was the first to describe the possibility of a pre-invasive lesion for 
testicular cancer in 1972, when he identified atypical germ cells in the testes of two infertile 
men who later developed TGCTs (Skakkebaek, 1972). Subsequent work by Skakkebaek et al. 
confirmed the existence of a precursor lesion for TGCTs. Historically, the terms carcinoma in 
situ and testicular intraepithelial neoplasia have been used to describe this lesion, but they 
are no longer preferred because these lesions do not possess epithelial features (Emerson & 
Ulbright, 2010). The preferred term used in recent literature, including this review, is 
intratubular germ cell neoplasia, unclassified (ITGCN). 
ITCGN plays an important role in the development of TGCTs. Since the seminal work by 
Skakkebaek, it has been generally accepted that most TGCTs arise from ITGCN, with the 
notable exception of pediatric germ cell tumors (yolk sac, mature teratoma) and the rare 
spermatocytic seminomas. Subsequent work by von der Maase et al. demonstrated that 
patients with ITGCN will ultimately progress to invasive cancer if left untreated(von der 
Maase et al., 1986). This malignant transformation has led researchers to focus on early 
detection and treatment in order to improve the outcomes in testicular cancer. Advances in 
molecular biology have helped us gain insight into the mechanisms involved in the 
transformation of ITGCN to TGCTs. In this chapter, we will focus on the pathogenesis, risk 
factors, diagnosis and treatment regimens utilized in the management of ITGCN and 
bilateral TGCTs. 
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2. Pathogenesis 
A close association between seminoma and non-seminoma was described long before the 
discovery of ITGCN (Akhtar & Sidiki, 1979; Mark & Hedinger, 1965). Numerous studies 
have since demonstrated that both histologies can often co-exist in the same tumor and 
share similar risk factors, hinting toward a common etiopathogenesis (Bray et al., 2006). The 
likelihood of common origin has also been supported by epidemiological studies. When 
analyzing the testicular cancer incidence between 1973 and 2002, Chia and colleagues found 
the incidence trends of seminoma and non-seminoma were similar to each other suggesting 
common risk factors (Chia et al., 2010). In contrast, these trends were not observed in those 
with pediatric testicular cancer, indicating different inciting factors are involved in this 
population (Lacerda et al., 2009). Histologic studies on orchiectomy specimens taken from 
patients with TGCTs also confirmed the high incidence of a common precursor lesion 
associated with both seminoma and non-seminoma. Following his initial description of 
ITGCN in 1972, Skakkebaek identified ITGCN in 77% of orchiectomy specimens taken from 
patients with seminoma, embryonal carcinoma or terato-carcinoma (Skakkebaek, 1975). 
ITGCN has also been found in as many as 98% of orchiectomy specimens containing both 
seminoma and non-seminoma (Jacobsen et al., 1981). Interestingly, while the majority of 
patients with ITGCN undoubtedly progress to TGCTs, those without evidence of ITGCN 
tend not to develop invasive testicular tumors (von der Maase et al., 1986). This finding 
lends support to the concept that ITGCN serves as the initial gateway to TGCTs.  
A strong connection between ITGCN and TGCTs can be realized through two large autopsies 
studies from Europe, which demonstrated similar prevalence of ITGCN to lifetime risk of 
TGCTs (Giwercman et al., 1991a; Linke et al., 2005). Subsequent studies on infertile men with 
untreated ITGCN found that many will progress to invasive tumors, with risk approaching 
70% at 7 years (von der Maase et al., 1986). There is strong evidence suggesting that ITGCN is 
present years prior to development of overt cancer. Muller and colleagues followed a 10 year-
old cryptorchid boy with repeated testicular biopsies, which showed ITGCN at age 13 and 
eventually invasive malignant growth at age 21 (Muller et al., 1984; Skakkebaek et al., 1987). 
This idea was further supported by the morphological similarity between ITGCN and human 
fetal gonocytes observed by Holstein and Korner in 1974 (Holstein & Korner, 1974). Through 
immunohistochemical and DNA studies, Jorgense and colleagues were able to support their 
hypothesis that ITGCN cells are of prenatal origin and may be a consequence of malignant 
transformation of fetal germ cells in utero (Jorgensen et al., 1993).  
Histologic and molecular studies have provided strong evidence supporting the close 
association between ITGCN and TGCTs. Due to its high serum concentration in seminoma 
patients, placental-like alkaline phosphatase (PLAP), a molecule of unknown biological 
function, was one of the first tumor markers studied for testicular cancer (Jacobsen & 
Norgaard-Pedersen, 1984). Through immunohistochemical experiments, PLAP was found to 
be highly expressed in seminomas, embryonal carcinomas, and ITGCN(Manivel et al., 1987). 
In contrast, expression of PLAP was not observed in normal testicular tissues (Manivel et al., 
1987). As a result of recent advances in molecular pathology, numerous markers specific for 
ITCGN and TGCTs have been discovered. These markers include M2A (Giwercman et al., 
1988a), 49-3F (Giwercman et al., 1990b), TRA-1-60 (Giwercman et al., 1993a), NANOG (Hart 
et al., 2005; Hoei-Hansen et al., 2005a), c-kit (Rajpert-De Meyts & Skakkebaek, 1994), AP-2y 
(Hoei-Hansen et al., 2004b), and OCT 3/4 (de Jong et al., 2005; Jones et al., 2006). Detailed 
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discussion of these markers is beyond the scope of this chapter, but some of them deserve 
further mention here. c-kit is a cell membrane tyrosine kinase receptor responsible for 
migration and survival of primordial germ cells. Its expression is seen in both ITGCN and 
seminoma. Mutations in the c-kit gene are frequently encountered in patients with bilateral 
germ cell tumors but rare in those with unilateral disease (Rajpert-De Meyts, 2006). This 
finding suggests that mutations had occurred prior to migration of primordial germ cells 
early in life and patients with c-kit mutations are prone to develop bilateral germ cell 
tumors. Recently, OCT3/4 has become one of the most widely used germ cell tumor 
markers due to its high specificity and sensitivity for seminoma, embryonal carcinoma and 
ITGCN (Jones et al., 2006). OCT3/4 has been praised as a possible screening tool for patients 
at risk for the development of TGCTs (Cheng et al., 2007; Jones et al., 2006).  
The exact mechanisms involved in the transformation of ITGCN to overt TGCTs are not well 
understood, partly due to the lack of good experimental and animal models (Hoei-Hansen 
et al., 2005b). Down regulation of PTEN and p18 expressions as well as induction of cyclin E 
have been implicated in the progression of ITGCN to invasive tumors (Bartkova et al., 2000; 
Di Vizio et al., 2005). Through comparative genomic analysis, Summersgill and colleagues 
were able to show that the gain of chromosome 12p, a consistent finding in TGCTs, is 
associated with survival of ITGCN independent of Sertoli cells leading to malignant 
transformation (Looijenga et al., 2003; Summersgill et al., 2001). While there is strong 
evidence indicating ITGCN is the precursor for all TGCTs, the question still remains: where 
does ITGCN come from? The most widely accepted hypothesis suggests that ITCGN 
originates from fetal gonocytes and the initiation of malignant transformation most likely 
takes place early in fetal development. This hypothesis was initially based on the close 
morphological similarities between ITGCN and fetal gonocytes noted by Skakkebaek as well 
as other investigators (Gondos et al., 1983; Holstein & Korner, 1974). Subsequent studies 
demonstrating similar expression patterns between ITGCN, TGCTs and fetal gonoctyes of 
many immunohistochemical markers lend further support to this hypothesis (Jorgensen et 
al., 1993). Interestingly, expression of these markers is not seen in the adult testis (Jorgensen 
et al., 1993). Recent development of high throughput expression technology has not only 
provided better characterization of gene expressions of ITGCN at the RNA level but also 
helped us gain further insights into the relationship between ITGCN and fetal gonocytes. By 
comparing the mRNA expression of ITGCN to normal testis tissue, Hoei-Hansen et al. was 
the first to focus on the expression pattern of ITGCN and subsequently identified several 
genes that are important to fetal testicular development (Hoei-Hansen et al., 2004a). In 2004, 
Almstrup and colleagues used genome-wide cDNA microarrays to compare genomic 
expression profiles of ITGCN and embryonic stem cells, a precursor to fetal gonocytes, and 
found a remarkable similarity in expression patterns between these two entities, providing 
additional support that ITGCN is of fetal origin (Almstrup et al., 2004). Similar conclusions 
have been reached by other investigators as well. A recent microarray analysis by Sonne et 
al. demonstrated that the expression patterns of ITGCN cells are more similar to those of 
gonocyte than embryonic stem cells, suggesting that ITGCN may simply be an arrested 
gonocyte that persisted in a postnatal testis (Sonne et al., 2009).  
Two mechanisms regarding the development of ITGCN can be proposed based on the 
current discussion. Whether the formation of ITGCN is related to spontaneous regression of 
spermatogonia toward a primordial germ cell state or an abnormal persistence of an 
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arrested gonocyte beyond the neonatal period remains unanswered. Some researchers have 
attempted to address this through epidemiologic studies by specifically examining the 
correlation between cancer incidence and differences in environmental factors during time 
of fetal development and birth. Moller’s work in 1989 demonstrated lower incidence of 
testicular cancer in men born around the time of World War II than expected from the 
overall increasing trend. His observation supports the hypothesis that environmental 
influences early in life, or in utero, may be the determining factor for testicular cancer 
development (Moller, 1989; 1993). Additional evidence supporting this hypothesis can be 
seen in two cohort studies from Denmark, a country known to have one of the highest 
incidences of testicular cancer. By looking at the incidence of testicular cancer according to 
residence at birth within Denmark, Myrup et al was able to show the risk for TGCTs is 
related to county of birth, rather than county of residence at diagnosis (Myrup et al., 2010). 
When evaluating the testicular cancer risk in first- and second–generation immigrants to 
Denmark, it was found that the first-generation immigrants have TGCT risk similar to their 
country of origin, whereas the second generation has a risk similar to the Danish incidence 
(Myrup et al., 2008). Similar results have been produced by investigators from Sweden as 
well (Hemminki & Li, 2002). All of the evidence presented thus far would argue that the fate 
of testicular cancer is determined early in life, and the transformation of a precursor cell to 
ITGCN is initiated during fetal development.  
3. Risk factors 
Since ITGCN is a precursor lesion for TGCTs, the presence of ITGCN is now recognized as a 
risk factor for TGCTs. However, the incidence of ITGCN in healthy men has not been well 
characterized as the diagnosis of ITGCN requires testicular biopsy. As mentioned earlier, 
two landmark pathological studies attempted to address this question. The researchers from 
Denmark analyzed 399 testes from men between age 18 to 50 years old who died 
unexpectedly and found the overall prevalence of ITGCN to be 0.8%, comparable to the 
lifetime risk of TGCTs in the Danish male population (Giwercman et al., 1991a). The autopsy 
study from Germany also demonstrated similar findings (Linke et al., 2005). A number of 
conditions with high prevalence of ITGCN haven been identified and will be discussed here. 
One of the greatest risk factors for developing TGCTs is a personal history of TGCTs. It has 
been shown that patients with a personal history of testicular cancer have a 25-fold 
increased risk of developing TGCTs in the contralateral testis (Dieckmann et al., 1993). 
Studies on men with TGCTs who underwent contralateral testicular biopsy demonstrated 
consistent rates of ITGCN at around 5-7% (Berthelsen et al., 1982; Dieckmann & Loy, 1996; 
von der Maase et al., 1986). Once again, the prevalence of ITGCN in the contralateral testis 
correlates well with the lifetime risk of developing contralateral TGCTs (Grigor & Rorth, 
1993; von der Maase et al., 1986). Additional studies on men with unilateral TGCTs have 
identified a number of risk factors associated with contralateral ITGCN. Several reports 
have demonstrated testicular atrophy as an independent risk factor for contralateral ITCGN, 
with 4.3-fold increased risk of having positive biopsies in this group of patients (Dieckmann 
& Loy, 1996; Harland et al., 1998). Age at presentation is also a concern for contralateral 
ITGCN. One study showed that diagnosis of TGCTs in patients younger than 30 is 
associated with significant increased risk of positive biopsies on the contralateral testes 
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(Harland et al., 1998). While these findings demonstrate testicular atrophy and age of 
presentation are both strong risk factors for ITGCN, it has also been shown that the majority 
of patients with ITGCN do not have these associated risk factors. A large portion of patients 
with ITGCN would be missed if contralateral biopsies were only performed in patients with 
these risk factors. Dieckmann et al. have advocated for performing biopsies in all men with a 
history of testicular cancer (Dieckmann & Skakkebaek, 1999). In addition to atrophy and age 
of presentation, an irregular echogenic pattern of the contralateral testis on ultrasound has 
been shown to be predictive of positive testicular biopsy for ITGCN in 78 men with 
unilateral TGCTs (Lenz et al., 1996). 
A recent study of 22,562 men in the US demonstrated that infertility is a strong risk factor 
for testicular cancer, suggesting that infertility and testicular cancer share a common 
etiology (Walsh et al., 2009). Similar findings were observed in a study of 2739 patients who 
underwent testicular biopsy for infertility (Bettocchi et al., 1994). In this cohort, 16 patients 
had unilateral ITGCN and testicular atrophy, 50% progressed to invasive TGCTs. Previous 
studies have shown that the incidence of ITGCN in infertile men is about 0.4-1.1% (Pryor et 
al., 1983; Skakkebaek, 1978). A recent retrospective review of biopsies from 453 subfertile 
men revealed a 2.2% risk of ITGCN, compared to an estimated risk of 0.45% in an age- and 
birth-matched cohort, suggesting that infertility is a risk factor for ITGCN (Olesen et al., 
2007). In agreement with previous findings, these authors concluded that severe 
oligospermia and atrophic testes are associated risks for ITGCN.  
Patients with cryptorchidism or undescended testes (UDT) are at an increased risk for 
developing testicular cancer. A recent meta-analysis review of 11 studies demonstrated that 
men with UDT are at a 6.3-fold increased risk for TGCTs, compared to 1.7-fold increase in 
the unaffected testes (Akre et al., 2009). Furthermore, there is strong evidence suggesting 
that orchiopexy before puberty has a protective effect against development of testicular 
cancer (Wood & Elder, 2009). While there is convincing evidence linking cryptorchidism to 
testicular cancer, the relationship between UDT and prevalence of ITGCN remains unclear. 
An early biopsy study on 50 men with cryptorchidism demonstrated the prevalence of 
ITGCN in this cohort is around 8% (Krabbe et al., 1979). In contrast, a larger study involving 
300 patients with UDT found the prevalence of ITGCN to be 1.7% (Giwercman et al., 1989). 
Furthermore, previous studies on the prevalence of ITGCN in patients with unilateral 
TCGTs found that history of cryptorchidism is not predictive of ITGCN (Dieckmann & Loy, 
1996; Harland et al., 1993). Unlike cryptorchidism, patients with sexual developmental 
disorders have been shown to have high rates of ITGCN and TGCTs in several small studies 
(Skakkebaek, 1979; Slowikowska-Hilczer et al., 2001).  
Significant controversy surrounds the association between testicular microlithiasis (TM) and 
the subsequent development of ITCGN and TGCTs. In an otherwise healthy population, TM 
is not considered a risk factor for TGCTs. One study involving 63 healthy men with TM 
demonstrated that 98.5% of this cohort remained cancer-free 5 years after the initial 
screening (DeCastro et al., 2008). Furthermore, the incidence of TM in asymptomatic young 
men is reportedly to be 1.5-5.6% (DeCastro et al., 2008; von Eckardstein et al., 2001). On the 
other hand, the association between TM and TGCTs is also well documented, with high 
incidence of TM observed in patients with testicular cancer (Ikinger et al., 1982; Sanli et al., 
2008). Recently, a large meta-analysis attempted to address this issue by looking at the 
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association of TM with TGCT and ITGCN (Tan et al., 2010). The authors found no 
association between TM and increased risk of TCGT in the otherwise healthy males. 
However, in those patients at risk for TGCTs, such as infertility, UDT or history of unilateral 
TGCT, the presence of TM is associated with approximately a 10-fold increased risk for 
concurrent diagnosis of TGCT or ITGCN. These findings are in an agreement with previous 
studies as well. Holm et al. demonstrated the presence of TM in the contralateral testis of 
men with unilateral TGCTs is associated with about a 30-fold increased risk of ITGCN 
(Holm et al., 2003). Furthermore, the incidence of TM in infertile men has been shown to be 
2-20%, which is considerably higher than that of the general population (de Gouveia Brazao 
et al., 2004; von Eckardstein et al., 2001). Others have suggested that bilateral microlithiasis 
and sonographic heterogeneity in subfertile men are associated with increased risk of 
developing ITGCN (de Gouveia Brazao et al., 2004; Elzinga-Tinke et al., 2010), indicating the 
need to follow these patients closely with frequent biopsy or ultrasound. 
4. Diagnosis 
There are no imaging modalities or serum tumor markers to accurately diagnose ITGCN. 
Currently, testicular biopsy is the only reliable method to diagnose ITGCN. The pathologic 
morphology of ITGCN is well-defined and is similar to that of seminoma. The ITGCN cells 
are larger than normal spermatogonia, and possess larger nuclei with prominent nucleoli 
(Gondos & Migliozzi, 1987). The cytoplasm is rich with glycogen and contains the enzyme 
PLAP (Dieckmann et al., 2011; Lauke, 1997). These abnormal cells are located at the 
basement membrane of the seminiferous tubules and the tubules vary from containing 
adjacent normal Sertoli cells and spermatogonia to complete dominance of ITGCN cells 
(Jacobsen et al., 1981). A good biopsy sample should be at least 3 x 3 mm in size and 
contains at least 30-40 tubules on microscopic examination (Holstein & Lauke, 1996). 
Testicular biopsies should be placed in Boulin’s or Stieve’s solution; Formalin fixation 
should be avoided because it can greatly alter the morphology of testicular architecture. 
Immunohistochemical markers are routinely used during histological examination to aid the 
diagnosis of ITGCN. The importance of immunohistochemistry (IHC) was highlighted in a 
recent review of 20 patients with TGCTs and prior negative testicular biopsy (van Casteren 
et al., 2009). Seven cases of ITGCNs and TGCTs were diagnosed by experienced pathologists 
based on morphology alone, but an additional 4 cases were identified with IHC. As 
mentioned earlier, PLAP has traditionally been the most widely used IHC marker to 
identify ITGCN, with sensitivity ranging from 83-98% (Jacobsen & Norgaard-Pedersen, 
1984; Manivel et al., 1987). Several studies recently have demonstrated a superior IHC 
marker for detecting ITGCN, OCT3/4, which has sensitivity and specificity approaching 
100% (Cheng et al., 2007; de Jong et al., 2005; Jones et al., 2006). A pathologic representation 
of ITGCN stained with OCT 3/4 is portrayed in Fig. 1. 
As open testicular biopsy is invasive and has the potential for complications, detection of 
ITGCN by semen analysis has been investigated. The ability to use semen to detect ITGCN is 
based on the original work by Giwercman when he observed the exfoliation of ITGCN cells 
from the seminiferous tubules into the seminal fluid in men with TGCTs (Giwercman et al., 
1988b). However, the detection rate of ITGCN cells in semen is far inferior to open surgical 
biopsy (Brackenbury et al., 1993). Subsequent studies have attempted to increase the sensitivity 
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of semen analysis for CIS by combining DNA flow cytometry and in situ hybridization 
without great success (Giwercman et al., 1990a). Recently, investigators from Denmark sought 
to improve the detection rate on semen analysis by developing a sophisticated model 
involving immunocytochemical staining of ejaculates from infertile men (Almstrup et al., 
2011). This approach demonstrated an overall sensitivity and specificity of 0.67 and 0.98, 
respectively, when compared to open surgical biopsy. These non-invasive methods for 
detection of ITGCN are promising but their clinical feasibility remains to be seen.  
Fig. 1. Pathologic features of ITGCN. A – H&E stained section demonstrates typical features 
of ITGCN: cells with large nuclei and prominent nucleoli located along the basement 
membrane of the seminiferous tubules. B – Immunohistochemical staining of ITGCN cells 
with OCT 4 demonstrating a nuclear staining pattern (Jones et al., 2004). (Courtesy of Liang 
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4.1 Testicular biopsy 
The distribution of ITGCN cells within a testis has been a subject of contention and is 
directly linked to the accuracy of testicular biopsy. Based on their biopsy simulation 
experiments, Berthelsen and Skakkebaek hypothesized that ITGCN cells are homogenously 
dispersed throughout the testis and demonstrated that a 3-mm biopsy is a sufficient 
representation of the entire testis (Berthelsen & Skakkebaek, 1981). Early studies had 
supported this theory by demonstrating the low false-negative biopsy rates associated with 
the single biopsy technique. In a study involving 1859 negative testicular biopsies in the 
contralateral testes of patients with TGCTs, only 5 patients (0.3%) developed TGCTs 
(Dieckmann & Loy, 2003). The same authors re-examined their data recently and, again, 
showed the overall proportion of false-negative biopsies for detecting ITCGN is about 0.5% 
(Dieckmann et al., 2005). Some investigators have sought to improve the sensitivity of 
testicular biopsy by performing multiple biopsies on the same testis. In a series of 2318 men 
with TGCTs who underwent double-biopsy of the contralateral testes, the discordance rate 
was 31% with an extra yield of 18% in diagnosis (Dieckmann et al., 2007). The high 
discordance rate in this study suggests that the distribution of ITGCN within a testis is 
heterogeneous rather than homogenous. This finding is further supported by several 
ITGCN mapping studies that demonstrated a focal pattern of ITGCN adjacent to TGCTs 
(Loy et al., 1990; Prym & Lauke, 1994). The heterogeneous distribution of ITGCN would also 
provide an explanation for the development of TGCTs despite prior negative biopsies. 
Based on this assumption, Dieckmann and colleagues were able to increase the diagnostic 
yield of ITGCN by performing a second biopsy at a different site (Dieckmann et al., 2007). 
This is in accord with a study involving triple biopsies of the contralateral testis, which 
demonstrated an 8% increase in detection of ITGCN (Kliesch et al., 2003). However, this 
approach may result in a higher complication rate especially in the setting of a solitary testis. 
Furthermore, it remains to be seen whether the benefit of multiple biopsies outweighs its 
risks. Even with this approach subsequent TGCTs in patients with prior negative double 
biopsy have been reported (Souchon et al., 2006). 
Complications associated with testicular biopsy remain a major concern and have prevented 
many clinicians from adopting this approach as routine screening protocol. Current 
literature suggests the overall rates of complication secondary to testicular biopsy range 
from 3 – 20% (Dieckmann et al., 2005; Heidenreich & Moul, 2002). In a prospective study of 
1874 men with testicular cancer who underwent contralateral testicular biopsy, the overall 
complication rate of 2.8% was noted with 0.64% requiring repeat surgery and one testis 
(0.05%) was lost (Dieckmann et al., 2005). In the same series, a subset of patients were 
followed with serial scrotal sonographic and magnetic resonance imaging, which 
demonstrated early post-operative changes, such as hematoma or edema, in 33% - 45% of 
patients. However, these changes spontaneously resolved in 96% of patients 18 months after 
the initial biopsy, suggesting testicular biopsy is a procedure with low-surgical risks. 
Despite resolution of post-surgical changes on imaging, the impact of surgical biopsy on 
testicular endocrine function remains to be addressed in this cohort of patients. Studies on 
infertile men have reported decrease in serum testosterone level following testicular biopsy, 
with some developing hypogonadism (Manning et al., 1998); however, these cases were 
done with significantly more biopsies per testis and the effect was self-limiting. 
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The question of which group of patients should undergo testicular biopsy has been a subject 
of controversy, with varying responses to the same data. The fundamental argument for 
routine testicular biopsy is early diagnosis of TGCTs at the precursor stages. The most 
common scenario in which testicular biopsy is performed to detect ITGCN is in the 
contralateral testes of patients with a history of unilateral TGCTs. Surgical biopsy of the 
contralateral testis at the time of initial orchiectomy is routinely done in Denmark and 
Germany, two counties with the world’s highest incidences of TGCTs (Dieckmann et al., 
2011). Others have advocated for biopsy only in those with TGCTs and risk factors for 
contralateral ITGCN, such as testicular atrophy, history of cryptorchidism, age less than 30 
years, infertility and TM (Dieckmann et al., 2011; Heidenreich, 2009). As demonstrated 
earlier, those who routinely perform testicular biopsy have consistently demonstrated a 5-
7% incidence rate of ITGCN in the contralateral testis, and 70% of them progress to TGCTs 
at 7 years (Dieckmann & Loy, 1996; von der Maase et al., 1986). Early identification of these 
high risk patients allows for organ-sparing therapy, which may potentially preserve 
endocrine function in contrast to a second orchiectomy (Dieckmann & Skakkebaek, 1999). 
Additionally, diagnostic delay in patients with TGCTs has been shown to significantly 
impact survival, which highlights the importance of early diagnosis (Huyghe et al., 2007). 
Since the rate of false-negative biopsy is exceedingly low (0.5%), a negative testicular biopsy 
translates into a very low probability of having a second TGCTs. This may dictate a less 
intensive surveillance protocol as well as alleviate psychological distress associated with 
diagnosis of cancer in high-risk patients. 
The arguments against the practice of routine testicular biopsy in these patients are also 
convincing. In contrast to the standard of care in Denmark and Germany, physicians in the 
US are less likely to perform routine testicular biopsy in patients with TGCTs partly due to a 
lower incidence of contralateral cancer (Coogan et al., 1998; Fossa et al., 2005). In a large 
series of nearly 30,000 patients with unilateral TGCT, the investigators demonstrated an 
overall risk of developing contralateral TGCTs is 1.9% in the US (Fossa et al., 2005), which is 
considerably lower than the 5-7% reported by the European studies. Furthermore, these 
authors demonstrated patients with contralateral TGCTs had excellent long-term prognosis, 
with an overall survival rate of 93% at 10 years after initial diagnosis, providing support for 
continuing the US approach of not subjecting contralateral testis to biopsy. Others have also 
demonstrated good clinical outcomes in patients with bilateral TGCTs who are treated 
appropriately for histology and stage (Holzbeierlein et al., 2003). Other arguments favoring 
the omission of routine biopsy include the added cost associated with surgery as well as 
exposing the majority of patients unnecessarily to the surgical risks in order to benefit a few 
individuals. As discussed earlier, testicular biopsy to screen for ITGCN is not a perfect 
technique; many cases of contralateral tumor occurrence have been reported in patients with 
negative prior biopsies, even with the double biopsy approach (Souchon et al., 2006). 
Finally, the most widely accepted organ-sparing therapy for ITGCN is radiotherapy, which 
has been shown to destroy both endocrine and exocrine function of a testis, with one study 
demonstrating high incidence of hypogonadisim after radiation requiring androgen 
supplementation (Petersen et al., 2002). Until methods of diagnosis are improved or a 
survival benefit is demonstrated with early diagnosis of ITGCN, treatment decisions need to 
be made based on data presented and individualized for patient risk factors and wishes.  
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the single biopsy technique. In a study involving 1859 negative testicular biopsies in the 
contralateral testes of patients with TGCTs, only 5 patients (0.3%) developed TGCTs 
(Dieckmann & Loy, 2003). The same authors re-examined their data recently and, again, 
showed the overall proportion of false-negative biopsies for detecting ITCGN is about 0.5% 
(Dieckmann et al., 2005). Some investigators have sought to improve the sensitivity of 
testicular biopsy by performing multiple biopsies on the same testis. In a series of 2318 men 
with TGCTs who underwent double-biopsy of the contralateral testes, the discordance rate 
was 31% with an extra yield of 18% in diagnosis (Dieckmann et al., 2007). The high 
discordance rate in this study suggests that the distribution of ITGCN within a testis is 
heterogeneous rather than homogenous. This finding is further supported by several 
ITGCN mapping studies that demonstrated a focal pattern of ITGCN adjacent to TGCTs 
(Loy et al., 1990; Prym & Lauke, 1994). The heterogeneous distribution of ITGCN would also 
provide an explanation for the development of TGCTs despite prior negative biopsies. 
Based on this assumption, Dieckmann and colleagues were able to increase the diagnostic 
yield of ITGCN by performing a second biopsy at a different site (Dieckmann et al., 2007). 
This is in accord with a study involving triple biopsies of the contralateral testis, which 
demonstrated an 8% increase in detection of ITGCN (Kliesch et al., 2003). However, this 
approach may result in a higher complication rate especially in the setting of a solitary testis. 
Furthermore, it remains to be seen whether the benefit of multiple biopsies outweighs its 
risks. Even with this approach subsequent TGCTs in patients with prior negative double 
biopsy have been reported (Souchon et al., 2006). 
Complications associated with testicular biopsy remain a major concern and have prevented 
many clinicians from adopting this approach as routine screening protocol. Current 
literature suggests the overall rates of complication secondary to testicular biopsy range 
from 3 – 20% (Dieckmann et al., 2005; Heidenreich & Moul, 2002). In a prospective study of 
1874 men with testicular cancer who underwent contralateral testicular biopsy, the overall 
complication rate of 2.8% was noted with 0.64% requiring repeat surgery and one testis 
(0.05%) was lost (Dieckmann et al., 2005). In the same series, a subset of patients were 
followed with serial scrotal sonographic and magnetic resonance imaging, which 
demonstrated early post-operative changes, such as hematoma or edema, in 33% - 45% of 
patients. However, these changes spontaneously resolved in 96% of patients 18 months after 
the initial biopsy, suggesting testicular biopsy is a procedure with low-surgical risks. 
Despite resolution of post-surgical changes on imaging, the impact of surgical biopsy on 
testicular endocrine function remains to be addressed in this cohort of patients. Studies on 
infertile men have reported decrease in serum testosterone level following testicular biopsy, 
with some developing hypogonadism (Manning et al., 1998); however, these cases were 
done with significantly more biopsies per testis and the effect was self-limiting. 
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The question of which group of patients should undergo testicular biopsy has been a subject 
of controversy, with varying responses to the same data. The fundamental argument for 
routine testicular biopsy is early diagnosis of TGCTs at the precursor stages. The most 
common scenario in which testicular biopsy is performed to detect ITGCN is in the 
contralateral testes of patients with a history of unilateral TGCTs. Surgical biopsy of the 
contralateral testis at the time of initial orchiectomy is routinely done in Denmark and 
Germany, two counties with the world’s highest incidences of TGCTs (Dieckmann et al., 
2011). Others have advocated for biopsy only in those with TGCTs and risk factors for 
contralateral ITGCN, such as testicular atrophy, history of cryptorchidism, age less than 30 
years, infertility and TM (Dieckmann et al., 2011; Heidenreich, 2009). As demonstrated 
earlier, those who routinely perform testicular biopsy have consistently demonstrated a 5-
7% incidence rate of ITGCN in the contralateral testis, and 70% of them progress to TGCTs 
at 7 years (Dieckmann & Loy, 1996; von der Maase et al., 1986). Early identification of these 
high risk patients allows for organ-sparing therapy, which may potentially preserve 
endocrine function in contrast to a second orchiectomy (Dieckmann & Skakkebaek, 1999). 
Additionally, diagnostic delay in patients with TGCTs has been shown to significantly 
impact survival, which highlights the importance of early diagnosis (Huyghe et al., 2007). 
Since the rate of false-negative biopsy is exceedingly low (0.5%), a negative testicular biopsy 
translates into a very low probability of having a second TGCTs. This may dictate a less 
intensive surveillance protocol as well as alleviate psychological distress associated with 
diagnosis of cancer in high-risk patients. 
The arguments against the practice of routine testicular biopsy in these patients are also 
convincing. In contrast to the standard of care in Denmark and Germany, physicians in the 
US are less likely to perform routine testicular biopsy in patients with TGCTs partly due to a 
lower incidence of contralateral cancer (Coogan et al., 1998; Fossa et al., 2005). In a large 
series of nearly 30,000 patients with unilateral TGCT, the investigators demonstrated an 
overall risk of developing contralateral TGCTs is 1.9% in the US (Fossa et al., 2005), which is 
considerably lower than the 5-7% reported by the European studies. Furthermore, these 
authors demonstrated patients with contralateral TGCTs had excellent long-term prognosis, 
with an overall survival rate of 93% at 10 years after initial diagnosis, providing support for 
continuing the US approach of not subjecting contralateral testis to biopsy. Others have also 
demonstrated good clinical outcomes in patients with bilateral TGCTs who are treated 
appropriately for histology and stage (Holzbeierlein et al., 2003). Other arguments favoring 
the omission of routine biopsy include the added cost associated with surgery as well as 
exposing the majority of patients unnecessarily to the surgical risks in order to benefit a few 
individuals. As discussed earlier, testicular biopsy to screen for ITGCN is not a perfect 
technique; many cases of contralateral tumor occurrence have been reported in patients with 
negative prior biopsies, even with the double biopsy approach (Souchon et al., 2006). 
Finally, the most widely accepted organ-sparing therapy for ITGCN is radiotherapy, which 
has been shown to destroy both endocrine and exocrine function of a testis, with one study 
demonstrating high incidence of hypogonadisim after radiation requiring androgen 
supplementation (Petersen et al., 2002). Until methods of diagnosis are improved or a 
survival benefit is demonstrated with early diagnosis of ITGCN, treatment decisions need to 
be made based on data presented and individualized for patient risk factors and wishes.  
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5. Treatment 
The primary goal of treating ITCGN is to prevent its malignant transformation to TGCT. 
Presently, there are four options to managing ITGCN: chemotherapy, radiation, orchiectomy 
and surveillance. With the exception of surveillance, the remaining three treatment 
modalities put patients at significant risk for infertility, hypogonadism, or both. The 
decision to proceed with a certain treatment modality has to be individualized based upon 
specific risk factors as well as patient wishes.  
5.1 Chemotherapy 
It was initially thought that chemotherapy could completely eradicate ITGCN and prevent 
development of contralateral TGCT. This idea was based on the observation that patients 
receiving chemotherapy had no progression of disease and had complete resolution of 
ITGCN on repeat biopsy, whereas 7 out of 18 patients without chemotherapy progressed to 
overt cancer (von der Maase et al., 1985). However, three years after their initial publication, 
the same investigators reported that one patient in the chemotherapy group had recurrence 
of ITGCN on repeat biopsy (von der Maase et al., 1988). Numerous reports since then 
demonstrated chemotherapy to be an ineffective regimen for treating ITGCN. One series 
estimated the risk of recurrent ITGCN 5 and 10 years after termination of chemotherapy to 
be 21% and 42%, respectively (Christensen et al., 1998). Histological analysis on orchiectomy 
specimens obtained from patients who had chemotherapy demonstrated persistence of 
ITGCN in 35% of patients (Bottomley et al., 1990). Possible explanations behind this 
phenomenon include the presence of blood-testis barrier or insensitivity of ITGCN cells to 
chemotherapy (Mortensen et al., 2011; Ploen & Setchell, 1992). In a recent study of 11 
patients with unilateral TGCTs and biopsy-proven ITGCN in the contralateral testis treated 
with chemotherapy, 64% of them had ITGCN on repeat biopsy, providing support that 
chemotherapy is ineffective at eradicating ITGCN (Kleinschmidt et al., 2009).  
5.2 Radical orchiectomy  
Unlike chemotherapy, orchiectomy is the most definitive treatment with the highest success 
rate and is the main treatment approach for three patient populations: those with unilateral 
ITGCN and contralateral normal testis; those with an atrophic testis; and those with 
infertility and unilateral ITGCN (Dieckmann & Skakkebaek, 1999; Mortensen et al., 2011). In 
patients with a solitary testis, orchiectomy in this population needs to be weighed against 
the risk of infertility and permanent dependence on exogenous testosterone replacement.  
5.3 Radiation 
Local radiation has become the preferred treatment modality for ITGCN because it is organ-
sparing and highly effective at eradicating ITGCN cells. The rationale behind employing 
radiotherapy is based on the finding that radiation has the propensity to destroy ITGCN 
and germ cells while preserving Leydig cell function (von der Maase et al., 1985). Therefore, 
it has the potential of preserving testicular endocrine function while eliminating neoplastic 
cells. Presently, three major concerns have been raised regarding radiotherapy in the 
treatment of ITGCN. First, the radiation dose for optimal oncologic control has not been 
determined (Mortensen et al., 2011). The current recommended dose according to guidelines 
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put forth by the European Association of Urology is 20 Gy delivered over 2 weeks (Albers et 
al., 2005). This dose has previously been shown to be very effective at eradicating ITGCN 
cells, with one series demonstrating complete resolution of ITGCN on repeat biopsy at a 
follow-up of 2 years (Giwercman et al., 1991b). Another group from Denmark studied the 
effect of radiotherapy in doses 14 to 20 Gy on eradication of ITGCN testes, and 
demonstrated that all patients treated with radiation dose level 16 to 20 Gy had complete 
resolution of ITGCN while one patient treated at dose level 14 Gy had a recurrence at a 
follow up of 5 years (Petersen et al., 2002). However, recurrences of ITGCN have been 
reported at all dose levels up to 20 Gy (Classen et al., 2003; Dieckmann et al., 2002; Dotsch et 
al., 2000; Petersen et al., 2002). Currently, there is no consensus on the optimal radiation 
dose to achieve cancer control, but most would agree that a dose level of 16 to 20 Gy is 
effective. The second concern is in regards to the effect of radiation on testicular exocrine 
function. Local radiation to the testis will result in the destruction of both ITGCN and germ 
cells, subsequently rendering these patients infertile. Proponents of local radiation to 
solitary testes argue that patients with ITGCN already have severely impaired 
spermatogensis prior to therapy (Giwercman et al., 1993b; Petersen et al., 1999); therefore, 
radiation should not have significant impact on the development of infertility. However, 
improvement in spermatogenesis has been noted following removal of unilateral TGCTs 
(Carroll et al., 1987) and cases of successful conception in patients with ITGCN have been 
reported (Heidenreich et al., 1997). Therefore, it is important to consider surveillance or 
postponing radiation to allow for paternity in patients with ITGCN in the solitary testis. The 
third concern is the impairment of testicular endocrine function by local radiation. 
According to one series of patients with ITGCN in solitary testis, serum luteinizing hormone 
remained significantly elevated post radiation and 25% of patients require permanent 
androgen supplementation (Giwercman et al., 1991b). This finding led to several 
investigations on dose reduction, with one study demonstrating the impairment on 
endocrine function was independent of radiation dose and the need for androgen 
substitutions was similar at all dose levels (Petersen et al., 2002). Others found less toxic 
effect on testicular Leydig cell function with lower radiation doses at 13 and 16 Gy (Bang et 
al., 2009; Sedlmayer et al., 2001). All patients undergoing radiation therapy need to have 
their hormone function checked on a regular basis in order to identify those where androgen 
supplementation is needed.  
5.4 Active surveillance  
For select patients, active surveillance may be the treatment of choice. This is particularly 
true for those with ITGCN in the solitary testis who desire to preserve fertility and hormone 
function. Surveillance can be justified in these patients but they must be counseled on the 
risk of developing invasive cancer and the need for subsequent orchiectomy. Furthermore, 
these patients need to be compliant with regular follow-up and, more importantly, frequent 
testicular self-examination. If preserving fertility is the goal, semen analysis should be obtained 
and cryopreservation of viable sperm should be considered before treatment is initiated 
(Dieckmann & Skakkebaek, 1999). For those patients who progress to TGCTs, partial 
orchiectomy may be an acceptable treatment if the tumor is organ-confined and less than 2cm 
in size (Heidenreich et al., 2001). Consistent with the discussion above, as most patients in this 
series (82%) had associated ITGCN, most were treated with adjuvant radiation and relapses 
were only observed in those who did not receive radiation treatment. Partial orchiectomy is 
 
Germ Cell Tumor 12
5. Treatment 
The primary goal of treating ITCGN is to prevent its malignant transformation to TGCT. 
Presently, there are four options to managing ITGCN: chemotherapy, radiation, orchiectomy 
and surveillance. With the exception of surveillance, the remaining three treatment 
modalities put patients at significant risk for infertility, hypogonadism, or both. The 
decision to proceed with a certain treatment modality has to be individualized based upon 
specific risk factors as well as patient wishes.  
5.1 Chemotherapy 
It was initially thought that chemotherapy could completely eradicate ITGCN and prevent 
development of contralateral TGCT. This idea was based on the observation that patients 
receiving chemotherapy had no progression of disease and had complete resolution of 
ITGCN on repeat biopsy, whereas 7 out of 18 patients without chemotherapy progressed to 
overt cancer (von der Maase et al., 1985). However, three years after their initial publication, 
the same investigators reported that one patient in the chemotherapy group had recurrence 
of ITGCN on repeat biopsy (von der Maase et al., 1988). Numerous reports since then 
demonstrated chemotherapy to be an ineffective regimen for treating ITGCN. One series 
estimated the risk of recurrent ITGCN 5 and 10 years after termination of chemotherapy to 
be 21% and 42%, respectively (Christensen et al., 1998). Histological analysis on orchiectomy 
specimens obtained from patients who had chemotherapy demonstrated persistence of 
ITGCN in 35% of patients (Bottomley et al., 1990). Possible explanations behind this 
phenomenon include the presence of blood-testis barrier or insensitivity of ITGCN cells to 
chemotherapy (Mortensen et al., 2011; Ploen & Setchell, 1992). In a recent study of 11 
patients with unilateral TGCTs and biopsy-proven ITGCN in the contralateral testis treated 
with chemotherapy, 64% of them had ITGCN on repeat biopsy, providing support that 
chemotherapy is ineffective at eradicating ITGCN (Kleinschmidt et al., 2009).  
5.2 Radical orchiectomy  
Unlike chemotherapy, orchiectomy is the most definitive treatment with the highest success 
rate and is the main treatment approach for three patient populations: those with unilateral 
ITGCN and contralateral normal testis; those with an atrophic testis; and those with 
infertility and unilateral ITGCN (Dieckmann & Skakkebaek, 1999; Mortensen et al., 2011). In 
patients with a solitary testis, orchiectomy in this population needs to be weighed against 
the risk of infertility and permanent dependence on exogenous testosterone replacement.  
5.3 Radiation 
Local radiation has become the preferred treatment modality for ITGCN because it is organ-
sparing and highly effective at eradicating ITGCN cells. The rationale behind employing 
radiotherapy is based on the finding that radiation has the propensity to destroy ITGCN 
and germ cells while preserving Leydig cell function (von der Maase et al., 1985). Therefore, 
it has the potential of preserving testicular endocrine function while eliminating neoplastic 
cells. Presently, three major concerns have been raised regarding radiotherapy in the 
treatment of ITGCN. First, the radiation dose for optimal oncologic control has not been 
determined (Mortensen et al., 2011). The current recommended dose according to guidelines 
Intratubular Germ Cell Neoplasms of the Testis  
and Bilateral Testicular Tumors: Clinical Significance and Management Options 13 
put forth by the European Association of Urology is 20 Gy delivered over 2 weeks (Albers et 
al., 2005). This dose has previously been shown to be very effective at eradicating ITGCN 
cells, with one series demonstrating complete resolution of ITGCN on repeat biopsy at a 
follow-up of 2 years (Giwercman et al., 1991b). Another group from Denmark studied the 
effect of radiotherapy in doses 14 to 20 Gy on eradication of ITGCN testes, and 
demonstrated that all patients treated with radiation dose level 16 to 20 Gy had complete 
resolution of ITGCN while one patient treated at dose level 14 Gy had a recurrence at a 
follow up of 5 years (Petersen et al., 2002). However, recurrences of ITGCN have been 
reported at all dose levels up to 20 Gy (Classen et al., 2003; Dieckmann et al., 2002; Dotsch et 
al., 2000; Petersen et al., 2002). Currently, there is no consensus on the optimal radiation 
dose to achieve cancer control, but most would agree that a dose level of 16 to 20 Gy is 
effective. The second concern is in regards to the effect of radiation on testicular exocrine 
function. Local radiation to the testis will result in the destruction of both ITGCN and germ 
cells, subsequently rendering these patients infertile. Proponents of local radiation to 
solitary testes argue that patients with ITGCN already have severely impaired 
spermatogensis prior to therapy (Giwercman et al., 1993b; Petersen et al., 1999); therefore, 
radiation should not have significant impact on the development of infertility. However, 
improvement in spermatogenesis has been noted following removal of unilateral TGCTs 
(Carroll et al., 1987) and cases of successful conception in patients with ITGCN have been 
reported (Heidenreich et al., 1997). Therefore, it is important to consider surveillance or 
postponing radiation to allow for paternity in patients with ITGCN in the solitary testis. The 
third concern is the impairment of testicular endocrine function by local radiation. 
According to one series of patients with ITGCN in solitary testis, serum luteinizing hormone 
remained significantly elevated post radiation and 25% of patients require permanent 
androgen supplementation (Giwercman et al., 1991b). This finding led to several 
investigations on dose reduction, with one study demonstrating the impairment on 
endocrine function was independent of radiation dose and the need for androgen 
substitutions was similar at all dose levels (Petersen et al., 2002). Others found less toxic 
effect on testicular Leydig cell function with lower radiation doses at 13 and 16 Gy (Bang et 
al., 2009; Sedlmayer et al., 2001). All patients undergoing radiation therapy need to have 
their hormone function checked on a regular basis in order to identify those where androgen 
supplementation is needed.  
5.4 Active surveillance  
For select patients, active surveillance may be the treatment of choice. This is particularly 
true for those with ITGCN in the solitary testis who desire to preserve fertility and hormone 
function. Surveillance can be justified in these patients but they must be counseled on the 
risk of developing invasive cancer and the need for subsequent orchiectomy. Furthermore, 
these patients need to be compliant with regular follow-up and, more importantly, frequent 
testicular self-examination. If preserving fertility is the goal, semen analysis should be obtained 
and cryopreservation of viable sperm should be considered before treatment is initiated 
(Dieckmann & Skakkebaek, 1999). For those patients who progress to TGCTs, partial 
orchiectomy may be an acceptable treatment if the tumor is organ-confined and less than 2cm 
in size (Heidenreich et al., 2001). Consistent with the discussion above, as most patients in this 
series (82%) had associated ITGCN, most were treated with adjuvant radiation and relapses 
were only observed in those who did not receive radiation treatment. Partial orchiectomy is 
 
Germ Cell Tumor 14
still in the investigational phase, and patients should be counseled on the risk of disease 
progression and the need for radical orchiectomy if a tumor recurs in that testis.  
6. Bilateral testicular cancer 
While the risk of developing contralateral testicular cancer is high in patients with unilateral 
TGCTs, there is no clear consensus on how these patients should be managed. Perhaps, we 
can gain further insight into this issue by looking at the outcome data of patients with 
bilateral testicular cancer. The reported incidence of bilateral TGCTs in the US and Europe is 
estimated to be 1- 4% (Bokemeyer et al., 1993; Che et al., 2002; Coogan et al., 1998; Fossa et 
al., 2005; Hentrich et al., 2005; Holzbeierlein et al., 2003; Pamenter et al., 2003). In these 
contemporary series, metachronous presentations were the majority (62-88%) and the 
median interval between first and second testicular tumor was 50 – 76 months. Recent 
studies demonstrated that the clinical outcomes of metachronous TGCTs were excellent 
(Albers et al., 1999; Che et al., 2002; Coogan et al., 1998; Fossa et al., 2005), with the majority 
of patients presenting with clinical stage 1 disease (44 – 90%). Furthermore, the 10-year 
survival rate following a diagnosis of metachronous bilateral testis cancer was 93%, which is 
comparable to patients diagnosed with unilateral TGCTs (95%)(Fossa et al., 2005). Single 
institution studies from Indiana, M.D. Anderson, and Memorial-Sloan-Kettering also 
demonstrated excellent prognosis in these patients, with most reporting very low mortality 
from TGCTs (Che et al., 2002; Coogan et al., 1998; Holzbeierlein et al., 2003). Despite such a 
high cure rate, most patients in these studies did not undergo contralateral testicular biopsy. 
This finding certainly questions the value of contralateral testicular biopsy to screen for 
ITGCN. Based on the excellent outcomes observed in bilateral TGCTs, active surveillance, 
perhaps, should play an important role in the management of patients with contralateral 
ITGCN.  
7. Conclusions 
The incidence of testicular cancer is increasing worldwide and it has nearly doubled in the 
last 40 years. This increasing incidence has led researchers to focus on the pathogenesis of 
ITGCN, which has now been established as the precursor lesion for most TGCTs. Several 
theories have been proposed regarding the origin of ITGCN, and recent studies seem to 
suggest it is abnormal persistence of an arrested gonocyte beyond the neonatal period. The 
fate of testicular cancer is determined early in life, and the transformation of a precursor cell 
to ITGCN cell is initiated in utero. Incidence trends of testicular cancer can potentially be 
altered by continued exploration of the contributing factors in the pre- and peri-natal period. 
The diagnosis and management of patients with ITGCN remain a challenging problem for 
clinicians, and indications for testicular biopsy to detect ITGCN are controversial. The 
decision to proceed with a certain treatment modality should be individualized and needs to 
be based on specific risk factors as well as patient wishes. Radical orchiectomy and radiation 
therapy are the only two effective means of preventing subsequent TGCTs in a testis with 
ITGCN. Both treatment options can result in infertility as well as hormone dysfunction. 
Metachronous bilateral TGCTs occur infrequently but the clinical outcomes are excellent, 
suggesting that the role of active surveillance needs to be emphasized in the management of 
contralateral ITGCN in a solitary testis.  
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1.1 Management options for clinical stage I non-seminomatous germ cell tumor of the 
testis 
1.1.1 Introduction to clinical stage I disease 
About 5-7/100,000 men are diagnosed with testis cancer annually. A large proportion of 
these are pathologically classified as non-seminomatous germ cell tumor (NSGCT). The 
majority of NSGCT patients present with clinical stage (CS) I disease, which is characterized 
by a germ cell tumor confined to the testis, a negative metastatic work-up which includes a 
chest X-ray (CXR), computed tomography scan of the abdomen and pelvis (CT A&P), and 
negative serum tumor markers (STM) post-orchiectomy. Patients who present with CS I 
testis cancer have a 30 percent chance of harboring occult metastatic disease post-
orchiectomy, and thus controversy exists as to what represents the best treatment strategy 
following radical orchiectomy. Currently, there are 3 treatment strategies available for 
patients with CS I testis cancer, each one associated with a 99% cure rate: surveillance, 
adjuvant chemotherapy, and primary retroperitoneal lymph node dissection (RPLND). 
1.2 Risk stratification for stage I disease 
The ability to risk classify CSI patients to “high risk” of harboring micrometastatic disease 
and “low risk” of having micrometastatic disease would aid in tailoring therapy. Those 
patients identified as “high risk” could more preferentially be treated with primary RPLND 
or adjuvant chemotherapy, as they would have a greater risk of relapse on surveillance. 
Conversely, “low risk” patients may be managed with surveillance as they would have a 
greater likelihood of being cured with orchiectomy alone and thus overtreated with primary 
RPLND or adjuvant chemotherapy. 
Several key studies have been published identifying pathologic factors predictive of 
metastatic disease in these patients. In 1987, a retrospective MRC trial identified four 
important negative prognostic indicators: presence of embryonal carcinoma, absence of yolk 
sac tumor, vascular invasion of the primary tumor, and lymphatic invasion of the primary 
tumor. (Freedman et al., 1987) These risk factors were then evaluated prospectively, 
revealing the presence of 3 or more risk factors as predictive of recurrence in approximately 
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negative serum tumor markers (STM) post-orchiectomy. Patients who present with CS I 
testis cancer have a 30 percent chance of harboring occult metastatic disease post-
orchiectomy, and thus controversy exists as to what represents the best treatment strategy 
following radical orchiectomy. Currently, there are 3 treatment strategies available for 
patients with CS I testis cancer, each one associated with a 99% cure rate: surveillance, 
adjuvant chemotherapy, and primary retroperitoneal lymph node dissection (RPLND). 
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The ability to risk classify CSI patients to “high risk” of harboring micrometastatic disease 
and “low risk” of having micrometastatic disease would aid in tailoring therapy. Those 
patients identified as “high risk” could more preferentially be treated with primary RPLND 
or adjuvant chemotherapy, as they would have a greater risk of relapse on surveillance. 
Conversely, “low risk” patients may be managed with surveillance as they would have a 
greater likelihood of being cured with orchiectomy alone and thus overtreated with primary 
RPLND or adjuvant chemotherapy. 
Several key studies have been published identifying pathologic factors predictive of 
metastatic disease in these patients. In 1987, a retrospective MRC trial identified four 
important negative prognostic indicators: presence of embryonal carcinoma, absence of yolk 
sac tumor, vascular invasion of the primary tumor, and lymphatic invasion of the primary 
tumor. (Freedman et al., 1987) These risk factors were then evaluated prospectively, 
revealing the presence of 3 or more risk factors as predictive of recurrence in approximately 
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50% of patients, and the presence of 2 or less risk factors as predictive of micrometastatic 
disease in about 20% of patients. Notably, vascular invasion of the primary tumor was most 
predictive. (Read et al., 1992) More recently, Vergouwe et al. reviewed 23 publications 
assessing predictors of occult metastases. (Vergouwe, Steyerberg, Eijkemans, Albers, & 
Habbema, 2003) Of the 2,587 total patients involved, 759 (29.3%) patients had occult 
metastasis. Pooled univariate odds ratios identified that lymphovascular invasion of the 
primary tumor, embryonal carcinoma component representing >50% of tumor, advanced 
pathologic stage (T2-4 versus T1), and monoclonal antibody MIB-1 staining greater than 70% 
of the tumor as the strongest predictors of occult metastases. Though somewhat variable, 
high risk groups, with the presence of either or both lymphovascular invasion and an 
embryonal dominant primary, carried a recurrence rate of approximately 50%. In patients 
without either pathologic variable, a recurrence rate of less than 20% was observed.  
At best, with current risk classification, 50% of the “high risk” group harbor micrometastatic 
disease and 50% are cured by orchiectomy alone. Thus any therapy beyond orchiectomy for 
the “high risk” group overtreats 50% of patients, who are never destined to relapse. As such, 
risk classification is less than ideal in determining treatment. Future research aims to 
improve the prognostic ability of risk classification. 
1.3 Surveillance for clinical stage I disease 
1.3.1 Clinical outcomes of surveillance 
The primary rationale for surveillance as a therapeutic modality is: 1) it avoids any further 
therapy in the 70% patients who do not harbor micrometastatic disease and who were cured 
by orchiectomy alone, and 2) those 30% of patients that relapse are curable with 
chemotherapy and/or surgery. To achieve a high cure rate, all patients on surveillance must 
be adherent to a strict follow-up schedule to identify those destined to relapse.  
While surveillance avoids therapy in the large proportion of patients who are not destined 
to recur, there remains a burden of therapy for those that do. Some surveillance patients 
relapsing in the retroperitoneum with normal serum tumor markers may be candidates for 
primary RPLND. The remainder will require 3 courses of chemotherapy, and approximately 
a quarter of these will require surgery following chemotherapy. In the single center 
surveillance series of testis cancer patients from Toronto, at a median follow up of 6.3 years, 
104 of 371 (28%) patients relapsed on surveillance. (Kakiashvili, Zuniga, & Jewett, 2009) Of 
the 104 patients that recurred, the burden of therapy included chemotherapy alone in 31, 
surgery alone in 31, and a combination of chemotherapy, surgery and radiation in the 
remaining 42 patients. Similar results were seen in a cohort of 223 patients from British 
Columbia and Oregon, where 26% relapsed on surveillance. (Kollmannsberger et al., 2010) 
No deaths were observed among those who recurred, although 20% of those who relapsed 
(8% of the original cohort) required post-chemotherapy retroperitoneal lymph node 
dissection (PC RPLND) in addition to chemotherapy.  
Despite those recurrences, the overall survival for patients on surveillance equals that of 
primary RPLND or adjuvant chemotherapy. In a pooled analysis of 3424 patients on 
surveillance in series that reported death, a 98.6% disease specific survival was 
demonstrated. (Groll, Warde, & Jewett, 2007)  
 
Management of Nonseminomatous Germ Cell Tumor of the Testis 25 
1.3.2 Follow up for surveillance 
While some patients on surveillance will bear the burden of therapy upon relapse, all 
patients on surveillance bear the burden of compliance. Studies indicate that up to a third of 
patients miss at least one clinic visit. (Divrik, Akdogan, Ozen, & Zorlu, 2006; Meinke, Estes, 
& Ernst, 1979) A recent evaluation of compliance of CS I patients at the University of 
Calgary showed extremely poor compliance with scheduled follow up. (Hao et al., 1998) In 
this study, compliance with clinic visits and tumor markers was only 61% during the first 
year and 35% in year 2. Furthermore, compliance with scheduled CT scans was only 25% in 
year 1 and 12% in year 2. The only two deaths in 76 total patients were in individuals who 
were non-compliant with follow up. There is concern that non-compliance may translate 
into a decrease in disease specific survival. (Colls et al., 1999; Gels et al., 1995; Kakehi, 
Kamoto, Kawakita, & Ogawa, 2002; Raghavan et al., 1988) Nevertheless, the true impact of 
non-compliance on survival is unknown. A national surveillance study in New Zealand 
failed to correlate non-compliance with compromise in cure. (Colls, et al., 1999) 
In addition to the risk of poor compliance, some patients on a surveillance protocol will 
experience anxiety due to the possibility of relapse. Although such anxiety is difficult to 
quantify, it is understandable that for some patient personalities, active therapy by way of 
primary RPLND or chemotherapy would be more desirable. 
The burden of compliance involves more than anxiety or clinic attendance. Compliance with 
scheduled imaging studies will result in increased radiation exposure, and this exposure 
carries a slightly increased risk of secondary malignancy in this young population. (Brenner 
& Hall, 2007) Given higher relapse rates in the first 2 years of surveillance, (Groll, et al., 
2007) more intensive follow-up is required in this time period using a combination of 
physical exam, CXR, STM, and CT A&P. In an effort to minimize radiation exposure, a 
randomized trial evaluated CT A&P at 3 and 12 months versus 3, 6, 9, 12, and 24 months 
and found no detection benefit in more frequent imaging. This study involved 414 patients 
with a median follow-up of 40 months, though only 10% of the patients were considered 
high risk based on vascular invasion. (Rustin et al., 2007) A popular follow-up schedule is 
that of the Toronto group, which is of moderate frequency compared to the aforementioned 
schedules, and is outlined in Table 1. 
 Month 2 Month 4 Month 6 Month 8 Month 10 Month 12 


















Year 3  STM,CXR  STM,CXR  STM,CXR 
Year 4   STM,CXR   STM,CXR 
Year 5      STM,CXR 
Table 1. Toronto CS I NSGCT Surveillance Schedule  
In addition to compliance issues, surveillance protocols also affect fertility rates, which 
approach 65% during surveillance, but decreases to 20% for surveillance patients that recur. 
(Herr, Bar-Chama, O'Sullivan, & Sogani, 1998).  
 
Germ Cell Tumor 24
50% of patients, and the presence of 2 or less risk factors as predictive of micrometastatic 
disease in about 20% of patients. Notably, vascular invasion of the primary tumor was most 
predictive. (Read et al., 1992) More recently, Vergouwe et al. reviewed 23 publications 
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metastasis. Pooled univariate odds ratios identified that lymphovascular invasion of the 
primary tumor, embryonal carcinoma component representing >50% of tumor, advanced 
pathologic stage (T2-4 versus T1), and monoclonal antibody MIB-1 staining greater than 70% 
of the tumor as the strongest predictors of occult metastases. Though somewhat variable, 
high risk groups, with the presence of either or both lymphovascular invasion and an 
embryonal dominant primary, carried a recurrence rate of approximately 50%. In patients 
without either pathologic variable, a recurrence rate of less than 20% was observed.  
At best, with current risk classification, 50% of the “high risk” group harbor micrometastatic 
disease and 50% are cured by orchiectomy alone. Thus any therapy beyond orchiectomy for 
the “high risk” group overtreats 50% of patients, who are never destined to relapse. As such, 
risk classification is less than ideal in determining treatment. Future research aims to 
improve the prognostic ability of risk classification. 
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therapy in the 70% patients who do not harbor micrometastatic disease and who were cured 
by orchiectomy alone, and 2) those 30% of patients that relapse are curable with 
chemotherapy and/or surgery. To achieve a high cure rate, all patients on surveillance must 
be adherent to a strict follow-up schedule to identify those destined to relapse.  
While surveillance avoids therapy in the large proportion of patients who are not destined 
to recur, there remains a burden of therapy for those that do. Some surveillance patients 
relapsing in the retroperitoneum with normal serum tumor markers may be candidates for 
primary RPLND. The remainder will require 3 courses of chemotherapy, and approximately 
a quarter of these will require surgery following chemotherapy. In the single center 
surveillance series of testis cancer patients from Toronto, at a median follow up of 6.3 years, 
104 of 371 (28%) patients relapsed on surveillance. (Kakiashvili, Zuniga, & Jewett, 2009) Of 
the 104 patients that recurred, the burden of therapy included chemotherapy alone in 31, 
surgery alone in 31, and a combination of chemotherapy, surgery and radiation in the 
remaining 42 patients. Similar results were seen in a cohort of 223 patients from British 
Columbia and Oregon, where 26% relapsed on surveillance. (Kollmannsberger et al., 2010) 
No deaths were observed among those who recurred, although 20% of those who relapsed 
(8% of the original cohort) required post-chemotherapy retroperitoneal lymph node 
dissection (PC RPLND) in addition to chemotherapy.  
Despite those recurrences, the overall survival for patients on surveillance equals that of 
primary RPLND or adjuvant chemotherapy. In a pooled analysis of 3424 patients on 
surveillance in series that reported death, a 98.6% disease specific survival was 
demonstrated. (Groll, Warde, & Jewett, 2007)  
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1.3.2 Follow up for surveillance 
While some patients on surveillance will bear the burden of therapy upon relapse, all 
patients on surveillance bear the burden of compliance. Studies indicate that up to a third of 
patients miss at least one clinic visit. (Divrik, Akdogan, Ozen, & Zorlu, 2006; Meinke, Estes, 
& Ernst, 1979) A recent evaluation of compliance of CS I patients at the University of 
Calgary showed extremely poor compliance with scheduled follow up. (Hao et al., 1998) In 
this study, compliance with clinic visits and tumor markers was only 61% during the first 
year and 35% in year 2. Furthermore, compliance with scheduled CT scans was only 25% in 
year 1 and 12% in year 2. The only two deaths in 76 total patients were in individuals who 
were non-compliant with follow up. There is concern that non-compliance may translate 
into a decrease in disease specific survival. (Colls et al., 1999; Gels et al., 1995; Kakehi, 
Kamoto, Kawakita, & Ogawa, 2002; Raghavan et al., 1988) Nevertheless, the true impact of 
non-compliance on survival is unknown. A national surveillance study in New Zealand 
failed to correlate non-compliance with compromise in cure. (Colls, et al., 1999) 
In addition to the risk of poor compliance, some patients on a surveillance protocol will 
experience anxiety due to the possibility of relapse. Although such anxiety is difficult to 
quantify, it is understandable that for some patient personalities, active therapy by way of 
primary RPLND or chemotherapy would be more desirable. 
The burden of compliance involves more than anxiety or clinic attendance. Compliance with 
scheduled imaging studies will result in increased radiation exposure, and this exposure 
carries a slightly increased risk of secondary malignancy in this young population. (Brenner 
& Hall, 2007) Given higher relapse rates in the first 2 years of surveillance, (Groll, et al., 
2007) more intensive follow-up is required in this time period using a combination of 
physical exam, CXR, STM, and CT A&P. In an effort to minimize radiation exposure, a 
randomized trial evaluated CT A&P at 3 and 12 months versus 3, 6, 9, 12, and 24 months 
and found no detection benefit in more frequent imaging. This study involved 414 patients 
with a median follow-up of 40 months, though only 10% of the patients were considered 
high risk based on vascular invasion. (Rustin et al., 2007) A popular follow-up schedule is 
that of the Toronto group, which is of moderate frequency compared to the aforementioned 
schedules, and is outlined in Table 1. 
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In addition to compliance issues, surveillance protocols also affect fertility rates, which 
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1.3.3 Summary: Surveillance for clinical stage I disease 
Surveillance offers an equal cure rate to either primary RPLND or adjuvant chemotherapy, 
and does so while avoiding further therapy in 70% of patients. Therefore, it is arguably the 
treatment option of choice in patients without significant pathologic risk factors for occult 
retroperitoneal metastases, who are willing to undergo serial imaging and intense follow-
up. However, patients who choose surveillance must be aware of the importance of 
adherence to their follow-up schedule, and the fact that 30% of patients will require 
chemotherapy at relapse. As a result, patients strongly averse to chemotherapy may not 
wish to choose a surveillance protocol, favoring primary RPLND instead.  
1.4 Adjuvant chemotherapy for clinical stage I disease 
1.4.1 Clinical outcomes of adjuvant chemotherapy 
The rationale for chemotherapy in CS I NSGCT is that it virtually eliminates the risk of 
recurrence, with an incidence rate much lower than that observed with either primary 
RPLND or surveillance. Recurrence rates were reported by the Spanish Germ Cell Group 
involving 231 high risk patients who received two courses of bleomycin, etoposide, and 
cisplatinum (BEP). (Maroto et al., 2005) Two patients (0.9%) relapsed and both are disease 
free after salvage therapy. Long-term follow up extending 10 years has confirmed the low 
relapse rates associated with adjuvant chemotherapy. (Chevreau et al., 2004; Westermann et 
al., 2008) Similarly low recurrence rates have been reported in other series also using 2 
courses of BEP, (Cullen et al., 1996; Oliver, Raja, Ong, & Gallagher, 1992) allowing clinicians 
to draw the conclusion that there is little doubt on the efficacy of chemotherapy in 
preventing recurrence and achieving cure rates similar to surveillance or RPLND strategies 
for CS I NSGCT patients. 
1.4.2 Morbidity of adjuvant chemotherapy 
While the recurrence rates following 2 cycles of adjuvant BEP are impressively low, all 
patients, including the 70% who did not require this additional therapy, are subjected to the 
burden of systemic chemotherapy. Given the young age of most testis cancer patients, a 
lifetime remains to accrue complications secondary to this treatment choice. Specifically, the 
Royal Marsden Hospital reported a 2-fold greater risk of developing cardiovascular disease 
in testis cancer patients treated with chemotherapy and radiation. (Huddart et al., 2003) 
Others have reported that cured patients treated with cisplatin-based chemotherapy have a 
higher prevalence of hypertension and an excessive weight gain compared with patients 
treated with other modalities, and compared to controls. (Sagstuen et al., 2005) A recent 
report evaluated the long-term toxicity of cisplatin-based chemotherapy in 1409 men at a 
median follow-up of 10.7 years. (Brydoy et al., 2009) All chemotherapy groups had 
statistically higher odds of toxicity than men who did not receive chemotherapy, and that 
toxicity most commonly included Raynaud-like phenomena in 39%, paresthesias in the 
hands or feet in 29%, hearing impairment in 21% and tinnitus in 22%. Finally, it is worth 
noting that fertility rates during chemotherapy will drop substantially, recovering to 
approximately an 85% conception rate for couples desiring children, with a mean of 3 years 
of follow up. (Huyghe et al., 2004)  
 
Management of Nonseminomatous Germ Cell Tumor of the Testis 27 
Bearing these concerning morbidity rates in mind, efforts have been made to decrease the 
toxicity of chemotherapy regimens by decreasing dose rates. Investigators have attempted to 
decrease the exposure to chemotherapy by treating clinical stage I patients with a single cycle 
of BEP. The Swiss Group for Clinical Cancer Research reported outcomes of high risk stage I 
patients receiving a single course of BEP in the adjuvant setting. (Westermann, et al., 2008) 
Data from 40 of the 44 patients were analyzed. Thirty-five showed no evidence of disease 
during a median follow up of 99 months. One patient developed pulmonary metastases after 
13 months and died of pneumonia. Two patients developed contralateral testis cancer, 
subsequently received three cycles of BEP, and were relapse free for 4 and 92 months, 
respectively, thereafter. Two final patients were free of disease at 10 and 31 months when lost 
to follow-up. Also utilizing one course of BEP, the German Testicular Cancer Study Group has 
reported a 2-year disease free survival of 99.5% after a median follow up of 4.7 years, with just 
2 recurrences observed in the intention-to-treat population. (Albers et al., 2008) 
1.4.3 Follow up for adjuvant chemotherapy 
During chemotherapy, serum markers are monitored prior to each cycle. Upon completion 
of 2 cycles of BEP, patient follow-up need be tailored based upon individual patient 
outcomes, and will include periodic physical examination, serum markers, and imaging of 
the chest, abdomen, and pelvis. (L. Wood et al., 2010) 
1.4.4 Summary: Adjuvant chemotherapy for clinical stage I disease 
To summarize chemotherapy as a treatment option, its greatest advantage lies in its 
recurrence rate of less than 2%. However, it subjects all patients, including the 70% never 
destined to recur, to the short and long term complications of systemic chemotherapy. While 
recent data suggest that one cycle of BEP may be adequate to achieve acceptably low 
recurrence rates, the standard of care continues to be two cycles of BEP, and the attendant 
morbidities of this therapeutic choice must be borne in mind. 
1.5 Primary RPLND for clinical stage I disease 
1.5.1 Clinical outcomes of primary RPLND – pathologic stage I disease 
Testis cancer is unique among urologic cancers in that surgery (RPLND) can cure patients 
that have metastatic disease. Of CS I patients choosing primary RPLND, 70% will have no 
metastatic disease in their retroperitoneum, and are classified as pathologic stage I. Despite 
negative lymph nodes, 10% will relapse, and thus these patients still require follow-up. The 
remaining 30% with occult cancer identified in the lymph nodes are classified as pathologic 
stage II. For patients with pathologic stage II disease, surgery alone is curative in 
approximately 70%, and those 30% that relapse are cured with chemotherapy. Irrespective 
of pathologic stage, 99% patients who choose primary RPLND will ultimately be cured of 
their disease. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993b) 
1.5.2 Clinical outcomes of primary RPLND – low volume pathologic stage II disease 
Management options for pathologic stage II disease include observation or adjuvant 
chemotherapy, as both have equal survival. This is based on a randomized trial of 
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1.3.3 Summary: Surveillance for clinical stage I disease 
Surveillance offers an equal cure rate to either primary RPLND or adjuvant chemotherapy, 
and does so while avoiding further therapy in 70% of patients. Therefore, it is arguably the 
treatment option of choice in patients without significant pathologic risk factors for occult 
retroperitoneal metastases, who are willing to undergo serial imaging and intense follow-
up. However, patients who choose surveillance must be aware of the importance of 
adherence to their follow-up schedule, and the fact that 30% of patients will require 
chemotherapy at relapse. As a result, patients strongly averse to chemotherapy may not 
wish to choose a surveillance protocol, favoring primary RPLND instead.  
1.4 Adjuvant chemotherapy for clinical stage I disease 
1.4.1 Clinical outcomes of adjuvant chemotherapy 
The rationale for chemotherapy in CS I NSGCT is that it virtually eliminates the risk of 
recurrence, with an incidence rate much lower than that observed with either primary 
RPLND or surveillance. Recurrence rates were reported by the Spanish Germ Cell Group 
involving 231 high risk patients who received two courses of bleomycin, etoposide, and 
cisplatinum (BEP). (Maroto et al., 2005) Two patients (0.9%) relapsed and both are disease 
free after salvage therapy. Long-term follow up extending 10 years has confirmed the low 
relapse rates associated with adjuvant chemotherapy. (Chevreau et al., 2004; Westermann et 
al., 2008) Similarly low recurrence rates have been reported in other series also using 2 
courses of BEP, (Cullen et al., 1996; Oliver, Raja, Ong, & Gallagher, 1992) allowing clinicians 
to draw the conclusion that there is little doubt on the efficacy of chemotherapy in 
preventing recurrence and achieving cure rates similar to surveillance or RPLND strategies 
for CS I NSGCT patients. 
1.4.2 Morbidity of adjuvant chemotherapy 
While the recurrence rates following 2 cycles of adjuvant BEP are impressively low, all 
patients, including the 70% who did not require this additional therapy, are subjected to the 
burden of systemic chemotherapy. Given the young age of most testis cancer patients, a 
lifetime remains to accrue complications secondary to this treatment choice. Specifically, the 
Royal Marsden Hospital reported a 2-fold greater risk of developing cardiovascular disease 
in testis cancer patients treated with chemotherapy and radiation. (Huddart et al., 2003) 
Others have reported that cured patients treated with cisplatin-based chemotherapy have a 
higher prevalence of hypertension and an excessive weight gain compared with patients 
treated with other modalities, and compared to controls. (Sagstuen et al., 2005) A recent 
report evaluated the long-term toxicity of cisplatin-based chemotherapy in 1409 men at a 
median follow-up of 10.7 years. (Brydoy et al., 2009) All chemotherapy groups had 
statistically higher odds of toxicity than men who did not receive chemotherapy, and that 
toxicity most commonly included Raynaud-like phenomena in 39%, paresthesias in the 
hands or feet in 29%, hearing impairment in 21% and tinnitus in 22%. Finally, it is worth 
noting that fertility rates during chemotherapy will drop substantially, recovering to 
approximately an 85% conception rate for couples desiring children, with a mean of 3 years 
of follow up. (Huyghe et al., 2004)  
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Bearing these concerning morbidity rates in mind, efforts have been made to decrease the 
toxicity of chemotherapy regimens by decreasing dose rates. Investigators have attempted to 
decrease the exposure to chemotherapy by treating clinical stage I patients with a single cycle 
of BEP. The Swiss Group for Clinical Cancer Research reported outcomes of high risk stage I 
patients receiving a single course of BEP in the adjuvant setting. (Westermann, et al., 2008) 
Data from 40 of the 44 patients were analyzed. Thirty-five showed no evidence of disease 
during a median follow up of 99 months. One patient developed pulmonary metastases after 
13 months and died of pneumonia. Two patients developed contralateral testis cancer, 
subsequently received three cycles of BEP, and were relapse free for 4 and 92 months, 
respectively, thereafter. Two final patients were free of disease at 10 and 31 months when lost 
to follow-up. Also utilizing one course of BEP, the German Testicular Cancer Study Group has 
reported a 2-year disease free survival of 99.5% after a median follow up of 4.7 years, with just 
2 recurrences observed in the intention-to-treat population. (Albers et al., 2008) 
1.4.3 Follow up for adjuvant chemotherapy 
During chemotherapy, serum markers are monitored prior to each cycle. Upon completion 
of 2 cycles of BEP, patient follow-up need be tailored based upon individual patient 
outcomes, and will include periodic physical examination, serum markers, and imaging of 
the chest, abdomen, and pelvis. (L. Wood et al., 2010) 
1.4.4 Summary: Adjuvant chemotherapy for clinical stage I disease 
To summarize chemotherapy as a treatment option, its greatest advantage lies in its 
recurrence rate of less than 2%. However, it subjects all patients, including the 70% never 
destined to recur, to the short and long term complications of systemic chemotherapy. While 
recent data suggest that one cycle of BEP may be adequate to achieve acceptably low 
recurrence rates, the standard of care continues to be two cycles of BEP, and the attendant 
morbidities of this therapeutic choice must be borne in mind. 
1.5 Primary RPLND for clinical stage I disease 
1.5.1 Clinical outcomes of primary RPLND – pathologic stage I disease 
Testis cancer is unique among urologic cancers in that surgery (RPLND) can cure patients 
that have metastatic disease. Of CS I patients choosing primary RPLND, 70% will have no 
metastatic disease in their retroperitoneum, and are classified as pathologic stage I. Despite 
negative lymph nodes, 10% will relapse, and thus these patients still require follow-up. The 
remaining 30% with occult cancer identified in the lymph nodes are classified as pathologic 
stage II. For patients with pathologic stage II disease, surgery alone is curative in 
approximately 70%, and those 30% that relapse are cured with chemotherapy. Irrespective 
of pathologic stage, 99% patients who choose primary RPLND will ultimately be cured of 
their disease. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993b) 
1.5.2 Clinical outcomes of primary RPLND – low volume pathologic stage II disease 
Management options for pathologic stage II disease include observation or adjuvant 
chemotherapy, as both have equal survival. This is based on a randomized trial of 
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pathologic stage II patients which compared adjuvant chemotherapy to close observation 
(with chemotherapy for recurrence). (Williams, et al., 1987) Analysis revealed no difference 
in survival (95%) between the two treatment arms at a median follow-up of 4 years. 
Outcomes for patients with low volume pathologic stage II disease who choose observation 
are well described in the literature. Pathologic stage II disease was identified in 112 of 464 
patients undergoing primary RPLND at Indiana for what was originally staged as clinical 
stage I disease, from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993c) 
Sixty-six percent of those patients with pathologic stage II disease were cured by RPLND 
alone. Memorial Sloan Kettering reported an 81% four-year progression free probability for 
pathologic stage II patients who did not receive adjuvant chemotherapy following a full, 
bilateral RPLND with less than a 2cm retroperitoneal mass. (Stephenson et al., 2005) Similar 
results were obtained in a series from Indiana University which included 118 RPLND 
patients with pathologic stage II disease, who did not receive adjuvant chemotherapy, and 
were followed for a minimum of 2 years. The 5 year disease free survival for this cohort was 
68%. ( S. D. Beck, Foster, Bihrle, Cheng, & Donohue, 2005; S. D. Beck et al., 2005) 
Thus, 70% of patients with pathologic stage II disease are cured with RPLND alone, and 
those 30% that do relapse remain curable with 3 courses of chemotherapy. An alternative 
approach in managing pathologic stage II disease is 2 courses of adjuvant chemotherapy. 
While this approach reduces recurrence rates to less than 2%, (Behnia, Foster, Einhorn, 
Donohue, & Nichols, 2000; Culine et al., 1996; Gerl, Clemm, Kohl, & al., 1994; Kennedy, 
Torkelson, & Fraley, 1994; Kondagunta et al., 2004; Vugrin, Whitmore, Herr, Sogani, & 
Golbey, 1982; Weissbach & Hartlapp, 1991; Williams et al., 1987) it subjects all patients to 
chemotherapy, including the 70% who were cured by surgery alone. (Donohue, Thornhill, 
Foster, Rowland, & Bihrle, 1993a, 1995a; Richie & Kantoff, 1991)  
Similar to risk stratification in CS I disease, efforts have been made to identify risk factors 
predictive of relapse for pathologic stage II disease after RPLND. Knowledge of such risk 
factors would allow “high risk” patients to receive adjuvant chemotherapy, and “low risk” 
patients to be observed. To date, no pathologic or clinical variable has been identified to 
predict relapse. (S. D. Beck, et al., 2007) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, & J. P. 
Donohue, 2005) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, T. M. Ulbright, et al., 2005) 
(Rabbani et al., 2001) (Richie & Kantoff, 1991)  
1.5.3 Primary RPLND technique 
The traditional full bilateral suprahilar RPLND involved removal of all lymphatic tissue 
from the suprahilar areas to the bifurcation of the common iliac arteries, from ureter to 
contralateral ureter. This was, by intent, a radical procedure, because chemotherapeutic 
rescue was not available when full bilateral RPLND was initially developed. All 
sympathetic efferent fibers were sacrificed, and lymphatic tissue was removed en bloc. 
Therefore, these patients suffered from anejaculation post-operatively. 
Since the original extent of dissection was developed, it has been discovered, through the 
advent of CT scanning, and with the aid of meticulous anatomic mapping studies, that 
patients with clinical stage I disease may be treated with a much more limited dissection in 
the retroperitoneum, ipsilateral to the affected testis. Specifically, patients with low-volume 
retroperitoneal tumor from a left sided primary characteristically had metastases localized 
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to the upper left periaortic zone, and patients with low-volume disease from a right-sided 
primary were found to have metastases to the interaortocaval or precaval zones. These facts 
led investigators to modify the traditional full bilateral RPLND further and limit the 
dissection to the left- and right-sided templates, as depicted in Figures 1 and 2.  
 
Fig. 1. Left-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
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pathologic stage II patients which compared adjuvant chemotherapy to close observation 
(with chemotherapy for recurrence). (Williams, et al., 1987) Analysis revealed no difference 
in survival (95%) between the two treatment arms at a median follow-up of 4 years. 
Outcomes for patients with low volume pathologic stage II disease who choose observation 
are well described in the literature. Pathologic stage II disease was identified in 112 of 464 
patients undergoing primary RPLND at Indiana for what was originally staged as clinical 
stage I disease, from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993c) 
Sixty-six percent of those patients with pathologic stage II disease were cured by RPLND 
alone. Memorial Sloan Kettering reported an 81% four-year progression free probability for 
pathologic stage II patients who did not receive adjuvant chemotherapy following a full, 
bilateral RPLND with less than a 2cm retroperitoneal mass. (Stephenson et al., 2005) Similar 
results were obtained in a series from Indiana University which included 118 RPLND 
patients with pathologic stage II disease, who did not receive adjuvant chemotherapy, and 
were followed for a minimum of 2 years. The 5 year disease free survival for this cohort was 
68%. ( S. D. Beck, Foster, Bihrle, Cheng, & Donohue, 2005; S. D. Beck et al., 2005) 
Thus, 70% of patients with pathologic stage II disease are cured with RPLND alone, and 
those 30% that do relapse remain curable with 3 courses of chemotherapy. An alternative 
approach in managing pathologic stage II disease is 2 courses of adjuvant chemotherapy. 
While this approach reduces recurrence rates to less than 2%, (Behnia, Foster, Einhorn, 
Donohue, & Nichols, 2000; Culine et al., 1996; Gerl, Clemm, Kohl, & al., 1994; Kennedy, 
Torkelson, & Fraley, 1994; Kondagunta et al., 2004; Vugrin, Whitmore, Herr, Sogani, & 
Golbey, 1982; Weissbach & Hartlapp, 1991; Williams et al., 1987) it subjects all patients to 
chemotherapy, including the 70% who were cured by surgery alone. (Donohue, Thornhill, 
Foster, Rowland, & Bihrle, 1993a, 1995a; Richie & Kantoff, 1991)  
Similar to risk stratification in CS I disease, efforts have been made to identify risk factors 
predictive of relapse for pathologic stage II disease after RPLND. Knowledge of such risk 
factors would allow “high risk” patients to receive adjuvant chemotherapy, and “low risk” 
patients to be observed. To date, no pathologic or clinical variable has been identified to 
predict relapse. (S. D. Beck, et al., 2007) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, & J. P. 
Donohue, 2005) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, T. M. Ulbright, et al., 2005) 
(Rabbani et al., 2001) (Richie & Kantoff, 1991)  
1.5.3 Primary RPLND technique 
The traditional full bilateral suprahilar RPLND involved removal of all lymphatic tissue 
from the suprahilar areas to the bifurcation of the common iliac arteries, from ureter to 
contralateral ureter. This was, by intent, a radical procedure, because chemotherapeutic 
rescue was not available when full bilateral RPLND was initially developed. All 
sympathetic efferent fibers were sacrificed, and lymphatic tissue was removed en bloc. 
Therefore, these patients suffered from anejaculation post-operatively. 
Since the original extent of dissection was developed, it has been discovered, through the 
advent of CT scanning, and with the aid of meticulous anatomic mapping studies, that 
patients with clinical stage I disease may be treated with a much more limited dissection in 
the retroperitoneum, ipsilateral to the affected testis. Specifically, patients with low-volume 
retroperitoneal tumor from a left sided primary characteristically had metastases localized 
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to the upper left periaortic zone, and patients with low-volume disease from a right-sided 
primary were found to have metastases to the interaortocaval or precaval zones. These facts 
led investigators to modify the traditional full bilateral RPLND further and limit the 
dissection to the left- and right-sided templates, as depicted in Figures 1 and 2.  
 
Fig. 1. Left-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
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Fig. 2. Right-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
With these templates, right and left sided dissection would remove lymphatic tissue at high 
risk of harboring metastatic disease, but preserve other retroperitoneal lymphatic tissue at low 
risk of containing metastasis. The advantages of limiting the dissection in patients with low 
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volume disease were shorter operative times, and shorter postoperative ileus. Additionally, 
and most importantly, these templates saved contralateral retroperitoneal efferent sympathetic 
fibers, thereby preserving emission and ejaculation in roughly 50% to 70% of patients. 
The most recent modification in technique for RPLND for low-stage disease is the nerve-
sparing dissection, in which efferent sympathetic fibers are prospectively identified and 
dissected, and modified lymphadenectomy is then performed. This advancement in 
technique preserves the staging and therapeutic aspect of RPLND, while additionally 
improving upon ejaculation preservation rates. In Figure 3, the right-sided post-synaptic 
sympathetic nerves are enveloped by vessel loops, and are seen exiting the sympathetic 
chain from underneath an anteriorly retracted inferior vena cava (IVC). 
 
Fig. 3. Nerve-Sparing RPLND Technique. A photograph of the retroperitoneum during 
RPLND. The post-synaptic sympathetic nerves are encircled by white vessel loops for better 
visualization. Following the course of these nerves proximally, they can be seen joining the 
right sympathetic chain, which travels parallel and posterior to the inferior vena cava. The 
inferior vena cava is retracted anteriorly with vein retractors, to allow better visualization of 
the sympathetic chain. 
A laparoscopic technique has been developed in an effort to further diminish primary 
RPLND’s already favorable morbidity profile. It remains unknown as to whether or not the 
laparoscopic technique offers a morbidity benefit compared to the open technique. (Abdel-
Aziz et al., 2006; Albqami & Janetschek, 2005; Janetschek, Hobisch, Holtl, & Bartsch, 1996; 
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Fig. 2. Right-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
With these templates, right and left sided dissection would remove lymphatic tissue at high 
risk of harboring metastatic disease, but preserve other retroperitoneal lymphatic tissue at low 
risk of containing metastasis. The advantages of limiting the dissection in patients with low 
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volume disease were shorter operative times, and shorter postoperative ileus. Additionally, 
and most importantly, these templates saved contralateral retroperitoneal efferent sympathetic 
fibers, thereby preserving emission and ejaculation in roughly 50% to 70% of patients. 
The most recent modification in technique for RPLND for low-stage disease is the nerve-
sparing dissection, in which efferent sympathetic fibers are prospectively identified and 
dissected, and modified lymphadenectomy is then performed. This advancement in 
technique preserves the staging and therapeutic aspect of RPLND, while additionally 
improving upon ejaculation preservation rates. In Figure 3, the right-sided post-synaptic 
sympathetic nerves are enveloped by vessel loops, and are seen exiting the sympathetic 
chain from underneath an anteriorly retracted inferior vena cava (IVC). 
 
Fig. 3. Nerve-Sparing RPLND Technique. A photograph of the retroperitoneum during 
RPLND. The post-synaptic sympathetic nerves are encircled by white vessel loops for better 
visualization. Following the course of these nerves proximally, they can be seen joining the 
right sympathetic chain, which travels parallel and posterior to the inferior vena cava. The 
inferior vena cava is retracted anteriorly with vein retractors, to allow better visualization of 
the sympathetic chain. 
A laparoscopic technique has been developed in an effort to further diminish primary 
RPLND’s already favorable morbidity profile. It remains unknown as to whether or not the 
laparoscopic technique offers a morbidity benefit compared to the open technique. (Abdel-
Aziz et al., 2006; Albqami & Janetschek, 2005; Janetschek, Hobisch, Holtl, & Bartsch, 1996; 
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Kenney & Tuerk, 2008) Furthermore, the vast majority of laparoscopic primary RPLND 
patients receive adjuvant chemotherapy following surgery, thus the therapeutic benefit of 
laparoscopic RPLND alone also remains unknown. (Rassweiler, Scheitlin, Heidenreich, 
Laguna, & Janetschek, 2008)  
1.5.4 Morbidity of primary RPLND 
Although primary RPLND as a treatment strategy offers excellent cure rates, it nonetheless 
subjects 70% of patients to unnecessary surgery. Fortunately, the morbidity of a primary 
RPLND is essentially that of a laparotomy. (Foster et al., 1994; Heidenreich et al., 2003; 
Jewett, 1990) A review of the experience at Indiana University showed that the only 
significant long-term morbidity is an approximate 1% chance of postoperative small bowel 
obstruction due to adhesions. (Baniel, Foster, Rowland, Bihrle, & Donohue, 1994) The same 
institution recently reviewed 75 consecutive primary retroperitoneal lymph node 
dissections. (S.D.W. Beck, Peterson, Foster, Bihrle, & Donohue, 2006) In this population the 
mean operative time was 132 minutes, mean blood loss was 207 cc. Nasogastric tubes are 
not routinely used in either primary or post chemotherapy surgery, and in this series only 2 
patients had NG tubes. The mean hospital stay was 2.8 days (range: 2-4). With nerve-sparing 
technique, 99% maintain antegrade ejaculation, and a 75% fertility rate is observed. (S. D. 
Beck, Bey, Bihrle, & Foster, 2010; Foster et al., 1994) (S. D. Beck, Bey, Bihrle, & Foster, 2010; 
Foster, et al., 1994) This compares favorably to fertility rates for surveillance, and is roughly 
equivalent to fertility rates seen with chemotherapy. 
1.5.5 Follow up for primary RPLND 
Irrespective of pathologic stage at primary RPLND, the risk of relapse in the retroperitoneum 
is exceedingly low, with most relapses identified by chest X-ray and/or serum tumor markers. 
As such abdominal imaging with CT scan is not routinely used and follow-up consists of 
periodic chest X-ray, serum tumor markers, and physical examination. Given the rarity of 
relapse more than 2 years after remission, especially in the RPLND population, (Baniel et al., 
1995) further follow-up accordingly becomes less rigorous in subsequent years. 
1.5.6 Summary: Primary RPLND for clinical stage I disease 
Though RPLND subjects all patients to a laparotomy (including the 70% that were 
pathologic stage I and did not require surgery), with nerve-sparing technique antegrade 
emission is preserved, and long term morbidity includes an abdominal scar and a 1% chance 
of latent small bowel obstruction. RPLND offers unique advantages over observation or 
adjuvant chemotherapy, including immediate pathologic staging, a simplified and less 
anxiety-prone follow-up involving less radiation exposure, and the potential for cure and 
the avoidance of chemotherapy for pathologic stage II patients.  
1.6 Special considerations in stage I disease 
1.6.1 Clinical stage I s patients 
A small percentage of patients have elevated serum tumor markers which do not normalize 
appropriately following radical orchiectomy, despite an otherwise normal metastatic work-
up, and are defined as clinical Stage I s disease. By virtue of the increased markers, these 
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patients continue to harbor disease. While some have advocated RPLND in such situations, 
confinement of disease to the retroperitoneum is not assured, thus additional chemotherapy 
may be necessary should RPLND not affect cure. As a result, chemotherapy is 
recommended for Stage Is patients. 
1.6.2 Chemoresistant pathology  
A small subset of patients have adenocarcinoma, teratoma with malignant transformation 
(such as primitive neuroectodermal tumour (PNET)), or a sex chord stromal tumor in their 
orchiectomy specimen. These histologies are chemoresistant, and a subsequent relapse is 
unlikely to be responsive to chemotherapy. Thus, first line treatment should be RPLND.  
1.7 Summary: Management options for clinical stage I non-seminomatous germ cell 
tumor of the testis 
Appropriate treatment of Stage I NSGCT requires knowledge of the risk factors associated 
with recurrence, foresight regarding the likely outcomes and percentages associated with 
the three treatment strategies, the morbidities unique to each modality, and most 
importantly a keen understanding of a patient’s desired approach to this complicated 
problem. Given that all three treatment modalities offer equivalent cure rates, a treatment 
strategy which focuses on minimizing overall morbidity, and approaches the problem in a 
manner which is synergistic with a patient’s wishes, is most likely to be successful. 
2. Management options for clinical stage II and III non-seminomatous germ 
cell tumor of the testis 
Patients with clinical stage II disease have evidence of disease confined to their 
retroperitoneum following radical orchiectomy. Clinical stage III patients have disease 
outside of the retroperitoneum following orchiectomy. Patients with small volume (<5cm) 
stage II disease and normal serum tumor markers post-orchiectomy may be treated with 
either primary RPLND or induction chemotherapy. Patients with “bulky” stage II disease, 
those with persistently elevated serum tumor markers, and all patients with clinical stage III 
disease, require cisplatinum-based chemotherapy. 
2.1 Primary RPLND for low volume clinical stage II disease 
2.1.1 Clinical outcomes of primary RPLND 
As with clinical stage I disease, primary RPLND in low volume clinical stage II disease is 
both a staging and a therapeutic procedure. Following RPLND, further treatment decisions 
are based upon the pathologic stage of disease, regardless of the initial clinical stage at 
presentation. Donohue reported on 174 clinical stage II patients undergoing full, bilateral 
primary RPLND from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1995b) 
Interestingly, 23% of patients originally staged as CS II disease were shown to be pathologic 
stage I disease following primary RPLND. 65% of those patients who were pathologic stage 
II with a nodal mass of less than 5 cm were cured by RPLND alone – that is, did not receive 
adjuvant chemotherapy. Thus patients with clinical stage II disease who are proven to be 
pathologic stage II are cured at roughly the 70% level with surgery alone.  
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Kenney & Tuerk, 2008) Furthermore, the vast majority of laparoscopic primary RPLND 
patients receive adjuvant chemotherapy following surgery, thus the therapeutic benefit of 
laparoscopic RPLND alone also remains unknown. (Rassweiler, Scheitlin, Heidenreich, 
Laguna, & Janetschek, 2008)  
1.5.4 Morbidity of primary RPLND 
Although primary RPLND as a treatment strategy offers excellent cure rates, it nonetheless 
subjects 70% of patients to unnecessary surgery. Fortunately, the morbidity of a primary 
RPLND is essentially that of a laparotomy. (Foster et al., 1994; Heidenreich et al., 2003; 
Jewett, 1990) A review of the experience at Indiana University showed that the only 
significant long-term morbidity is an approximate 1% chance of postoperative small bowel 
obstruction due to adhesions. (Baniel, Foster, Rowland, Bihrle, & Donohue, 1994) The same 
institution recently reviewed 75 consecutive primary retroperitoneal lymph node 
dissections. (S.D.W. Beck, Peterson, Foster, Bihrle, & Donohue, 2006) In this population the 
mean operative time was 132 minutes, mean blood loss was 207 cc. Nasogastric tubes are 
not routinely used in either primary or post chemotherapy surgery, and in this series only 2 
patients had NG tubes. The mean hospital stay was 2.8 days (range: 2-4). With nerve-sparing 
technique, 99% maintain antegrade ejaculation, and a 75% fertility rate is observed. (S. D. 
Beck, Bey, Bihrle, & Foster, 2010; Foster et al., 1994) (S. D. Beck, Bey, Bihrle, & Foster, 2010; 
Foster, et al., 1994) This compares favorably to fertility rates for surveillance, and is roughly 
equivalent to fertility rates seen with chemotherapy. 
1.5.5 Follow up for primary RPLND 
Irrespective of pathologic stage at primary RPLND, the risk of relapse in the retroperitoneum 
is exceedingly low, with most relapses identified by chest X-ray and/or serum tumor markers. 
As such abdominal imaging with CT scan is not routinely used and follow-up consists of 
periodic chest X-ray, serum tumor markers, and physical examination. Given the rarity of 
relapse more than 2 years after remission, especially in the RPLND population, (Baniel et al., 
1995) further follow-up accordingly becomes less rigorous in subsequent years. 
1.5.6 Summary: Primary RPLND for clinical stage I disease 
Though RPLND subjects all patients to a laparotomy (including the 70% that were 
pathologic stage I and did not require surgery), with nerve-sparing technique antegrade 
emission is preserved, and long term morbidity includes an abdominal scar and a 1% chance 
of latent small bowel obstruction. RPLND offers unique advantages over observation or 
adjuvant chemotherapy, including immediate pathologic staging, a simplified and less 
anxiety-prone follow-up involving less radiation exposure, and the potential for cure and 
the avoidance of chemotherapy for pathologic stage II patients.  
1.6 Special considerations in stage I disease 
1.6.1 Clinical stage I s patients 
A small percentage of patients have elevated serum tumor markers which do not normalize 
appropriately following radical orchiectomy, despite an otherwise normal metastatic work-
up, and are defined as clinical Stage I s disease. By virtue of the increased markers, these 
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patients continue to harbor disease. While some have advocated RPLND in such situations, 
confinement of disease to the retroperitoneum is not assured, thus additional chemotherapy 
may be necessary should RPLND not affect cure. As a result, chemotherapy is 
recommended for Stage Is patients. 
1.6.2 Chemoresistant pathology  
A small subset of patients have adenocarcinoma, teratoma with malignant transformation 
(such as primitive neuroectodermal tumour (PNET)), or a sex chord stromal tumor in their 
orchiectomy specimen. These histologies are chemoresistant, and a subsequent relapse is 
unlikely to be responsive to chemotherapy. Thus, first line treatment should be RPLND.  
1.7 Summary: Management options for clinical stage I non-seminomatous germ cell 
tumor of the testis 
Appropriate treatment of Stage I NSGCT requires knowledge of the risk factors associated 
with recurrence, foresight regarding the likely outcomes and percentages associated with 
the three treatment strategies, the morbidities unique to each modality, and most 
importantly a keen understanding of a patient’s desired approach to this complicated 
problem. Given that all three treatment modalities offer equivalent cure rates, a treatment 
strategy which focuses on minimizing overall morbidity, and approaches the problem in a 
manner which is synergistic with a patient’s wishes, is most likely to be successful. 
2. Management options for clinical stage II and III non-seminomatous germ 
cell tumor of the testis 
Patients with clinical stage II disease have evidence of disease confined to their 
retroperitoneum following radical orchiectomy. Clinical stage III patients have disease 
outside of the retroperitoneum following orchiectomy. Patients with small volume (<5cm) 
stage II disease and normal serum tumor markers post-orchiectomy may be treated with 
either primary RPLND or induction chemotherapy. Patients with “bulky” stage II disease, 
those with persistently elevated serum tumor markers, and all patients with clinical stage III 
disease, require cisplatinum-based chemotherapy. 
2.1 Primary RPLND for low volume clinical stage II disease 
2.1.1 Clinical outcomes of primary RPLND 
As with clinical stage I disease, primary RPLND in low volume clinical stage II disease is 
both a staging and a therapeutic procedure. Following RPLND, further treatment decisions 
are based upon the pathologic stage of disease, regardless of the initial clinical stage at 
presentation. Donohue reported on 174 clinical stage II patients undergoing full, bilateral 
primary RPLND from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1995b) 
Interestingly, 23% of patients originally staged as CS II disease were shown to be pathologic 
stage I disease following primary RPLND. 65% of those patients who were pathologic stage 
II with a nodal mass of less than 5 cm were cured by RPLND alone – that is, did not receive 
adjuvant chemotherapy. Thus patients with clinical stage II disease who are proven to be 
pathologic stage II are cured at roughly the 70% level with surgery alone.  
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2.2 Induction chemotherapy for clinical stage II and III disease 
2.2.1 Clinical outcomes of induction chemotherapy 
All patients with persistently elevated tumor markers post orchiectomy and CS III 
patients should initially be treated with induction chemotherapy. Chemotherapy for germ 
cell tumors is cisplatinum-based, and the specific regimen is dictated by risk classification, 
using the International Germ Cell Cancer Consensus (IGCCC) classification system, which 
assigns risk based on the site of the primary tumor, post-orchiectomy serum tumor 
markers, and the site(s) of metastatic disease (Table 2). ("International Germ Cell 
Consensus Classification: a prognostic factor-based staging system for metastatic germ 
cell cancers. International Germ Cell Cancer Collaborative Group," 1997) Good risk 
patients are treated with 3 courses of bleomycin, etoposide, and cisplatinum (BEP). 
(Culine et al., 2007; Einhorn et al., 1989) In good risk patients over age 50 or with a strong 
smoking history, bleomycin may be omitted and 4 cycles of EP may be given instead. 
(Bosl et al., 1988; Culine, et al., 2007; Xiao et al., 1997) Standard therapy for intermediate 
and poor risk patients is 4 courses of BEP. Randomized trials evaluating high dose 
chemotherapy (HDCT) versus 4 cycles of BEP in poor risk patients as initial therapy failed 
to show an improved outcome in the HDCT arm. (Motzer et al., 2007) Overall, depending 
upon the patient population selected, roughly 70% of patients treated with induction 
chemotherapy for CS II or III disease will obtain a complete clinical response (CR) with 
normalization of serum tumor markers and complete radiographic resolution of all 
metastatic disease.  
 Good Prognosis Intermediate Prognosis Poor Prognosis 














LDH<1.5 x Normal 
upper limit 
AFP 1-10,000 ng/mL 
βhcG 5-50,000IU/L 




LDH>10 x Normal 
upper limit 
Table 2. International Germ Cell Consensus Classification of Non Seminoma 
2.3.1 Post-chemotherapy RPLND following complete response to induction 
chemotherapy 
Following induction chemotherapy for CS II or III disease, patients achieving a CR are 
observed, as the risk of relapse is approximately 5%. (Ehrlich, Brames, Beck, Foster, & 
Einhorn, 2010) Recently, it has been shown that 20-25% of CR patients undergoing PC 
RPLND harbour microscopic teratoma in their retroperitoneum. (Karellas et al., 2007; 
Oldenburg et al., 2003) Thus there has emerged a controversy due to the disconnect between 
the pathologic finding of microscopic teratoma (20-25%) and clinically observed relapse 
rates (5%). The concern for physicians advocating immediate PC RPLND in this population 
is that with longer follow-up, the relapse rate will approach 20-25%. However, at 15 year 
follow-up, the relapse rate remains roughly 5%, thus the data continues to support 
surveillance as an appropriate strategy for CR patients. 
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2.3.2 PC RPLND for residual mass following induction chemotherapy 
It is accepted worldwide that patients with normalization of serum tumor markers and 
persistent retroperitoneal mass following chemotherapy undergo PC RPLND. In this 
population, pathology reveals necrosis in 45%, teratoma in 45%, and active cancer in 10% 
(Toner et al., 1990).  
For patients with necrosis at PC RPLND, surgery is a staging procedure only, and offers no 
therapeutic benefit. Relapse rates are approximately 5%, and no additional chemotherapy is 
required.  
For patients with teratoma at PC RPLND, adjuvant chemotherapy is not given, as teratoma 
is chemotherapy insensitive. Nonetheless, teratoma at PC RPLND requires careful follow-
up, as recurrence rates are not insignificant, and range from 5-20% with increasing size of 
mass. With a median post chemotherapy mass size of 3.0 cm, Memorial Sloan Kettering 
reported disease free survival of 83% at 5-years for resected teratoma. (Carver et al., 2007) In 
this study, patients with residual mass size less than 2 cm, 2 to 5 cm and > 5 cm had 5-year 
probabilities of freedom from recurrence of 94%, 91% and 59%, respectively (p < 0.0005). 
Other authors have had similar results. (Carver, et al., 2007; Loehrer et al., 1986; Svatek et al., 
2009) Investigators from Indiana University recently reported recurrence rates after 
resection of large volume (> 10 cm) teratoma. (S. D.W. Beck, Foster, Bihrle, Donohue, & 
Einhorn, 2007) The 2 and 5-year recurrence free survival for the 99 patients was 86% and 
75%, with a mean follow up of 42 months, suggesting that in large volume masses, 
recurrence rates are also noteworthy. As a result, follow-up of teratoma at PC RPLND need 
include serial abdominal CT scan.  
The presence of active cancer at PC RPLND portends a poor prognosis, and it has been 
standard practice to give two courses of adjuvant chemotherapy. In this population, Spiess 
reported the 5 year disease-free survival rate to be 50%. (Spiess et al., 2007) An international 
study group on testis cancer reported the outcomes of 238 patients with active cancer at PC 
RPLND. Variables predictive of survival included incomplete surgery, viable malignant 
cells > 10% of surgical specimen, and poor or intermediate IGCCC risk category. (Fizazi et 
al., 2001)Patients with no adverse factors experienced a 5-year progression free survival of 
90% compared to 41% for 2 or more risk factors. Furthermore, on multivariate analysis 
postoperative chemotherapy was associated with a significantly better progression free 
survival (p < 0.001), but not overall survival (p = 0.26). Thus, while adjuvant chemotherapy 
does not improve overall survival, it does reduce recurrence rates to 30%, and thereby 
avoids the morbidity of second line chemotherapy for those who do not recur.  
2.3.3 Follow-up after PC RPLND  
PC RPLND follow-up is based upon retroperitoneal pathology. Patients with necrosis are at 
low risk of relapse, and follow-up should include physical exam, serial chest imaging and 
serum tumor markers. Routine abdominal imaging is not necessary in this population. In 
addition to the routine follow-up necessary for necrosis, patients with teratoma are at some 
risk of retroperitoneal relapse, and therefore require serial abdominal CT scans. Follow-up 
for active cancer should be tailored individually, though will include physical exam, serum 
tumor markers, chest X-ray and abdominal imaging.  
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population, pathology reveals necrosis in 45%, teratoma in 45%, and active cancer in 10% 
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For patients with necrosis at PC RPLND, surgery is a staging procedure only, and offers no 
therapeutic benefit. Relapse rates are approximately 5%, and no additional chemotherapy is 
required.  
For patients with teratoma at PC RPLND, adjuvant chemotherapy is not given, as teratoma 
is chemotherapy insensitive. Nonetheless, teratoma at PC RPLND requires careful follow-
up, as recurrence rates are not insignificant, and range from 5-20% with increasing size of 
mass. With a median post chemotherapy mass size of 3.0 cm, Memorial Sloan Kettering 
reported disease free survival of 83% at 5-years for resected teratoma. (Carver et al., 2007) In 
this study, patients with residual mass size less than 2 cm, 2 to 5 cm and > 5 cm had 5-year 
probabilities of freedom from recurrence of 94%, 91% and 59%, respectively (p < 0.0005). 
Other authors have had similar results. (Carver, et al., 2007; Loehrer et al., 1986; Svatek et al., 
2009) Investigators from Indiana University recently reported recurrence rates after 
resection of large volume (> 10 cm) teratoma. (S. D.W. Beck, Foster, Bihrle, Donohue, & 
Einhorn, 2007) The 2 and 5-year recurrence free survival for the 99 patients was 86% and 
75%, with a mean follow up of 42 months, suggesting that in large volume masses, 
recurrence rates are also noteworthy. As a result, follow-up of teratoma at PC RPLND need 
include serial abdominal CT scan.  
The presence of active cancer at PC RPLND portends a poor prognosis, and it has been 
standard practice to give two courses of adjuvant chemotherapy. In this population, Spiess 
reported the 5 year disease-free survival rate to be 50%. (Spiess et al., 2007) An international 
study group on testis cancer reported the outcomes of 238 patients with active cancer at PC 
RPLND. Variables predictive of survival included incomplete surgery, viable malignant 
cells > 10% of surgical specimen, and poor or intermediate IGCCC risk category. (Fizazi et 
al., 2001)Patients with no adverse factors experienced a 5-year progression free survival of 
90% compared to 41% for 2 or more risk factors. Furthermore, on multivariate analysis 
postoperative chemotherapy was associated with a significantly better progression free 
survival (p < 0.001), but not overall survival (p = 0.26). Thus, while adjuvant chemotherapy 
does not improve overall survival, it does reduce recurrence rates to 30%, and thereby 
avoids the morbidity of second line chemotherapy for those who do not recur.  
2.3.3 Follow-up after PC RPLND  
PC RPLND follow-up is based upon retroperitoneal pathology. Patients with necrosis are at 
low risk of relapse, and follow-up should include physical exam, serial chest imaging and 
serum tumor markers. Routine abdominal imaging is not necessary in this population. In 
addition to the routine follow-up necessary for necrosis, patients with teratoma are at some 
risk of retroperitoneal relapse, and therefore require serial abdominal CT scans. Follow-up 
for active cancer should be tailored individually, though will include physical exam, serum 
tumor markers, chest X-ray and abdominal imaging.  
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2.3.4 Summary: Induction chemotherapy and PC RPLND 
Following induction chemotherapy for clinical stage II or III disease, patients with a 
complete response to chemotherapy are most commonly managed with observation. 
Patients with a persistent retroperitoneal mass and negative serum tumor markers routinely 
undergo PC RPLND. 45% of PC RPLND patients will harbor necrosis, with a relapse rate of 
5%. 45% harbor teratoma with relapses ranging from 5-20%, depending on mass size. The 
10% of patients with active cancer in their retroperitoneum at PC RPLND are treated with 
adjuvant chemotherapy to improve disease-free survival. Adjuvant chemotherapy has yet to 
demonstrate improved overall survival in this population. 
2.4 Special considerations in stage II and III disease 
2.4.1 Induction chemotherapy failure 
Patients with disease relapse or disease progression despite first line chemotherapy are 
candidates for salvage therapy. Disease progression may be identified by persistently 
elevated tumor markers or increasing mass size. A minority of such patients will have 
anatomically confined disease that is amenable to surgical resection, and may undergo 
“desperation surgery”. (S. D. Beck, Foster, Bihrle, Einhorn, & Donohue, 2005; Murphy et al., 
1993) For the remaining patients with multifocal disease, treatment options include salvage 
chemotherapy with cisplatin plus ifosfamide plus vinblastine, (Loehrer, Gonin, Nichols, 
Weathers, & Einhorn, 1998) or paclitaxel (Motzer, Sheinfeld, et al., 2000) for four courses, or 
high-dose chemotherapy with autologous hematopoietic stem-cell transplantation to rescue 
the bone marrow from the myeloablative effect of chemotherapy. (Einhorn et al., 2007; 
Motzer, Mazumdar, et al., 2000; Rick et al., 1998) 
2.4.2 Determining the extent of dissection at PC RPLND  
Many patients from the 1970’s and 1980’s undergoing post chemotherapy surgery had high 
volume residual disease and the decision to perform a full, bilateral RPLND was therefore 
rational and appropriate. Since chemotherapy is now being administered for relatively low 
volume retroperitoneal disease, and since these tumors are typically restricted to the 
primary landing zone of the affected testicle, the question has arisen as to the 
appropriateness of full bilateral PC RPLND in this population.  
Proponents of modified dissections note that with appropriate patient selection, the risk of 
extra-template disease and its clinical significance is low. In 1992, investigators from 
Memorial Sloan-Kettering published a series of 113 patients undergoing full bilateral PC 
RPLND, with an 8% incidence of disease (cancer/teratoma) identified in the contralateral 
landing zone. (D. P. Wood, Jr., Herr, Heller, et al., 1992) This cohort all presented with 
“bulky disease”, and were treated with cisplatin- or carboplatin-based chemotherapy. Based 
upon these findings, the authors concluded that a modified dissection should be considered 
in patients with 1) no palpable residual tumor mass, 2) a left primary tumor, or 3) a right 
primary tumor and no evidence of cancer/teratoma on frozen section analysis of the 
residual mass. Fossa et al. reported the results of 87 patients with residual masses less than 
20 mm undergoing modified PC RPLND. (Oldenburg, et al., 2003) Pathology revealed 
necrosis in 67%, teratoma in 26%, and cancer in 7%. Five relapses occurred in this study, 
with no recurrences in the retroperitoneum, indicating that the template of dissection was  
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adequate. Indiana University recently reported outcomes of 100 patients undergoing a 
modified post chemotherapy dissection. (S.D.W. Beck, Foster, Bihrle, & Donohue, 2005) The 
selection criteria included low-volume retroperitoneal disease (< 5 cm) both pre- and 
postchemotherapy, restricted to the primary landing zone of the affected testicle. Pathology 
revealed cancer in 2%, teratoma in 62% and necrosis in 36%. Three patients relapsed, all 
outside the boundaries of a full bilateral dissection, and the 2-year progression free survival 
was 95%. Others have also demonstrated the safety of a modified PC RPLND in select 
patients, (Ehrlich, Yossepowitch, Kedar, & Baniel, 2006; Rabbani et al., 1998) thus it appears 
that a modified dissection may be appropriate in select patients. 
Though limited dissection is appropriate in a subset of patients, the vast majority of patients 
undergoing PC RPLND require a full, bilateral dissection. 
2.4.3 Complicated PC RPLND 
Complicated PC RPLND is defined as: 1) PC RPLND after more than induction 
chemotherapy (“salvage RPLND”), PC RPLND after previous RPLND (“redo RPLND”), or 
PC RPLND in the setting of persistently elevated markers or progression of disease after 
chemotherapy (“desperation RPLND”). (Donohue, et al., 1998) 
Indiana University reported the outcomes of patients undergoing “complicated” RPLND. 
The incidence of active cancer at “salvage” RPLND was 50%, with an overall survival of 
50% to 60%. There appeared to be no benefit with adjuvant chemotherapy in this 
population. Overall survival for the 188 patients undergoing “redo” surgery was 63%. 
Memorial Sloan-Kettering reported a 67% 5-year disease specific survival for 57 patients 
undergoing redo surgery. (McKiernan et al., 2003) Historically, persistent serum tumor 
marker elevation after chemotherapy has been considered a relative contraindication to 
surgery, due to supposed systemic disease and low chance of cure with local therapy alone. 
These “desperation” patients were therefore treated with salvage chemotherapy. Over the 
last 15 years, however, several centers have experienced surgical cures in this population. (S. 
D. Beck, R. S. Foster, R. Bihrle, L. H. Einhorn, et al., 2005; Eastham, Wilson, Russell, 
Ahlering, & Skinner, 1994; Murphy, et al., 1993; D. P. Wood, Jr., Herr, Motzer, et al., 1992) 
Thus, a subset of patients with elevated serum tumor markers after chemotherapy are 
curable with surgery. Approximately 50% of patients undergoing post chemotherapy 
surgery with elevated serum tumor markers are alive at 5-years. Half of these patients are 
found to harbor viable non-teratomatous germ cell tumor, and a third of these are alive at 5-
years. Interestingly, this small subset population observes no benefit from adjuvant 
chemotherapy. Clearly, there is a role for surgery in selected patients with elevated serum 
tumor markers. The decision to proceed with surgery in lieu of second or third line 
chemotherapy involves identifying patients that are unlikely to obtain a complete response 
with systemic therapy, are of acceptable surgical candidacy, are harboring resectable tumors 
which could potentially be curable with negative margins, and following resection are 
offered acceptable morbidity profiles.  
2.4.4 Surgical management of pulmonary extraperitoneal disease 
Selection of patients for pulmonary resection typically includes patients with residual lung 
nodules and normal serum tumor markers after chemotherapy. Much like PC RPLND, 
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chemotherapy with cisplatin plus ifosfamide plus vinblastine, (Loehrer, Gonin, Nichols, 
Weathers, & Einhorn, 1998) or paclitaxel (Motzer, Sheinfeld, et al., 2000) for four courses, or 
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adequate. Indiana University recently reported outcomes of 100 patients undergoing a 
modified post chemotherapy dissection. (S.D.W. Beck, Foster, Bihrle, & Donohue, 2005) The 
selection criteria included low-volume retroperitoneal disease (< 5 cm) both pre- and 
postchemotherapy, restricted to the primary landing zone of the affected testicle. Pathology 
revealed cancer in 2%, teratoma in 62% and necrosis in 36%. Three patients relapsed, all 
outside the boundaries of a full bilateral dissection, and the 2-year progression free survival 
was 95%. Others have also demonstrated the safety of a modified PC RPLND in select 
patients, (Ehrlich, Yossepowitch, Kedar, & Baniel, 2006; Rabbani et al., 1998) thus it appears 
that a modified dissection may be appropriate in select patients. 
Though limited dissection is appropriate in a subset of patients, the vast majority of patients 
undergoing PC RPLND require a full, bilateral dissection. 
2.4.3 Complicated PC RPLND 
Complicated PC RPLND is defined as: 1) PC RPLND after more than induction 
chemotherapy (“salvage RPLND”), PC RPLND after previous RPLND (“redo RPLND”), or 
PC RPLND in the setting of persistently elevated markers or progression of disease after 
chemotherapy (“desperation RPLND”). (Donohue, et al., 1998) 
Indiana University reported the outcomes of patients undergoing “complicated” RPLND. 
The incidence of active cancer at “salvage” RPLND was 50%, with an overall survival of 
50% to 60%. There appeared to be no benefit with adjuvant chemotherapy in this 
population. Overall survival for the 188 patients undergoing “redo” surgery was 63%. 
Memorial Sloan-Kettering reported a 67% 5-year disease specific survival for 57 patients 
undergoing redo surgery. (McKiernan et al., 2003) Historically, persistent serum tumor 
marker elevation after chemotherapy has been considered a relative contraindication to 
surgery, due to supposed systemic disease and low chance of cure with local therapy alone. 
These “desperation” patients were therefore treated with salvage chemotherapy. Over the 
last 15 years, however, several centers have experienced surgical cures in this population. (S. 
D. Beck, R. S. Foster, R. Bihrle, L. H. Einhorn, et al., 2005; Eastham, Wilson, Russell, 
Ahlering, & Skinner, 1994; Murphy, et al., 1993; D. P. Wood, Jr., Herr, Motzer, et al., 1992) 
Thus, a subset of patients with elevated serum tumor markers after chemotherapy are 
curable with surgery. Approximately 50% of patients undergoing post chemotherapy 
surgery with elevated serum tumor markers are alive at 5-years. Half of these patients are 
found to harbor viable non-teratomatous germ cell tumor, and a third of these are alive at 5-
years. Interestingly, this small subset population observes no benefit from adjuvant 
chemotherapy. Clearly, there is a role for surgery in selected patients with elevated serum 
tumor markers. The decision to proceed with surgery in lieu of second or third line 
chemotherapy involves identifying patients that are unlikely to obtain a complete response 
with systemic therapy, are of acceptable surgical candidacy, are harboring resectable tumors 
which could potentially be curable with negative margins, and following resection are 
offered acceptable morbidity profiles.  
2.4.4 Surgical management of pulmonary extraperitoneal disease 
Selection of patients for pulmonary resection typically includes patients with residual lung 
nodules and normal serum tumor markers after chemotherapy. Much like PC RPLND, 
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resection of residual teratoma or active cancer in the pulmonary system can be therapeutic 
and therefore the morbidity of thoracotomy is justified. Conversely, resection of residual 
necrosis is a staging procedure only.  
Efforts to predict pulmonary histology prior to surgical resection have been somewhat 
successful. Excluding series with less than 100 patients, there are 2 retrospective studies 
identifying variables predictive of pulmonary histology. Tognini et al reviewed 143 post 
chemotherapy patients who underwent resection of residual retroperitoneal and chest disease 
under the same anesthetic. (Tognoni et al., 1998) Pathologic concordance between pulmonary 
and retroperitoneal masses existed in 77.5% of patients with necrosis, 70% with teratoma, and 
69% with active cancer. For surgery-naïve patients experiencing normalization of tumor 
markers following first line chemotherapy, a pathologic concordance between pulmonary and 
retroperitoneal masses of 86% for patients with necrosis was seen. An international, 
multicenter, retrospective review evaluated the concordance of retroperitoneal and pulmonary 
histology in 215 patients. (Steyerberg et al., 1997) The strongest predictor of pulmonary 
histology was the histology found at PC RPLND -- if PC RPLND histology revealed necrosis, 
the probability of necrosis at thoracotomy was 89%.  
As such, patients with small pulmonary nodules may be observed with serial chest imaging. 
Masses which enlarge on observation are thus identified, and represent the small proportion 
of patients with residual disease in the form of teratoma (5%) or active cancer (1-4%). Such 
patients could conceivably then undergo surgical resection without a decrease in their 
expected survival rate. In fact, in subgroups with pulmonary nodules and necrosis in the 
retroperitoneum, such an approach would spare more than 90% of patients the morbidity of 
thoracotomy.  
There is no data comparing immediate resection of residual pulmonary nodules versus 
delayed resection upon progression. Decision-making with regard to residual pulmonary 
mass resection must take into account technical feasibility, patient morbidity and potential 
benefit, future access to health care, and of course patient preference. 
2.4.5 Surgical management of nonpulmonary extraperitoneal disease 
NSGCT metastatic to extraperitoneal sites beyond the pulmonary system are quite rare, and 
require specific site-based therapeutic approaches.  
Residual post-chemotherapy mediastinal or neck masses are typically removed either at 
time of RPLND or as a staged procedure.  
Brain metastases occur in 1% of patients, and Cisplatin-based chemotherapy is 
recommended as initial therapy in patients with brain metastases at initial presentation. 
Balmaceda et al reported a 57% complete response rate in 68 patients with brain 
involvement with chemotherapy alone. (Balmaceda et al., 1996) Surgical resection should be 
considered for residual disease. Radiotherapy does not appear to influence survival in this 
select population, and confers considerable morbidity by way of declining functional 
cognitive status. 
Indiana University demonstrated that approximately 70% of resected liver lesions are 
necrosis and the histologic concordance between retroperitoneal histology and liver 
histology is 94.4% for necrosis, 25.9% for teratoma and 38.5% for active cancer. (Jacobsen et 
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al.) With this data in mind, observation of liver metastases should be considered when 
retroperitoneal histology reveals necrosis or when the volume and/or location of the hepatic 
involvement require a significant surgical undertaking. If the mass enlarges on surveillance, 
then surgery or second-line chemotherapy should be considered.  
2.4.6 Management of late relapse  
Late relapse of testis cancer is defined as recurrence of disease later than 2 years after initial 
successful treatment. In a pooled analysis of 5880 patients, late relapse occurred in 119 of 
3704 (3.2%) patients with non-seminoma. The retroperitoneum is the predominant site of 
relapse, followed by the lung, and 70% present with an elevated AFP. About 40% to 50% of 
patients with late relapse are curable, predominantly through surgery, as these tumors are 
by and large chemoresistant. (Baniel, et al., 1995; George et al., 2003)  
2.5 Summary: Management options for clinical stage II and III non-seminomatous 
germ cell tumor of the testis 
Patients with low-volume clinical stage II disease with normal serum tumor markers may 
undergo primary RPLND in lieu of systemic chemotherapy. Surgery alone without 
chemotherapy can cure 50-70% of patients with pathologic stage II disease. The remainder 
are cured with chemotherapy at relapse.  
Patients with elevated serum tumor markers, bulky clinical stage II disease, and all clinical 
stage III patients require induction chemotherapy. 70% of these patients will achieve CR, 
and these patients are observed, as the relapse rate is less than 5%. Patients with 
normalization of serum tumor markers and a persistent retroperitoneal mass routinely 
require PC RPLND. Outcome is dependent upon pathology. 
Patients with more complicated disease require individualized therapy, which may involve 
salvage chemotherapy, surgery, or both. Relapses occurring more than two years since last 
treatment are best approached with surgery. Patients requiring “complicated” PC RPLND, 
presenting with late relapse, or harboring extraperitoneal disease are candidates for referral 
to tertiary centers of considerable experience in these difficult scenarios. 
3. Explanation of terms and abbreviations 
Adjuvant Chemotherapy – A term denoting chemotherapy that is administered after first 
receiving definitive local therapy (such as surgery). This second therapy is given to patients 
under the assumption that micrometastatic disease persists despite the initial local therapy.  
CT A & P – Computed Tomography Scan of the Abdomen and Pelvis. Providing detailed 
information about the size and location of potential sites of metastatic testis cancer in the 
abdomen and pelvis, these scans are the pelvic imaging modality of choice for surveillance 
and investigation of nonseminomatous germs cell tumors. 
CXR – Chest X-ray. A chest imaging modality for the surveillance and investigation of 
patients with nonseminomatous germ cell tumors of the testis. 
Induction Chemotherapy – A term denoting chemotherapy that is administered as initial 
treatment where disease is too advanced for other modalities (such as surgery). 
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resection of residual teratoma or active cancer in the pulmonary system can be therapeutic 
and therefore the morbidity of thoracotomy is justified. Conversely, resection of residual 
necrosis is a staging procedure only.  
Efforts to predict pulmonary histology prior to surgical resection have been somewhat 
successful. Excluding series with less than 100 patients, there are 2 retrospective studies 
identifying variables predictive of pulmonary histology. Tognini et al reviewed 143 post 
chemotherapy patients who underwent resection of residual retroperitoneal and chest disease 
under the same anesthetic. (Tognoni et al., 1998) Pathologic concordance between pulmonary 
and retroperitoneal masses existed in 77.5% of patients with necrosis, 70% with teratoma, and 
69% with active cancer. For surgery-naïve patients experiencing normalization of tumor 
markers following first line chemotherapy, a pathologic concordance between pulmonary and 
retroperitoneal masses of 86% for patients with necrosis was seen. An international, 
multicenter, retrospective review evaluated the concordance of retroperitoneal and pulmonary 
histology in 215 patients. (Steyerberg et al., 1997) The strongest predictor of pulmonary 
histology was the histology found at PC RPLND -- if PC RPLND histology revealed necrosis, 
the probability of necrosis at thoracotomy was 89%.  
As such, patients with small pulmonary nodules may be observed with serial chest imaging. 
Masses which enlarge on observation are thus identified, and represent the small proportion 
of patients with residual disease in the form of teratoma (5%) or active cancer (1-4%). Such 
patients could conceivably then undergo surgical resection without a decrease in their 
expected survival rate. In fact, in subgroups with pulmonary nodules and necrosis in the 
retroperitoneum, such an approach would spare more than 90% of patients the morbidity of 
thoracotomy.  
There is no data comparing immediate resection of residual pulmonary nodules versus 
delayed resection upon progression. Decision-making with regard to residual pulmonary 
mass resection must take into account technical feasibility, patient morbidity and potential 
benefit, future access to health care, and of course patient preference. 
2.4.5 Surgical management of nonpulmonary extraperitoneal disease 
NSGCT metastatic to extraperitoneal sites beyond the pulmonary system are quite rare, and 
require specific site-based therapeutic approaches.  
Residual post-chemotherapy mediastinal or neck masses are typically removed either at 
time of RPLND or as a staged procedure.  
Brain metastases occur in 1% of patients, and Cisplatin-based chemotherapy is 
recommended as initial therapy in patients with brain metastases at initial presentation. 
Balmaceda et al reported a 57% complete response rate in 68 patients with brain 
involvement with chemotherapy alone. (Balmaceda et al., 1996) Surgical resection should be 
considered for residual disease. Radiotherapy does not appear to influence survival in this 
select population, and confers considerable morbidity by way of declining functional 
cognitive status. 
Indiana University demonstrated that approximately 70% of resected liver lesions are 
necrosis and the histologic concordance between retroperitoneal histology and liver 
histology is 94.4% for necrosis, 25.9% for teratoma and 38.5% for active cancer. (Jacobsen et 
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al.) With this data in mind, observation of liver metastases should be considered when 
retroperitoneal histology reveals necrosis or when the volume and/or location of the hepatic 
involvement require a significant surgical undertaking. If the mass enlarges on surveillance, 
then surgery or second-line chemotherapy should be considered.  
2.4.6 Management of late relapse  
Late relapse of testis cancer is defined as recurrence of disease later than 2 years after initial 
successful treatment. In a pooled analysis of 5880 patients, late relapse occurred in 119 of 
3704 (3.2%) patients with non-seminoma. The retroperitoneum is the predominant site of 
relapse, followed by the lung, and 70% present with an elevated AFP. About 40% to 50% of 
patients with late relapse are curable, predominantly through surgery, as these tumors are 
by and large chemoresistant. (Baniel, et al., 1995; George et al., 2003)  
2.5 Summary: Management options for clinical stage II and III non-seminomatous 
germ cell tumor of the testis 
Patients with low-volume clinical stage II disease with normal serum tumor markers may 
undergo primary RPLND in lieu of systemic chemotherapy. Surgery alone without 
chemotherapy can cure 50-70% of patients with pathologic stage II disease. The remainder 
are cured with chemotherapy at relapse.  
Patients with elevated serum tumor markers, bulky clinical stage II disease, and all clinical 
stage III patients require induction chemotherapy. 70% of these patients will achieve CR, 
and these patients are observed, as the relapse rate is less than 5%. Patients with 
normalization of serum tumor markers and a persistent retroperitoneal mass routinely 
require PC RPLND. Outcome is dependent upon pathology. 
Patients with more complicated disease require individualized therapy, which may involve 
salvage chemotherapy, surgery, or both. Relapses occurring more than two years since last 
treatment are best approached with surgery. Patients requiring “complicated” PC RPLND, 
presenting with late relapse, or harboring extraperitoneal disease are candidates for referral 
to tertiary centers of considerable experience in these difficult scenarios. 
3. Explanation of terms and abbreviations 
Adjuvant Chemotherapy – A term denoting chemotherapy that is administered after first 
receiving definitive local therapy (such as surgery). This second therapy is given to patients 
under the assumption that micrometastatic disease persists despite the initial local therapy.  
CT A & P – Computed Tomography Scan of the Abdomen and Pelvis. Providing detailed 
information about the size and location of potential sites of metastatic testis cancer in the 
abdomen and pelvis, these scans are the pelvic imaging modality of choice for surveillance 
and investigation of nonseminomatous germs cell tumors. 
CXR – Chest X-ray. A chest imaging modality for the surveillance and investigation of 
patients with nonseminomatous germ cell tumors of the testis. 
Induction Chemotherapy – A term denoting chemotherapy that is administered as initial 
treatment where disease is too advanced for other modalities (such as surgery). 
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IVC – Inferior Vena Cava. Anatomical term for large vein coursing through 
retroperitoneum, returning venous blood to the right atrium. Metastatic testis cancer 
frequently intimately involved with this structure. 
PC RPLND – Post-chemotherapy retroperitoneal lymph node dissection. Surgical procedure 
to remove all lymphatic tissue in the retroperitoneal space which lies between the ureters, 
superior to the common iliac vessels, and inferior to the crus of the diaphragm, performed 
after patient has received chemotherapy.  
RPLND – Retroperitoneal lymph node dissection. Surgical procedure to remove all 
lymphatic tissue in the retroperitoneal space which lies between the ureters, superior to the 
common iliac vessels, and inferior to the crus of the diaphragm. 
Salvage Chemotherapy – A term denoting chemotherapy given after relapse or progression of 
disease, despite prior induction chemotherapy  
STM – Serum tumor markers. In nonseminomatous germ cell tumor of the testis, the most 
important markers are alpha fetoprotein (AFP), the beta subunit of human chorionic 
gonadotropin (βhCG) and lactate dehydrogenase (LDH). These proteins are easily isolated 
from blood samples, and are highly reliable in terms of their ability to quantify disease 
burden and/or assess response to therapy. 
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retroperitoneum, returning venous blood to the right atrium. Metastatic testis cancer 
frequently intimately involved with this structure. 
PC RPLND – Post-chemotherapy retroperitoneal lymph node dissection. Surgical procedure 
to remove all lymphatic tissue in the retroperitoneal space which lies between the ureters, 
superior to the common iliac vessels, and inferior to the crus of the diaphragm, performed 
after patient has received chemotherapy.  
RPLND – Retroperitoneal lymph node dissection. Surgical procedure to remove all 
lymphatic tissue in the retroperitoneal space which lies between the ureters, superior to the 
common iliac vessels, and inferior to the crus of the diaphragm. 
Salvage Chemotherapy – A term denoting chemotherapy given after relapse or progression of 
disease, despite prior induction chemotherapy  
STM – Serum tumor markers. In nonseminomatous germ cell tumor of the testis, the most 
important markers are alpha fetoprotein (AFP), the beta subunit of human chorionic 
gonadotropin (βhCG) and lactate dehydrogenase (LDH). These proteins are easily isolated 
from blood samples, and are highly reliable in terms of their ability to quantify disease 
burden and/or assess response to therapy. 
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CNS GCTs are histologically classified into several histological subtypes, i.e. germinoma, 
teratoma (mature teratoma, immature teratoma, teratoma with malignant transformation), 
embryonal carcinoma, yolk sac tumor and choriocarcinoma [3, 4], and some are composed 
of a mixture of these subtypes. Germinomas are the most frequent histological subtype, 
followed in order by teratomas, choriocarcinomas, embryonal carcinomas and yolk sac 
tumors. Mixtures of these tumors are also common, and in fact one third of intracranial 
germ cell tumors are of mixed types. Among these, germinomas show typical histological 
patterns, being similar to dysgerminoma of the ovary or seminoma of the testis. They are 
composed of large round cells and small lymphocytes, thus their histological feature is 
known as the “two cell pattern”.  
The most frequently affected site is the pineal gland, followed by the neurohyphophyseal 
(or “suprasellar”) region (Figure 2). However, these tumors can also arise in the basal 
ganglia or any other intracranial location. 
 
Fig. 2. Location and distribution of histological subtypes (according to Matsutani et al. (2)). 
Although, biologically, all intracranial germ cell tumors, except for mature teratomas, are 
malignant, their clinical characteristics differ. Germinomas respond well to chemo-
radiotherapy and their prognosis is relatively good. Mixed tumors composed of any type of 
teratoma and germinoma are also responsive to appropriate forms of combined therapy 
including surgery, radiation and/or chemotherapy, and thus their prognosis is better than 
that of other histological subtypes such as embryonal carcinoma, yolk sac tumor, 
choriocarcinoma or their mixtures (the so-called “poor prognosis” group), which require 
more intensive forms of chemo-radiotherapy [5, 6]. For this reason, accurate differential 
diagnosis of these histological subtypes is very important in a clinical setting. 
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2. Modalities important for diagnosis of CNS GCTs 
Although pathological diagnosis by biopsy is essential for the planning of appropriate 
treatment for CNS GCTs, tentative histological diagnosis also plays a significant role in 
deciding the optimal surgical strategy. In this connection, both neuroimaging and 
assessment of tumor markers are important. Some CNS GCTs produce tumor markers that 
are helpful for indicating the histological subtype (Table 1). Typically, choriocarcinoma 
produces the beta-subunit of human chorionic gonadotropin (-hCG) whereas yolk sac 
tumor produces alpha-fetoprotein (-FP). If the serum level of -hCG alone is elevated to 
more than 500 mIU/ml, or if that of -FP alone is elevated to more than 500 ng/mL, then 
pure choriocarcinoma or yolk sac tumor is considered highly likely, respectively. The levels 
of markers associated with mixed germ cell tumors may vary according to the histological 
elements present. These tumor markers, together with the neuroimaging features discussed 
later, allow the histological subtypes of CNS GCTs to be assessed before surgery. As is the 
case for other CNS neoplasms, etiologic factors such as tumor location and patient age are 
also helpful for accurate diagnosis. As mentioned previously, the pineal gland is one of the 
most frequent sites for CNS GCTs. If a tumor is found in the pineal region in a teenage boy, 
it is highly likely to be a CNS GCT. Other tumors can arise in this region, but at a lower 
frequency in this age group. More detailed diagnosis should be made on the basis of 
neuroimaging features, together with tumor markers. 
 
Table 1. Tumor markers and histological subtypes 
2.1 MRI and CT features of CNS GCTs 
2.1.1 Pineal tumors 
For tumors in the pineal gland in children or young adults, differential diagnoses are 
limited. Although many CNS tumors can occur in this location, those that apparently arise 
within the pineal gland itself are limited. Many tumors, such as meningiomas, gliomas or 
ependymomas, can occur in the pineal region, but they extend from neighboring structures 
and do not arise in the pineal gland itself. Most pineal tumors in the true sense are CNS 
GCTs or pineal parenchymal tumors, i.e. pineocytoma, pineal parenchymal tumor of 
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intermediate differentiation, or pineoblastoma. All of these tumors can cause obstructive 
hydrocephalus due to compression to the aqueduct. Thus, the initial symptoms and 
neuroimaging finding of pineal CNS GCTs often reflect increased intracranial pressure due 
to hydrocephalus (Figure 3). 
 
Fig. 3. Computed tomography (CT) scans of a pineal germinoma on admission. Marked 
hydrocephalus is evident together with the pineal mass.  
Among CNS GCTs, germinomas and teratomas each show a peculiar pattern. Germinomas 
show slightly high to high density on plain (non-enhanced) CT scans. The border is clear 
where the tumor faces the cerebrospinal fluid space (cistern or ventricle), but somewhat 
obscure where the tumor faces the brain parenchyma. These tumors show marked 
homogeneous enhancement with contrast media [7-9]. Small intratumoral cysts may be 
present [9], and calcifications within the tumor are frequently evident [10, 11]. On T1-
weighted MRI (the most basic MRI scanning), they appear as a well demarcated mass with a 
slightly low signal intensity. On T2-weighted images (which is another basic MRI scanning 
and in which tissues containing more water molecules show high signal) the germinomas 
show slightly high intensity (Figure 4) [9, 12-14]. Teratomas appear as heterogeneous 
masses, since they contain many histological elements [9, 12, 14]. CT shows that they are 
well demarcated, containing multiple small and large cysts and some calcifications. The 
entire tumor, or some part of it, may be well enhanced [9]. Teratomas sometimes contain 
fatty tissue, which is well detected by MRI, showing high signal intensity on both T1- and 
T2-weighted images. If such fatty tissues are detected by MRI, the tumor is highly likely to 
be a teratoma, or at least to contain a teratomatous component [9, 14]. On MRI, teratomas are 
well enhanced with gadolinium, except for cystic components (Figure 5). As mentioned above, 
teratomas may be benign or contain immature elements or malignant components. When the 
tumor’s growth rate is high, perifocal edema may be detected on T2-weighted images [15]. 
 




Fig. 4. Pineal germinoma in an 18-year-old boy. (A) CT scan shows a slightly high-density 
mass in the pineal region, together with a cyst and some calcifications. A ventricular drainage 
tube is inserted into the posterior horn of the right lateral ventricle. The tumor shows slightly 
low signal intensity on the T1-weighted image (B) and slightly high signal intensity on the T2-
weighted image (D). The tumor is homogeneously well enhanced by gadolinium (C). 
Other malignant subtypes are difficult to diagnose on the basis of neuroimaging features 
alone, but certain tendencies are evident for some tumors; yolk sac tumors tend to be 
irregular in shape, and unlike germimonas, show isodensity or slightly low density by non-
enhanced CT [9]. Occasionally, the onset of choriocarcinoma may be accompanied by 
intracranial bleeding (Figure 6). In young adult or pediatric patients presenting with 
intraventricular hemorrhage, the possible presence of occult choriocarcinoma other than 
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cerebrovascular conditions such as arteriovenous malformation should be considered. As 
mentioned above, measurement of the serum -hCG level is helpful in this situation. These 
malignant subtypes or mixed germ cell tumors with these elements are more aggressive 




Fig. 5. Mixed germ cell tumor composed of immature teratoma and yolk sac tumor. The 
tumor contains calcification and fatty tissue. The low-density area evident on CT (white 
arrow, A) or the area of high signal intensity (white arrow, B) on the T1-weighted image 
indicates the presence of fatty tissue. The tumor is heterogeneously enhanced (C). The T2-
weighted image also shows a heterogeneous pattern (D).  
 




Fig. 6. A 16-year-old boy who was admitted in a comatose state. CT scans show 
intraventricular hemorrhage with hydrocephalus. The level of beta-hCG was markedly 
elevated. The diagnosis of choriocarcinoma was confirmed by biopsy three weeks later. 
 
Fig. 7. A 26-year-old woman with a pineal parenchymal tumor showing intermediate 
differentiation. The tumor extends to the quadrigeminal and supracerebellar cisterns. 
Pineal parenchymal tumors are rare, and reports on their neuroimaging features are limited. 
However, CT scan can often detect calcifications, and the pattern differs from that of germ 
cell tumors. Such calcifications correspond to an “exploded” pattern of preexisting pineal 
calcification, whereas those of germinomas are included within the tumor [10]. On MRI, 
differentiation between CNS GCTs and pineal parenchymal tumors is difficult [15]. For 
example, pineocytoma also shows slightly high signal intensity on T2-weighted images. 
However, pineoblastoma, the most malignant form of pineal parenchymal tumor, shows a 
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signal that is iso-intense with gray matter on T2-weighted images, and invades into 
surrounding structures [15]; perifocal edema may also be present. If a tumor extends 
expansively to fill the quadrigeminal to supracerebellar cistern frontal to the cerebellar culmen, 
it may be a pineal parenchymal tumor rather than a germ cell tumor (Figure 7) [13, 15]. 
2.1.2 Tumors of the neurohypophyseal region 
The neurohypophysis or suprasellar area is the second-most frequent site for CNS GSTs. The 
basic neuroimaging characteristics of CNS GSTs in this location are not different from those of 
pineal ones in terms of density or signal intensity, enhancement pattern, and so on (Figure 8). 
However, calcification demonstrated by CT is somewhat different, as there is no “preexisting 
pineal calcification” in this area. Other tumors such as pituitary adenoma and 
craniopharyngioma, or inflammatory diseases such as Langerhans cell histiocytosis (LCH), can 
arise here [16, 17]. Most CNS GCTs arise from the pituitary stalk or hypothalamic area, 
whereas pituitary adenomas occur within the pituitary gland itself. Moreover, pituitary 
adenomas are relatively rare in the pediatric population. For these reasons, there is generally 
no problem in recognizing pituitary adenomas. However, differentiation between CNS GCTs 
and some of the other tumors mentioned above is sometimes not so easy. Any tumor showing 
multiple cysts and calcifications in this area might be a teratoma or a craniopharyngioma [18]. 
However, teratomas arise more often in the pineal region than in the neurohypophysis. 
Matsutani et al. reported that among 153 CNS GCTs, only 4 teratomas arose in the 
neurohypophyseal region.[2]. The incidence of CNS GCTs in the pediatric population is 15% 
or less [1]. Thus the frequency of neurohypophyseal teratoma among all pediatric brain 
tumors might be around 0.4%. In contrast, the incidence of craniopharyngioma in the pediatric 
population is around 9% [1]. Thus a tumor with multiple cysts and calcifications is 20 times 
more likely to be a craniopharyngioma. Inflammatory diseases in this location, for example 
LCH, are sometimes difficult to differentiate from small CNS GCTs [19].  
 
Fig. 8. Neurohypophyseal germinoma in a 12-year-old girl. A large tumor is evident in the 
basal cistern. The tumor shows slightly low signal intensity on the T1-weighted image (A) 
and slightly high signal intensity on the T2-weighted image (B). A coronal image after 
enhancement shows that the tumor is well enhanced. 
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Sometimes “bifocal” tumors arise in the neurohypophysis and pineal region (Figure 9). Most 
of these tumors are germinomas [20], but other histological subtypes of CNS GCT have also 
been reported [21]. As other central nervous system tumors rarely present this “bifocal” 
pattern, it is strongly suggestive of CNS GCT, especially germinoma. 
 
Fig. 9. A “bifocal” pattern germinoma is demonstrated on an enhanced sagittal image.  
2.1.3 Other locations 
Although CNS GCTs sometimes affect the basal ganglia, the neuroimaging features of GCTs 
in this location differ from those at other locations. Most CNS GCTs affecting the basal 
ganglia are germinomas, and are invasive. They show no mass effect or enhancement, 
initially [22-26]. Slightly high signal intensity on FLAIR or T2-weighted images is sometimes 
the only prominent finding. Thus, diagnosis at this stage is often difficult, and may be 
delayed even if a patient has undergone neuroimaging at an earlier stage. Later, the tumor 
may show exhibit a mass effect, enhancement, or even cysts. Tumor invasion to the 
pyramidal tract can cause hemiparesis. Hemiatrophy of the cerebral peduncle due to 
pyramidal tract impairment can be observed in patients with long-standing neurological 
symptoms (Figure 10) [24]. 
2.1.4 Spinal images 
Occasionally, but not rarely, a tumor may show dissemination via the cerebrospinal fluid at 
initial presentation (Figure 11). Therefore, once a CNS GCT is suspected, enhanced MRI of 
the whole spine should be conducted. 
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signal that is iso-intense with gray matter on T2-weighted images, and invades into 
surrounding structures [15]; perifocal edema may also be present. If a tumor extends 
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Fig. 10. Germinoma in the basal ganglia of a 21-year-old man. A gadolinium-enhanced MR 
image at initial presentation was diagnosed as normal, although the patient presented with 
slight left hemiparesis (A). Eight months later, enhanced MRI demonstrated slight 
enhancement (B), and biopsy confirmed the diagnosis of germinoma (B). The tumor was 
well controlled after chemo-radiotherapy, but the patient remained hemiparetic. 
Hemiatrophy of the cerebral peduncle was evident after 12 years (C). 
 
Fig. 11. MRI scans obtained at initial presentation, showing dissemination along the 
cerebrospinal fluid or subpial space in an 18-year-old boy (A) and a 13-year-old boy (B). 
2.2 Other modalities for neuroimaging of CNS GCTs 
Recently, more advanced techniques such as magnetic resonance spectroscopy (MRS) or 
positron emission tomography (PET) have been employed for diagnosing CNS diseases. 
Although reports on imaging of CNS GCTs using advanced techniques such as PET or MRS 
are limited, some have indicated the usefulness of these modalities for diagnosis or decision-
making in a clinical setting. Increased tracer uptake has been demonstrated using both 
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methionine-PET (MET-PET) and fluorodeoxyglucose-PET (FDG-PET) in patients with 
germinomas. However, FDG-PET does not demonstrate increased uptake in some 
germinomas [22, 27]. For invasive tumors in the basal ganglia, Kawai et al. reported that 
they were able to decide an appropriate biopsy point on the basis of MET-PET images when 
the exact location of the tumor was unclear in usual MRI or CT images.[23] 
On the basis of a MRS study, Harris et al. described that CNS GCTs have a high lipid and 
macromolecule (LMM) concentration in comparison with other brain tumors. They also 
detected taurine in germinomas and pineal parenchymal tumors [28]. Although at a 
preliminary stage of evaluation, MRS seems to be an interesting modality for diagnosis of 
CNS GCTS. 
3. Conclusion 
Through detailed interpretation of neuroimaging findings, together with tumor markers and 
other demographic clinical information, it is possible to determine the histological subtypes 
of CNS GCTs. With advanced imaging techniques, further improvement of diagnostic 
accuracy may be achievable, together with better understanding of the detailed biological 
characteristics of CNS GCTs. 
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1. Introduction 
Testicular Germ Cell tumours (TGCTs) account for between 1% and 1.5% of male neoplasms 
and 5% of urological tumours in general, with 3-10 new cases occurring per 100,000 
males/per year in Western society (1-3). Testicular germ cell tumours (TGCTs) are the most 
frequent solid tumour of Caucasian adolescents and young adult males and are a diverse 
group of neoplasms that can also present in extragonadal sites. Within Europe, there has 
been a general increase in the incidence of TGCTs noted initially in the 1970s and 1980s (4). 
Over recent years the incidence of TGCTs has risen markedly, making it imperative to 
understand how and why these tumours arise. 
In this book chapter we present the incidence and clinical presentation, classification, 
epidemiology and aetiology, molecular developments, tumour markers, staging, 
management strategies including the role of chemotherapy, radiotherapy and 
Reteroperitoneal lymph node dissection (RPLND) and follow up protocol followed in the 
United Kingdom (UK) and Europe as per the 2011 European Association of Urology (EAU) 
guidelines.  
2. Incidence and clinical presentation 
Testicular Germ Cell tumours (TGCTs) are broadly divided into Seminomas, which 
resemble primordial germ cells (PGCs) and Non-Seminoma, which are either 
undifferentiated (embryonal carcinoma) or differentiated (exhibiting a degree of embryonic 
(teratoma) or extra-embryonic (yolk sac choriocarcinoma) pattern (5). The commonest age 
range of presentation of TGCTs is between 20-45 years. Patients rarely tend to be younger 
than 15 years or older than 60 years. Based on the type of TGSTs, Seminomas typically arise 
later in life, with a mean age at presentation of 35 years of age compared with 25 years of 
age for non-seminomas. Although these morphologies and differences in age at presentation 
could suggest underlying differences between seminomas and non-seminomas, several lines 
of evidence support a common underlying pathogenesis. Approximately 15% of TGCTs are 
mixed tumours that contain both seminoma and non-seminoma elements (6). 
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could suggest underlying differences between seminomas and non-seminomas, several lines 
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mixed tumours that contain both seminoma and non-seminoma elements (6). 
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The commonest presentation of TGCTs is a painless unilateral mass in the scrotum when the 
patient feels the mass itself. In other situations the patient has an incidental mass diagnosed 
when presenting with other symptoms of a concomitant testicular pathology such as 
epididymitits. It is interesting to note that 10% of patients presenting with epididymitis 
present can present with a TGCTs (1, 2). Another common symptom of presentation is 
testicular pain (1) seen in up to 20% of patient with TGCTs. In certain cases up to 27% of 
patients have local pain which could be attributed to a degree of local invasion (1). Up to 1-
2% of TGCTs present bilaterally. Paraneoplastic symptoms such as gynaecomastia can be 
seen in up to 7% of patients at initial presentation. Additional symptoms include lower back 
pain and loin pain (1, 2). 
When a patient presents with a testicular mass it is extremely important to elicit a detailed 
history which includes duration of symptoms, whether the mass is painful or painless, change 
in size of mass, sexual history, concomitant lower urinary tract symptoms, previous history of 
surgery, infertility or mumps and family history of testicular cancer. There is evidence to 
suggest that delay in presentation is more of a problem than delay in referral and this has 
prompted some authors to suggest that a public education campaign might be helpful (7,8). 
The radiological investigation of choice for testicular cancer is an ultrasound throughout 
Europe. The main advantage lies with the fact that an ultrasound is non radiation exposure 
scan and is relatively inexpensive. The current sensitivity and specificity of an ultrasound of 
testis is 100% (9). In patients with an equivocal diagnosis a Magnetic resonance imaging 
(MRI) offers a sensitivity of 100% and a specificity of 95-100% (10), but its high cost does not 
justify its use for diagnosis. 
3. Classification 
As the 2011 European Association of Urology (EAU) guidelines testicular cancer is classified 
according to the 2004 World health organization (WHO) guidelines (11). From the perspective 
of this book chapter we will confine our discussion to Testicular Germ Cell Tumours only. 
1. Germ cell tumours 
 Intratubular germ cell neoplasia, unclassified type (IGCNU) 
 Seminoma (including cases with syncytiotrophoblastic cells) 
 Spermatocytic seminoma (mention if there is sarcomatous component) 
 Embryonal carcinoma 
 Yolk sac tumour 
 Choriocarcinoma 
 Teratoma (mature, immature, with malignant component) 
 Tumours with more than one histological type (specify percentage of individual 
components) 
2. Sex cord/gonadal stromal tumours 
 Leydig cell tumour 
 Malignant Leydig cell tumour 
 Sertoli cell tumour 
 lipid-rich variant 
 sclerosing 
 large cell calcifying 
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 Malignant Sertoli cell tumour 
 Granulosa cell tumour 
 adult type 
 juvenile type 
 Thecoma/fibroma group of tumours 
 Other sex cord/gonadal stromal tumours 
 incompletely differentiated 
 mixed 
 Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma) 
3. Miscellaneous non-specific stromal tumours 
 Ovarian epithelial tumours 
 Tumours of the collecting ducts and rete testis 
 Tumours (benign and malignant) of non-specific stroma. 
4. Epidemiology and aetiology 
The Epidemiology and Aetiology of TGCTs has evolved over the past two decades.  
4.1 Age 
In the paediatric population i.e., patients ≤ 16 years, the commonest form of Testicular 
Tumours are Mature teratomas, rhabdomyosarcoma, epidermoid cyst, yolk sac and germ 
cell tumours. The commonest age group of patients affected with TGCTs is between 20-45 
years. Teratomas are common between the age of 20-35 years while seminomas are more 
common between the ages of 25-45 years. In men above the age of 60 years the commonest 
tumour is a lymphoma.  
4.2 Cryptorchidism 
When patients present with cryptorchidism, there is risk of development of testicular 
tumour on both the effected side and contralateral side in the long term. The risk of TGCT in 
the Undescended Testis (UDT) is increased by 4 - 13 , with up to 7-10% of Testicular Cancers 
developing in UDT (12). There is a 5-10% risk of developing testicular cancer in the 
contralateral testis in those with a history of UDT (13). Premalignant changes within the 
UDT commence by the age of 3 years. However, an early orchidopexy does not completely 
eliminate the risk of developing testicular cancer in the long term. 
4.3 Intratubular Germ Cell Neoplasia (IGCNU) 
Intratubular germ cell neoplasia (IGCNU) is also known as carcinoma in situ (CIS) of the 
testis. The incidence of IGCNU in the overall population is 0.9%. Intratubular germ cell 
neoplasia is defined as a pre-invasive testicular germ cell lesion and is now believed an 
important precursor of TGCTs. The only TGCT not associated with IGCNU is a 
spermatocytic seminoma. When IGNU is present, the probability of progression to TGCTs 
increases by 50% over a duration of 5 years. At 7 years, the cumulative probability of 
developing a TGCTs increased to 70% (14).  
The incidence of IGCNU is the contralateral testis in patients with TGCTs is 5-9%. The 
incidence however rises to 34% when the primary TGCTs has been diagnosed before the age 
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The commonest presentation of TGCTs is a painless unilateral mass in the scrotum when the 
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of 40 years and the testicular volume is less than 12 ml. In both the above mentioned 
scenarios , the EAU guidelines recommends a biopsy of the contralateral testis. It is 
important to note that the presence of IGCNU in the ipsilateral testis does not have any 
bearing on the patients overall prognosis. Risk factors for IGCNU include cryptorchidism 
(UDT), extra-gonadal germ cell tumour, previous or contralateral TGCT (5%), atrophic 
testicle with a volume of less than 12 ml, early age of diagnosis of TGCTs i.e., ≤ 40 years, 
45XO karyotype, Klinefelter's syndrome and infertility. Once IGCNU is diagnosed, local 
radiotherapy is the treatment of choice in solitary testis. Because this may produce 
infertility, the patient must be carefully counselled before treatment commences.  
4.4 Maternal oestrogen exposure 
Maternal Oestrogen Exposure (MOE) increases during pregnancy and hence increases the 
risk of crytorchidism and TGCT in the male offspring. The MOE with diethylstilboestrol 
increases the risk of TGCTs by a relative risk of 2.8 - 5.3% (13). 
4.5 Subfertility 
A history of subfertility and poor quality semen analysis increases the risk of testicular 
cancer by upto 1.6 times and from the Surveillance Epidemiology and End Results database 
by 20 times (14) . 
4.6 Family history 
Familial history of testicular tumours among first-grade relatives (father/brothers) has been 
associated with isochromosome of the short arm of chromosome 12 – i(12p) (15).  
4.7 Additional factors 
Additional factors such as tallness, previous history of Marijuana exposure, vasectomy, 
trauma, mumps and Human Immunodeficiency Virus (HIV) infection continue to be 
evaluated (13-15). 
5. Genetic and cellular markers 
Current research has indentified deregulation in the pluripotent programme of fetal germ 
cells (identified by specific markers such as M2A, C-KIT and OCT4/NANOG) is probably 
responsible for the development of IGCNU and germ cell neoplasia. There is overlap in the 
development to seminoma and embryonal carcinoma as shown by genomewide expression 
analysis and detection of alpha-fetoprotein (AFP) mRNA in some atypical seminoma 
(16,17).Continued genome wide screening studies and gene expression analysis data suggest 
testis cancer specific gene mutations on chromosomes 4, 5, 6 and 12 (namely expressing 
SPRY4, kit-Ligand and Synaptopodin) (18-20). Intratubular germ cell neoplasia shows 
alterations in the p53 in upto 66% of cases.  
Newer developments continue to be made with regards to further molecular profiling of 
TGCTs. The current molecular developments include characterization of newer markers 
such as MAGEC2 expression. This newer marker allows a reliable distinction of seminoma 
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from embryonal carcinomas. Therefore, MAGEC2 represents an additional tool for the 
differential diagnosis of testicular germ cell tumours (21). 
6. Serum markers for TGCTs 
For the successful management of TGCTs it is crucial to understand the molecular details, 
half lives and clinical applications of testicular tumour markers. In clinical practice with 
Europe and the UK, the three common tumour markers used include Alpha-fetoprotein 
(AFP), β- human chorionic gonadotrophin (β-HCG) and lactate dehydrogenase (LDH). All 
testicular tumour markers contribute to the patients diagnosis and more importantly to the 
final prognosis. When a patient is diagnosed with a TGCTs, tumour markers will be 
elevated in 51% of cases (22).  
Alpha-fetoprotein (AFP) is expressed by trophoblastic elements within 50-70% of non-
seminomatous germ cell tumour (NSGCT) and yolk sac tumours. In patients with an 
elevated AFP with Seminoma alone, this raises the suspicion of the presence of Non-
seminomatous elements. The half life of AFP is 5-7 days and the normal serum levels are 
<10 ng/ml. β- human chorionic gonadotrophin (β-HCG) is produced by syntiotrophoblast 
elements. In patients with choriocarcinomas , β-HCG is elevated in 100% of cases. From the 
perspective of other TGCTs, β-HCG is elevated in 40% of cases of NSGCT and 10% of 
Seminomas. The half life of β-HCG is 24-36 hours and normal serum levels are < 5mIU/ml. 
About 90% of non-seminomatous tumours present with a rise in one or two of the markers. 
Lactate dehydrogenase (LDH) is a less specific marker and is an ubiquitous enzyme 
elevated in serum from various causes, therefore is less specific. It is elevated in 10-20% of 
seminomas but may be elevated in 80% of patients with advanced testicular cancer (23). 
Other markers studied include Placental alkaline phosphatase (PLAP), which may be of 
value in monitoring patients with pure seminoma. placental alkaline phosphatase (PLAP) is 
a foetal enzyme and may be falsely elevated in smokers. Cytogenetic and molecular markers 
are available in specific centres, but at present only contribute to research studies. 
Measurement of serum AFP, hCG and LDH is mandatory, while that of PLAP is optional. 
Testicular tumour serum markers are normally measured when a patient presents with a 
TGCT clinically. In Europe the Testicular tumour markers are measured 1-2 weeks following 
radical orchidectomy. The testicular tumour markers play an important role in assessing 
response to treatment and follow up. The presence of normal testicular tumour markers 
prior to orchidectomy does not normally exclude the presence of micrometastatic disease. 
However, the persistence of testicular tumour markers following post radical inguinal 
orchidectomy may occur in patients with hepatic dysfunction, hypogonadotropism and 
most importantly in metastatic disease.  
It is also important to note that other malignancies may cause an elevation of testicular 
tumour markers. Liver, pancreatic, gastric and lung malignancies may cause an elevated 
AFP level. Pancreatic, liver, gastic, lung, breast, kidney and bladder cancer may cause an 
elevated β-HCG level. Prior to commencing chemotherapy all tumour markers must be 
performed to classify patients according to the International Germ Cell Cancer Collaborative 
Group (IGCCCG) risk classification. 
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Once a patient is diagnosed with a TGCTs the patient is staged with a through history and 
clinical examination. In the patients history it is important to ask the following questions 
with regards to the testicular lump. The crucial points in the history include the duration of 
symptoms, whether the lump is painful or painless, change in size of the lump, previous 
surgical history of UDT, sexual history , history of lower urinary tract symptoms and family 
history. Clinical examination includes assessment of supraclavicular lymph node, chest 
examination and abdominal examination for inguinal lymph nodes. At this stage a full set of 
Testicular tumour markers is performed which includes serum AFP, β-hCG and LDH is 
mandatory, while that of PLAP is optional. In cases of disseminated disease and life-
threatening metastases, it is current practice to start with up-front chemotherapy, and 
orchidectomy may be delayed until clinical stabilisation has occurred. 
In patients with a suspected testicular mass a radical inguinal orchidectomy is performed. 
The main principal of this procedure lies with exteriorisation of the testicle within its tunics. 
Prior to mobilization of the testis and cord, the cord is isolated and clamped to allow control 
of the draining lymphatics in order to minimize spillage and metastatic spread. If the 
diagnosis is not clear, a testicular biopsy (an enucleation of the intraparenchymal tumour) is 
taken for frozen section histological examination.  
When the testicle is sent for pathological analysis, the EAU 2011 guidelines recommend a 
mandatory assessment of the specimen for the following features as these features further 
help prognosticate the patients outcome. The features include :- 
1. Macroscopic features: side, testis size, maximum tumour size, and macroscopic features 
of epididymis, spermatic cord, and tunica vaginalis. 
2. Sampling: a 1 cm2 section for every centimetre of maximum tumour diameter, including 
normal macroscopic parenchyma (if present), albuginea and epididymis, with selection 
of suspected areas. At least one proximal and one distal section of spermatic cord plus 
any suspected area. 
3. Microscopic features and diagnosis: histological type (specify individual components 
and estimate amount as percentage) according to WHO 2004 (11):- 
a. Presence or absence of peri-tumoural venous and/or lymphatic invasion; 
b. Presence or absence of albuginea, tunica vaginalis, rete testis, epididymis or spermatic 
cord invasion; 
c. Presence or absence of intratubular germ cell neoplasia (IGCNU) in non-tumour 
parenchyma intratubular germ cell neoplasia. 
d. pT category according to Tumour Node Metastasis (TNM) 2009. 
e. Immunohistochemical studies: in seminoma and mixed germ cell tumour, AFP and 
hCG. 
Following radical inguinal orchidectomy, the main aim of clinical staging is to determine 
whether the patient has metastatic or occult disease at the time of presentation. The 
investigations of choice to determine the above and accurately stage the TGCTs at 
presentation include the post-orchidectomy half-life kinetics of serum tumour markers; the 
status of retroperitoneal and supraclavicular lymph nodes, and the liver; the presence or 
absence of mediastinal nodal involvement and lung metastases; the status of brain and bone, 
if any suspicious symptoms are present. At this point all patients must have a serial 
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testicular tumour markers measured and a thorough assessment of the retroperitoneum 
staging CT of the Chest, Abdomen and Pelvis. Retroperitoneal and mediastinal lymph 
nodes are best assessed by means of a CT scan. The supraclavicular nodes are best assessed 
by physical examination.  
Hence, in Europe and the UK all patients with newly diagnosed TGCTs have the following 
invesigations performed:- 
a. Serum testicular tumour markers (AFP, β-hCG and LDH) 
b. CT - Chest, Abdomen and Pelvis 
c. Ultrasound Testis (Bilateral) 
A bone scan is organized in patients with suspected advances metastatic disease. A Brain CT 
is organized in patients In case of symptoms and patients with metastatic disease with 
multiple lung metastases and high beta-hCG levels. In some centre a detailed hormonal 
profile (Serum Testosterone, FSH, LH) and semen analysis is performed. 
In all patients undergoing a radical inguinal orchidectomy it is important to counsel patients 
on the options of sperm banking and insertion of a testicular prosthesis. The 2011 EAU 
guidelines recommend cryopreservation of sperm prior to orchidectomy. This should be 
specifically offered in all patients with a history of Subfertility and atropic contralateral 
testis. In patients keen to pursue the insertion of a testicular prosthesis at the time of an 
inguinal orchidectomy, the risk of a possible delay to chemotherapy secondary to prosthesis 
related infection (0.6-2%) (24) must be highlighted. 
7.1 Staging and prognostic classifications 
The staging system recommended in these guidelines is the 2009 TNM of the International 
Union Against Cancer (UICC) (25) include the following parameters :- 
a. Determination of the anatomical extent of disease 
b. Assessment of serum tumour markers, including nadir values of hCG, AFP and LDH 
after orchidectomy (S category) 
c. Clear definition of regional nodes 
d. N-category modifications related to node size 
The 2009 TNM of the International Union Against Cancer (UICC) is summarized in Table 1. 
1. pT Primary tumour 
pTX Primary tumour cannot be assessed  
pT0 No evidence of primary tumour (e.g. histological scar in testis) 
pTis Intratubular germ cell neoplasia (testicular intraepithelial neoplasia) 
pT1 Tumour limited to testis and epididymis without vascular/lymphatic invasion: tumour 
may invade tunica albuginea but not tunica vaginalis 
pT2 Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour 
extending through tunica albuginea with involvement of tunica vaginalis 
pT3 Tumour invades spermatic cord with or without vascular/lymphatic invasion 
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pT4 Tumour invades scrotum with or without vascular/lymphatic invasion 
2. Regional lymph nodes clinical 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph 
nodes, none more than 2 cm in greatest dimension 
N2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest 
dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm 
in greatest dimension 
N3 Metastasis with a lymph node mass more than 5 cm in greatest dimension 
3. pN Pathological 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer 
positive nodes, none more than 2 cm in greatest dimension 
pN2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest 
dimension; or more than 5 nodes positive, none more than 5 cm; or evidence or extranodal 
extension of tumour 
pN3 Metastasis with a lymph node mass more than 5 cm in greatest dimension 
4. M Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) or lung 
M1b Other sites 
5. S Serum tumour markers 
Sx Serum marker studies not available or not performed 
S0 Serum marker study levels within normal limits 
 
   LDH (U/l) hCG (mIU/ml) AFP (ng/ml 
S1 <1.5 X N and < 5000 and < 1000 
S2 1.5 - 10 X N or 5000 - 50,000 or 1,000-10,000 
S3 > 10 X N or > 50,000 or > 10,000 
Table 1. 
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On the attaining the TNMS information using the 2009 TNM of the International Union 
Against Cancer (UICC), patients are then staged using the American Joint Committee of 
Cancer (AJCC) staging classification (26) summarized in Table 2.  
 
Stage 0  
pTis, N0, M0, S0 
Stage I  
pT1-4, N0, M0, SX 
 
Stage IA  
pT1, N0, M0, S0 
 
Stage IB  
pT2, N0, M0, S0 
pT3, N0, M0, S0 
pT4, N0, M0, S0 
Stage IC  
Any pT/Tx, N0, M0, S1-3 
Stage II  
Any pT/Tx, N1-3, M0, SX  
 
Stage IIA  
Any pT/Tx, N1, M0, S0 
Any pT/Tx, N1, M0, S1 
Stage IIB  
Any pT/Tx, N2, M0, S0 
Any pT/Tx, N2, M0, S1 
 
Stage IIC  
Any pT/Tx, N3, M0, S0 
Any pT/Tx, N3, M0, S1 
Stage III  
Any pT/Tx, Any N, M1, SX  
 
Stage IIIA  
Any pT/Tx, Any N, M1a, S0 
Any pT/Tx, Any N, M1a, S1 
Stage IIIB  
Any pT/Tx, N1-3, M0, S2 
Any pT/Tx, Any N, M1a, S2 
 
Stage IIIC  
Any pT/Tx, N1-3, M0, S3 
Any pT/Tx, Any N, M1a, S3 
Any pT/Tx, Any N, M1b, Any S 
Table 2. The AJCC staging groupings of Testicular Tumours 
8. Management 
Within Europe and the UK the management of TGCTs differs mainly for the indications of 
Retroperitoneal Lymph Node Dissection (RPLND) in both Stage I and Stage II disease. We 
classify the management of TGCTs as followed in Europe and the UK based on whether the 
tumour is a Seminoma or Non-Seminoma.  
8.1 Management of Seminoma 
Of all Seminomas diagnosed, 75% are confined to the testicle itself at the time of clinical 
presentation and a complete cure is thus achieved with a thorough radical inguinal 
orchidectomy. In upto 10-15% of patients metastasis is present at the time of diagnosis with 
a further 5-10% of patients having more advanced disease. 
In patients with Non-metastatic Stage I seminoma (T1N0M0S0-1) the risk of subsequent 
para-aortic lymph node relapse is 20%. Adjuvant therapy with either chemotherapy or 
radiotherapy reduces the risk of recurrence to <1%.  
8.1.1 Management of stage I Seminoma  
The options in a patient with Stage 1 Seminoma include surveillance, adjuvant 
chemotherapy or adjuvant radiotherapy. The option of surveillance is indicated as 75% of 
Seminoma are cured following a radical inguinal orchidectomy. In a large study of 1500 
patients (28) indicated the overall rate of retroperitoneal disease relapse to be 16.8%. It is 
important to characterize patients with high risk Stage I Seminoma based on initial 
pathology. The 2 most important factors associated with poor prognosis includes the 
presence of rete-testis invasion and tumours size of ≥ 4 cm. The overall cancer-specific 
survival rate reported with surveillance performed by experienced centres is 97-100% for 
seminoma stage I (29-31). The main drawback of surveillance is the need for more intensive 
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follow-up, especially with repeated imaging examinations of the retroperitoneal lymph 
nodes, for at least 5 years after orchidectomy. 
 
Prognostic Group Progression free survival (PFS) 
and  
overall survival (OS) 
Clinical Criteria 
Good prognostic group 
(Non Seminoma) 
Non-seminoma (56% of cases) 
5-year PFS 89% 
5-year survival 92% 
All of the following criteria: 
• Testis/retroperitoneal primary 
• No non-pulmonary visceral metastases 
• AFP < 1,000 ng/mL 
• hCG < 5,000 IU/L (1,000 ng/mL) 
• LDH < 1.5 x ULN 
Good prognostic group 
(Seminoma) 
Seminoma (90% of cases) 
5-year PFS 82% 
5-year survival 86% 
All of the following criteria: 
• Testis/retroperitoneal primary 
• No non-pulmonary visceral metastases 
• AFP < 1,000 ng/mL 
• hCG < 5,000 IU/L (1,000 ng/mL) 




Non-seminoma (28% of cases) 
5 years PFS 75% 
5-year survival 80% 
• Testis/retroperitoneal primary 
• No non-pulmonary visceral metastases 
• AFP 1,000 - 10,000 ng/mL or 
• hCG 5,000 - 50,000 IU/L or 




Seminoma (10% of cases) 
5-year PFS 67% 
5-year survival 72% 
Any of the following criteria: 
• Any primary site 
• Non-pulmonary visceral metastases 
• Normal AFP 
• Any hCG 
• Any LDH 
Poor prognosis group 
(Non Seminoma) 
Non-seminoma (16% of cases) 
5-year PFS 41% 
5-year survival 48% 
Any of the following criteria: 
• Mediastinal primary 
• Non-pulmonary visceral metastases 
• AFP > 10,000 ng/mL or 
• hCG > 50,000 IU/L (10,000 ng/mL) or 
• LDH > 10 x ULN 
Poor prognosis group 
(Seminoma) 
No patients classified as poor 
prognosis 
N/A 
Table 3. Prognostic-based staging system for metastatic germ cell cancer (International Germ 
Cell Cancer Collaborative Group). 
Patients with Stage I Seminoma can also be given adjuvant chemotherapy with one cycle of 
Carboplatin (33). An alternative to surveillance or chemotherapy in patients with 
radiotherapy (34).  
Within Europe and the UK, a RPLND is not recommended in patients with Stage 1 
Seminoma. In prospective, non-randomised study comparing radiotherapy and RPLND in 
stage I seminoma, there was a trend towards a higher incidence of retroperitoneal relapses 
(9.5%) after RPLND as primary treatment (35). 
In summary, it is important to stratify patients with Stage 1 Seminoma into high risk based 
on the presence of rete testis invasion and tumour volume of ≥ 4 cm. In these patients the 
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option of adjuvant chemotherapy and radiotherapy is justifiable. In patients without rete 
testis invasion or in whom the testicular tumour volume is ≤ 4 cm the option of surveillance 
alone is recommended.  
8.1.2 Management of stage II Seminoma  
The options in a patient with Stage II Seminoma is radiotherapy. However, chemotherapy is 
an alternative management strategy.  
8.2 Management of Non-Seminoma 
In patients with Non-Seminomas, 30% with Stage I disease will have subclinical metastases 
and will relapse if surveillance alone is applied following orchidectomy. Within this groups 
of patients the options of treatment include surveillance, chemotherapy and RPLND. It is 
important to stratify Non-Seminomas into high risk based tumours depeding on the 
following parameters which include the presence of Vascular/lymphatic in or peri-
tumoural invasion, proliferation rate > 70% or percentage of embryonal carcinoma > 50%. 
8.2.1 Management of stage I Non-Seminoma  
In patients on surveillance, the incidence of relapse is 30% (36). When a patient relapses 
about 35% have normal levels of serum tumour markers at relapse and approximately 60% 
of relapses are within the retroperitoneum. Upto 11% of relapsing patients have large-
volume recurrent disease at representation. Based on the above, the option of surveillance 
should be offered to a compliant patient who will agree for very regular and close follow up. 
The commonest option of management of patients within Europe and the UK with Stage I 
Non-Seminoma is chemotherapy. The current recommendation is two courses of 
chemotherapy with cisplatin, etoposide and bleomycin (PEB) as primary treatment for high-
risk patients (having about 50% risk of relapse). Patient receiving adjuvant chemotherapy 
must be monitored closely as there is a risk of slow-growing retroperitoneal teratomas after 
primary chemotherapy. 
A Nerve sparing / template based RPLND can also be offered to patient who are not keen to 
receive chemotherapy. It is interesting to note that about 30% of patients are diagnosed to 
have a retroperitoneal lymph node metastases corresponding to pathological stage II (PS2) 
disease. In patients with no retroperitoneal metastases found at RPLND (PS1), 
approximately 10% of the PS1 patients relapse at distant sites. Within the UK, RPLND is 
normally indicated in post chemotherapy recurrence.  
As with seminomas a further risk adaptive strategy can be adapted for Non-Seminomas. If the 
risk-adapted policy is applied, patients with vascular invasion are recommended to undergo 
adjuvant chemotherapy with two cycles of PEB, and patients without vascular invasion are 
recommended to undergo surveillance. In summary patients with CS1A (pT1, no vascular 
invasion), low risk Stage I Non Seminoma can be offered the option of surveillance. If patients 
are not willing (or suitable) to undergo surveillance, adjuvant chemotherapy or nerve-sparing 
RPLND are alternative treatment options. If RPLND reveals PN+ (nodal involvement) disease, 
chemotherapy with two courses of PEB should be considered. Patients with Stage I Non-
Seminoma CS1B (pT2-pT4) high risk disease receive either primary chemotherapy with two 
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courses of PEB or Surveillance or nerve-sparing RPLND in high-risk patients remain options 
for those not willing to undergo adjuvant chemotherapy. 
8.2.2 Management of stage II Non-Seminoma 
In patients with Stage II Non-Seminoma with normal testicular tumour markers can be 
managed with primary RPLND or surveillance. In patients with elevated tumour markers 
primary chemotherapy is recommended. When surveillance is commenced for a lesion the 
lesion can either regress, resolve or progress with either a rise or no rise in concomitant 
testicular markers.  
When a lesion regresses in the absence of rising tumour markers it is unlikely to be a 
malignancy. A lesion growing represents either a teratoma or a well differentiated tumour 
in the absence of rising testicular tumour markers. In this situation a RPLND should be 
performed by an experienced surgeon. Patients with a growing lesion and a concomitant 
increase in tumour markers AFP or beta-hCG should not undergo surgery. These patients 
require chemotherapy with PEB according to the treatment algorithm for patients with 
metastatic disease and IGCCCG. Patients who are unwilling to commence primary 
chemotherapy have an option of a nerve-sparing RPLND with adjuvant chemotherapy (two 
cycles of PEB) in case of metastatic disease (pII A/B).  
9. Follow up 
Follow-up care with an oncologist, urologist or both, is vital for the patient with testicular 
cancer. Regular assessments are required to monitor tumour markers in the blood, chest X-
rays, CT scans of the abdomen and a full medical examination with psychological support. 
This process may continue for several years and may vary depending on the type and stage 
of the disease.  
10. Conclusion 
In conclusion the management of TGCTs within the UK and Europe is based on the 
individuals management (surveillance, chemotherapy or radiotherapy) which has to be 
balanced according to clinical features and the risk of short-term and long-term toxic effects. 
Although cure rates for Stage 1 disease are high, there continues to be significant morbidity 
due to chemotherapy, RPLND and Radiotherapy for concomitant additional treatment. We 
recommend individualizing patient treatment using a Multidisciplinary team approach 
using the latest regional, national and international guidelines and developments.  
11. Abbreviations 
TGCTs Testicular Germ Cell tumours 
PGC Primordial germ cells 
UDT Undescended Testis 
IGCNU Intratubular germ cell neoplasia 
MOE Maternal Oestrogen Exposure 
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HCG Human chorionic gonadotrophin 
AFP Alpha-fetoprotein 
LDH Lactate dehydrogenase  
PLAP Placental alkaline phosphatase  
IGCCCG International Germ Cell Cancer Collaborative Group  
AJCC American Joint Committee of Cancer 
RPLND Retroperitoneal Lymph Node Dissection 
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Germ cell tumors arise from anomalies in primordial germ cells (PGCs) (Stevens, 1967), the 
embryonic precursors of oocytes and sperm. Their normal development follows three steps: 
migration, proliferation and differentiation into mature germ cells (Mauduit et al., 1999). 
Abnormalities in these steps can result in sterility, reduced fertility, or in some cases to 
transformation into ovarian tumors in females or testicular germ cell tumors (TGCTs) in 
males (Stevens, 1967), both of which present remarkable cellular and tissue heterogeneity 
reflecting the pluripotent nature of the TGCT stem cell. 
Although representing only 1-2% of all cancers in men, TGCTs are the most common 
malignancy affecting young men 15-35 years of age (Buetow, 1995). Over the past decade, 
TGCT incidence has risen ~1.2% per year with about 8,300-8,400 new cases reported in the 
United States (American Cancer Society, www.cancer.org). TGCT risk varies more than 5-
fold among ethnic groups and geographic regions (McGlynn et al., 2005; www.cancer.org). 
In addition, developmental anomalies such as undescended testis are indicators of TGCT 
risk (Dieckmann & Pichlmeier, 2004). Finally, environmental factors such as pesticides or 
insecticides strongly influence susceptibility. However, the mechanisms by which genetic 
and environmental factors affect susceptibility remain elusive.  
Genetic factors account for 25% of susceptibility to TGCTs, making these tumors the third 
most heritable cancer (Gilbert et al., 2011). Family history is a significant risk factor with 8- 
to 10-fold risk for brothers of men with TGCTs and 4- to 6-fold risk for sons (Hutter et al., 
1967). The risk increases 75-fold for monozygotic twins (Swerdlow et al., 1999). Genome-
wide association studies (GWAS) in humans reveal various loci that contribute to 
susceptibility, but the identity of these genes has not yet been established (Gilbert et al., 
2011). Discovery of TGCTs in the 129 family of inbred strains of mice has enabled 
identification and characterization of specific genes and their interactions (Stevens & Little, 
1954; Stevens, 1973).  
In this chapter, after discussing the various mouse models for TGCTs, we review the 
evidence for TGCT genes and their role in tumorigenesis in both humans and mice. We 
consider the consequence of their mutation, as well as the role of gene interactions, to better 
understand molecular pathways of PGC transformation and pathogenesis. Finally, we 
discuss evidence for transgenerational effects that influence TGCT incidence.  
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2. Mouse models for human TGCTs 
Studies of TGCT development before birth are not feasible in humans. Laboratory mice 
therefore provide unique opportunities to determine the genetic basis for TGCT 
susceptibility and for characterizing key components contributing to PGC transformation. 
2.1 TGCT predisposition in the 129 inbred strain 
During gastrulation in the mouse embryo, PGCs arise from the ectoderm and the precursors 
of Leydig and Sertoli cells arise from the coelomic epithelium (Clark & Eddy, 1975; Karl & 
Capel, 1998). At 8 days post-coitum (E8), 50-100 PGCs are evident at the base of the allantois 
where they begin to be highly mobile (Fig. 1) (Clark & Eddy, 1975; Molyneaux et al., 2001). 
From E9.5 onwards, PGCs rapidly exit the hind-gut epithelium and migrate toward the 
genital ridges (Molyneaux et al., 2001). During migration, PGCs proliferate reaching a 
maximum of 20,000-25,000 cells at E13.5 (Mauduit et al., 1999). Then, in males, PGCs become 
quiescent (mitotic arrest) and are called gonocytes (Mauduit et al., 1999). Pre-Sertoli cells 
appear in male gonads around E11 for playing roles in: (1) sex determination because of 
their SRY factor released (Albrecht & Eicher, 2001); (2) migration of PGCs depending on 
chemotactic factors (i.e. KITLG, a specific-Sertoli factor) and germ-Sertoli interactions 
(Griswold, 1995); and (3) the arrest of male germ cell mitosis in G1/S phase (Karl & Capel, 
1998). Mitotic arrest is maintained until three days after the birth (P3) (Mauduit et al., 1999).  
At P6, gonocytes differentiate into Type A1 spermatogonia and begin radial migration in the 
seminiferous tubule (Nagano et al., 2000). Germ cells undergo either a proliferative period 
(to maintain the progenitor population throughout the reproductive life of males) or meiosis 
(to mature germ cells) (Nagano et al., 2000). During these postnatal days, pre-Sertoli cells 
transform into mature Sertoli cells that support germ cell differentiation and 
spermatogenesis (Griswold, 1995; Hess et al., 2006). Remarkably, a significant proportion of 
PGCs remains scattered along the migratory route. These ectopic PGCs are eliminated 
between E10 and E17 by activating the intrinsic cell death pathway (Stallock et al., 2003). 
This intrinsic pathway is regulated by BCL2 family members (i.e. BAX, BAK and BCL2), 
which activate mitochondria leading to secretion of cytochrome C, an initiator of apoptosis 
(Shimizu et al., 1999; Stallock et al., 2003). Another BAX-dependent apoptotic control point 
occurs at P10-P13 before meiosis to eliminate germ cells that fail either to migrate in the 
seminiferous tubules or to repair DNA (de Rooij, 2001).  
In the 129 family of inbred strains, 5%-10% of males develop spontaneous TGCTs (Fig. 1) 
(Stevens & Little, 1954; Stevens, 1967), making these strains highly relevant for learning 
about TGCT development in humans. Indeed, TGCTs in mice are most similar to pediatric 
TGCTs in humans, and both species have a similar left-sided preference of the tumors. 
Bilateral TGCTs are infrequent in mice and usually involve less than 5% of all cases in 
humans (Dieckmann & Pichlmeier, 2004). The critical period for transformation is between 
E11.5-E13.5 in mice (Stevens & Little, 1954; Stevens, 1967). Interestingly, syncytial masses of 
atypical gonocytes are detected in embryonic testis cords from E13 onward in 129 wild-type 
and mutant males (Stevens, 1967; T. Noguchi & M. Noguchi, 1985; Rivers & Hamilton, 1986; 
Matin et al., 1999). These atypical cells may result from incomplete cell cycle, mitotic arrest 
defects, or de-differentiation after their entrance in quiescence (Rivers & Hamilton, 1986). 
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These so-called embryonal carcinoma (EC) cells escape necrosis, and then proliferate and 
aggregate together to form clusters, which are correlated with partial or complete germ cell 
deficiency (Stevens, 1967; T. Noguchi & M. Noguchi, 1985; Rivers & Hamilton, 1986; Matin 
et al., 1999). Furthermore, EC clusters have been suggested as the precursors of either 
testicular abnormalities, which have been found in an appreciable frequency (18%) in 129 
males, or TGCTs (Rivers & Hamilton, 1986). Similar abnormalities, termed carcinoma in situ, 
have been found in humans many years before invasive malignancy (Skakkebaek, 1972). 
Why some germ cells transform into EC clusters while others develop normally is unclear, 
just as why some abnormal gonocytes die while others persist.  
 
Fig. 1. Male germ cell development in mouse models for TGCTs in the 129 strain. 
2.2 TGCTs in the 129-Ter strain 
The Ter allele, also known as Teratoma, has dramatic effects on PGC biology and TGCT 
susceptibility (Stevens, 1973; T. Noguchi & M. Noguchi, 1985), and was recently identified 
as a spontaneous mutation in the Dead-end (Dnd1) gene (Youngren et al., 2005). Ter 
homozygosity causes severe germ cell deficiency in both sexes, probably mediated through 
BAX-dependent apoptosis after E8.5 (Stevens, 1973; T. Noguchi & M. Noguchi, 1985; Cook 
et al., 2009). EC clusters develop from E13 in 129-Ter/Ter male embryos probably due to a 
defect in G1/S mitotic arrest (Rivers & Hamilton, 1986). The few surviving PGCs 
successfully migrate to the genital ridges, suggesting that DND1 is not essential for 
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migration (Youngren et al., 2005). Deficiency progresses with age until P11 when PGCs are 
no longer detectable (T. Noguchi & M. Noguchi, 1985; Cook et al., 2009). As a result, adult 
mutant males are sterile (Fig. 1) (T. Noguchi & M. Noguchi, 1985). Somatic development of 
Sertoli and Leydig progenitors is not affected in accordance with the PGC-specific 
expression of Dnd1 (Weidinger et al., 2003). Interestingly, 17% of 129-Ter/+ males develop 
tumors, 10% of which are bilateral, but these males are fertile. This rate increases to 94% in 
homozygotes with 75% of cases having bilateral tumors (T. Noguchi & M. Noguchi, 1985).  
DND1 was originally proposed to be a component of the cytidine to uridine RNA editing 
complex given its similarity with the Apobec complementation factor (A1CF) (Weidinger et 
al., 2003). More recently, DND1 was shown to block miRNA access to their mRNA targets 
(Kedde et al., 2007). The reactivated target genes are involved in PGC pluripotency (i.e. Sox2, 
Nanos1 and Nanog), in cell cycle regulation (i.e. Cyclin-dependent kinase inhibitors (Cdkn) 1b, 
Cdkn1a) and in PGC survival (i.e. Transformation related protein (Trp53), apoptotic factor Bax 
and Phosphatase and tensin homolog (Pten)) (Kedde et al., 2007; Cook et al., 2011; R. Zhu et al., 
2011). Dnd1 is expressed throughout embryogenesis with an up-regulation between E12.5 
and E15.5 in males, the critical period for TGCT development (Youngren et al., 2005; Cook et 
al., 2009). Thus, loss of DND1 in Ter mutants strongly affects differentiation, survival and 
entry in quiescence of PGCs and dramatically enhances the TGCT frequency in the 129 
strain. 
2.3 Consomic 129 inbred strains 
Chromosome Substitution Strains (CSSs, consomic strains) carry entire chromosomes 
derived from another inbred strain. Some CSSs were created to study the genetic linkage of 
the MOLF-derived TGCT modifier genes. MOLF is derived from Mus musculus molossinus, 
which is genetically distinct from 129 and has no predisposition for TGCTs (Mieno et al., 
1989; Matin et al., 1998). We will review results for two consomic strains. 
2.3.1 129-M18  
The 129-M18 CSS substitutes MOLF-derived chromosome 18 for its homologue in 129 wild-
type mice (Anderson et al., 2009a). 129-M18 males show complete resistance to develop 
TGCTs with no homozygous males affected. Four quantitative trait loci (QTLs, Region I-IV) 
were identified independent of the Dnd1 gene, which is also located on this chromosome.  
Region I shows homology with the 10p11 region in humans (Copeland et al., 1993). One 
candidate gene may be Map3k8, which encodes a mitogen-activated protein kinase (MAPK) 
that acts downstream of tyrosine kinase-dependent pathway (Patriotis et al., 1994). Region II 
belongs to a conserved region 5q in humans (Copeland et al., 1993). In mice, this region 
contains Eif1a gene, which encodes a translational regulator that is functionally related to 
eIF2α, encoded by Eif2s2 gene, loss of which suppresses TGCT development (Heaney et al., 
2009) (Section 3.5). However, the three homologues of Eif1a gene are EIF1AD on 
chromosome 11, and EIF1AX and EIF1AY on sex chromosomes in humans. Region III 
contains at least one TGCT enhancer and is conserved with the 18q region in humans 
(Copeland et al., 1993). An interesting candidate gene is Noxa, which encodes a 
mitochondria-mediated apoptotic factor (Krishna et al., 2011). Interestingly, Noxa is 
activated by the TGCT suppressor TRP53 (Michalak et al., 2005; Donehower et al., 1992) 
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(Section 3.3). Region IV contains the F-box only protein 15 gene, one of the few known targets 
of the stem cell pluripotent factor OCT3/4 (Tokuzawa et al., 2003).  
2.3.2 129-M19  
The 129-M19 CSS substitutes MOLF-derived chromosome 19 for its homolog in 129 wild-
type mice (Matin et al., 1999). Surprisingly, 80% of the homosomic males develop TGCTs 
and this unusually high tumor frequency remain elevated (20%) when only one copy of M19 
is present (129-M19/+) compared with 129 wild-type mice (5%), suggesting a semi-
dominant effect of the MOLF susceptibility locus (Matin et al., 1999; Youngren et al., 2003). 
In contrast with the 129-Ter strain, M19 does not cause complete germ cell deficiency (Fig. 
1). Indeed, some PGCs can develop normally leading to fertility in both homozygous and 
heterozygous males. Furthermore, the incidence of bilateral tumors in 129-M19/M19 is 
reduced (57%) compared with the 129-Ter strain (75%) and are non-existent in heterozygous 
males (similar than in 129 wild type males) (Matin et al., 1999; Youngren et al., 2003). Thus, 
the phenotype of this consomic M19 strain is less severe than in the 129-Ter strain.  
Regions on chromosome 19 are homologous to either 9p, which contains the TGCT modifier 
doublesex- & Mab3-related transcription factor 1 (Dmrt1) gene (Section 3.4), 9q, 10q, which 
contains the TGCT modifier Pten (Section 3.2) and 11q in humans (Copeland et al., 1993). An 
interesting candidate gene is Splicing factor 1 (Sf1), which encodes an RNA binding protein 
that functions as a pre-mRNA splicing factor (Z. Liu et al., 2001). Interestingly, Sf1 deficiency 
(heterozygous Sf1-/+) in 129-M19/+ males reduces the incidence of TGCTs (R. Zhu et al., 
2010), suggesting that Sf1 may be one of the TGCT enhancer genes on chromosome 19. 
D19Bwg1357e is a predicted gene down-regulated in the gonads of MOLF strain mice (R. 
Zhu et al., 2007). This gene has an RNA-binding domain homologous to those in Pum1 and 
Pum2 genes, which encode two major components of P-bodies, the center of RNA 
processing (Moore et al., 2003), suggesting a similar role for D19Bwg1357e.  
Thus, CSSs are powerful tools for identifying new genes that, alone or in combination and 
with conventional additive or epistatic effects, confer susceptibility to TGCTs. These 
candidate genes are involved in RNA biology, epigenetic regulation and intracellular 
pathways regulating PGC survival, proliferation and pluripotency.  
3. TGCT modifier genes in the 129 strain 
Spontaneous and engineered mutations are essential for characterizing molecular pathways 
involved in PGC development and transformation into TGCTs. In this section, we review 
the phenotypic traits of 129 mice that carry mutations on TGCT modifier genes.  
3.1 Kit and Kitlg 
In the mouse, mutations at the White-spotting (W) or Steel (Sl) loci cause sterility and severe 
anemia that lead to in utero or perinatal death in homozygotes (McCoshen & McCallion, 
1975; Nocka et al., 1990). The W locus, located on chromosome 5 in mice (region 4q12 in 
humans), encodes KIT, a tyrosine kinase receptor (Manova et al., 1990). The ligand of KIT, 
named KITLG, is encoded at the Sl locus on chromosome 10 in mice (region 12q21 in 
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migration (Youngren et al., 2005). Deficiency progresses with age until P11 when PGCs are 
no longer detectable (T. Noguchi & M. Noguchi, 1985; Cook et al., 2009). As a result, adult 
mutant males are sterile (Fig. 1) (T. Noguchi & M. Noguchi, 1985). Somatic development of 
Sertoli and Leydig progenitors is not affected in accordance with the PGC-specific 
expression of Dnd1 (Weidinger et al., 2003). Interestingly, 17% of 129-Ter/+ males develop 
tumors, 10% of which are bilateral, but these males are fertile. This rate increases to 94% in 
homozygotes with 75% of cases having bilateral tumors (T. Noguchi & M. Noguchi, 1985).  
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Nanos1 and Nanog), in cell cycle regulation (i.e. Cyclin-dependent kinase inhibitors (Cdkn) 1b, 
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al., 2009). Thus, loss of DND1 in Ter mutants strongly affects differentiation, survival and 
entry in quiescence of PGCs and dramatically enhances the TGCT frequency in the 129 
strain. 
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derived from another inbred strain. Some CSSs were created to study the genetic linkage of 
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were identified independent of the Dnd1 gene, which is also located on this chromosome.  
Region I shows homology with the 10p11 region in humans (Copeland et al., 1993). One 
candidate gene may be Map3k8, which encodes a mitogen-activated protein kinase (MAPK) 
that acts downstream of tyrosine kinase-dependent pathway (Patriotis et al., 1994). Region II 
belongs to a conserved region 5q in humans (Copeland et al., 1993). In mice, this region 
contains Eif1a gene, which encodes a translational regulator that is functionally related to 
eIF2α, encoded by Eif2s2 gene, loss of which suppresses TGCT development (Heaney et al., 
2009) (Section 3.5). However, the three homologues of Eif1a gene are EIF1AD on 
chromosome 11, and EIF1AX and EIF1AY on sex chromosomes in humans. Region III 
contains at least one TGCT enhancer and is conserved with the 18q region in humans 
(Copeland et al., 1993). An interesting candidate gene is Noxa, which encodes a 
mitochondria-mediated apoptotic factor (Krishna et al., 2011). Interestingly, Noxa is 
activated by the TGCT suppressor TRP53 (Michalak et al., 2005; Donehower et al., 1992) 
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(Section 3.3). Region IV contains the F-box only protein 15 gene, one of the few known targets 
of the stem cell pluripotent factor OCT3/4 (Tokuzawa et al., 2003).  
2.3.2 129-M19  
The 129-M19 CSS substitutes MOLF-derived chromosome 19 for its homolog in 129 wild-
type mice (Matin et al., 1999). Surprisingly, 80% of the homosomic males develop TGCTs 
and this unusually high tumor frequency remain elevated (20%) when only one copy of M19 
is present (129-M19/+) compared with 129 wild-type mice (5%), suggesting a semi-
dominant effect of the MOLF susceptibility locus (Matin et al., 1999; Youngren et al., 2003). 
In contrast with the 129-Ter strain, M19 does not cause complete germ cell deficiency (Fig. 
1). Indeed, some PGCs can develop normally leading to fertility in both homozygous and 
heterozygous males. Furthermore, the incidence of bilateral tumors in 129-M19/M19 is 
reduced (57%) compared with the 129-Ter strain (75%) and are non-existent in heterozygous 
males (similar than in 129 wild type males) (Matin et al., 1999; Youngren et al., 2003). Thus, 
the phenotype of this consomic M19 strain is less severe than in the 129-Ter strain.  
Regions on chromosome 19 are homologous to either 9p, which contains the TGCT modifier 
doublesex- & Mab3-related transcription factor 1 (Dmrt1) gene (Section 3.4), 9q, 10q, which 
contains the TGCT modifier Pten (Section 3.2) and 11q in humans (Copeland et al., 1993). An 
interesting candidate gene is Splicing factor 1 (Sf1), which encodes an RNA binding protein 
that functions as a pre-mRNA splicing factor (Z. Liu et al., 2001). Interestingly, Sf1 deficiency 
(heterozygous Sf1-/+) in 129-M19/+ males reduces the incidence of TGCTs (R. Zhu et al., 
2010), suggesting that Sf1 may be one of the TGCT enhancer genes on chromosome 19. 
D19Bwg1357e is a predicted gene down-regulated in the gonads of MOLF strain mice (R. 
Zhu et al., 2007). This gene has an RNA-binding domain homologous to those in Pum1 and 
Pum2 genes, which encode two major components of P-bodies, the center of RNA 
processing (Moore et al., 2003), suggesting a similar role for D19Bwg1357e.  
Thus, CSSs are powerful tools for identifying new genes that, alone or in combination and 
with conventional additive or epistatic effects, confer susceptibility to TGCTs. These 
candidate genes are involved in RNA biology, epigenetic regulation and intracellular 
pathways regulating PGC survival, proliferation and pluripotency.  
3. TGCT modifier genes in the 129 strain 
Spontaneous and engineered mutations are essential for characterizing molecular pathways 
involved in PGC development and transformation into TGCTs. In this section, we review 
the phenotypic traits of 129 mice that carry mutations on TGCT modifier genes.  
3.1 Kit and Kitlg 
In the mouse, mutations at the White-spotting (W) or Steel (Sl) loci cause sterility and severe 
anemia that lead to in utero or perinatal death in homozygotes (McCoshen & McCallion, 
1975; Nocka et al., 1990). The W locus, located on chromosome 5 in mice (region 4q12 in 
humans), encodes KIT, a tyrosine kinase receptor (Manova et al., 1990). The ligand of KIT, 
named KITLG, is encoded at the Sl locus on chromosome 10 in mice (region 12q21 in 
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humans) (Flanagan et al., 1991). These two factors are essential for hematopoiesis, 
melanogenesis and gametogenesis (Bernstein et al., 1991; Besmer et al., 1993).  
In the testis, KIT is expressed on the surface of PGCs from E7.5 to E13.5, and then at P5, on 
differentiating germ cells and interstitial Leydig cells (Manova et al., 1990; Yoshinaga et al., 
1991). KITLG is only expressed by the pre-Sertoli and Sertoli cells (Rossi et al., 1991; Tajima 
et al., 1991). The two forms of KITLG, soluble and membrane-bound, are differentially 
expressed depending on developmental stages (Matsui et al., 1990; Flanagan et al., 1991; E.J. 
Huang et al., 1992). The membrane-bound KITLG is predominantly expressed during 
proliferative periods: between E8 and E14 and just after the birth (P3), and the soluble form 
when PGCs are quiescent (between E13.5 and P3) (Matsui et al., 1990; Flanagan et al., 1991; 
E.J. Huang et al., 1992). In addition of their essential role during migration, the interaction of 
KITLG with its receptor leads to the dimerization of KIT and its auto-phosphorylation 
activates two major pathways: (1) the PI3K/AKT signaling cascade regulates transcription 
of mitotic inhibitors such as CDKN1a, CDKN1b and cyclin D1, and enhances the 
translational factor eIF4E; (2) the MAPK pathway regulates factors involved in pluripotency 
such as NANOG and SOX2, and in proliferation (Mithraprabhu & Loveland, 2009). By 
acting on TRP53 activity, KIT/KITLG pathway controls apoptosis of PGCs by regulating the 
BCL2 components (i.e. BAX, BAK, BCL2) and their cofactors (i.e. PUMA, NOXA) (Pesce et 
al., 1993; Carson et al., 1994), explaining why ectopic PGCs that lose KIT/KITLG interaction 
in 129 wild-type mice are eliminated by apoptosis.  
Loss of KIT (KitW and KitWv) or KITLG (KitlgSl, KitlgSlJ and KitlgSlgb) leads to massive PGC 
loss, resulting from high levels of apoptosis beginning on or before E9 (Stevens, 1967; 
McCoshen & McCallion, 1975; Nocka et al., 1990; Heaney et al., 2008). In these Kit and Kitlg 
heterozygous mutants, the wild-type allele is sufficient to rescue PGC viability at E13.5 and 
fertility in adult males. Loss of only membrane-bound KITLG in the KitlgSld deletion leads to 
a mild phenotype characterized by partial PGC deficiency because of a proliferation defect 
(Fig. 1) (Flanagan et al., 1991; Tajima et al., 1991). At later stages, this mutation adversely 
affects PGC differentiation resulting in sterility. In KitlgSl17H mutants, the membrane-bound 
form is not functional due to absence of its cytoplasmic tail (Brannan et al., 1992). These 
mutants present a slight phenotype apparent after birth with anomalies in spermatogenesis, 
leading to sterility (Fig. 1). Surprisingly, KitlgSld and KitlgSl17H mutants have normal 
apoptosis when mice lacking KIT or KITLG have a high apoptotic rate, suggesting that 
soluble KITLG alone is sufficient to re-establishing normal apoptosis (Flanagan et al., 1991; 
Brannan et al., 1992). Nonetheless, neither KitlgSld nor KitlgSl17H mutants are fertile, 
suggesting that membrane-bound KITLG is necessary for complete PGC development 
(proliferation and differentiation). Thus, the KIT/KITLG pathway controls the migration, 
proliferation and survival of PGCs during embryogenesis, and the proliferation, 
differentiation and the radial development of germ cells after birth. 
Although loss of KIT and KITLG have similar effects on PGC development, only KitlgSl, 
KitlgSlJ and KitlgSlgb heterozygotes have 2-fold increase in occurrence of TGCT-affected males 
(Fig. 1) (Stevens, 1967; Heaney et al., 2008), suggesting that KIT is haplosufficient to promote 
TGCT formation. Interestingly, KitlgSld allele has no effect on TGCT susceptibility (Heaney et 
al., 2008), suggesting that soluble KITLG is sufficient to suppress TGCT formation. The 
presence of EC clusters and the frequency of testicular abnormalities in KitlgSl and KitW 
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heterozygous males remain to be evaluated. However, given that EC clusters are probably 
the origin of TGCTs and that some clusters have been described in mice lacking the PI3K 
binding site on KIT (Kissel et al., 2000), we expect to find EC clusters at least in KitlgSl, KitlgSlJ 
and KitlgSlgb heterozygous males. Determining whether soluble KITLG in KitlgSld mutants 
reduces the frequency of these clusters, or whether KitW mutants also carry EC clusters 
without transformation into tumors, could highlight the molecular pathway involved in 
transformation of benign EC masses into malignant tumors. 
3.2 Pten 
Pten encodes a phosphatase that antagonizes both PI3K/AKT and MAPK signaling cascades 
through its dual phosphatase activities (Myers et al., 1997). Thus, PTEN is a key element of 
the KIT/KITLG pathway. Interestingly, PTEN regulates its own expression by stabilizing its 
transcriptional activator TRP53 (Tang & Eng, 2006).  
In the testis, PTEN is expressed in PGCs, but not in Sertoli cells (Kimura et al., 2003). Loss of 
PTEN leads to embryonic death, and heterozygotes have a high tumor incidence (Di 
Cristofano et al., 1998). PGCs lacking PTEN have defects in mitotic arrest and slow 
pluripotency loss after E13.5 (Fig. 1), and form EC clusters (Kimura et al., 2003). A high 
apoptotic rate is observed in the testis after E13.5 but remains insufficient to counterbalance 
abnormal proliferation. All mutant males develop bilateral TGCTs (Kimura et al., 2003). Pten 
transcript levels are reduced at least 2-fold in E13.5 gonads in MOLF males compared with 129 
males (R. Zhu et al., 2007), suggesting that Pten is one of the genes on chromosome 19 that 
contribute to the high TGCT frequency. Furthermore, Pten is the only genetic variant that 
increases TGCT susceptibility to 100% in a mixed genetic background (Kimura et al., 2003).  
Adenosine triphosphate-binding domains on PTEN regulate its subcellular localization 
(Lobo et al., 2009). Defect in these domains results in a predominantly nuclear localization, a 
DNA repair defect, and an inappropriate regulation of G1/S progression associated with a 
reduced apoptotic rate (He et al., 2011). PTEN mislocalization also leads to a reduced 
nuclear TRP53 level and transcriptional activity (He et al., 2011). Thus, PTEN plays an 
important role in cell growth and tumorigenesis, by regulating apoptosis, pluripotency, 
chromosome stability, DNA repair and cell cycle arrest (Kimura et al., 2003; Shen et al., 2007; 
Saal et al., 2008; He et al., 2011). Whether PTEN localization affects TGCT susceptibility is an 
open question. 
3.3 Trp53 
The Trp53 gene encodes a tumor suppressor expressed in both PGCs and pre-Sertoli cells 
during embryogenesis, down-regulated after the birth in spermatogonia, and re-expressed 
in primary spermatocytes at pachytene, suggesting a role for TRP53 in control of meiosis 
(Almon et al., 1993; Schwartz et al., 1993). TRP53 activity is under the control of the 
PI3K/AKT pathway and depends of TRP53 phosphorylation (Xu, 2003). TRP53 regulates 
expression of several genes encoding mitotic regulators (i.e. CDKN1a, cyclin G1), the tumor 
suppressor PTEN, the pluripotent factor NANOG, and several apoptotic regulators (i.e. 
BAX, NOXA, PUMA) (Lin et al., 2005; Michalak et al., 2005; Tang & Eng, 2006). TRP53 also 
activates PUMA, which controls activity of BCL2 components and induces a mitochondria-
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humans) (Flanagan et al., 1991). These two factors are essential for hematopoiesis, 
melanogenesis and gametogenesis (Bernstein et al., 1991; Besmer et al., 1993).  
In the testis, KIT is expressed on the surface of PGCs from E7.5 to E13.5, and then at P5, on 
differentiating germ cells and interstitial Leydig cells (Manova et al., 1990; Yoshinaga et al., 
1991). KITLG is only expressed by the pre-Sertoli and Sertoli cells (Rossi et al., 1991; Tajima 
et al., 1991). The two forms of KITLG, soluble and membrane-bound, are differentially 
expressed depending on developmental stages (Matsui et al., 1990; Flanagan et al., 1991; E.J. 
Huang et al., 1992). The membrane-bound KITLG is predominantly expressed during 
proliferative periods: between E8 and E14 and just after the birth (P3), and the soluble form 
when PGCs are quiescent (between E13.5 and P3) (Matsui et al., 1990; Flanagan et al., 1991; 
E.J. Huang et al., 1992). In addition of their essential role during migration, the interaction of 
KITLG with its receptor leads to the dimerization of KIT and its auto-phosphorylation 
activates two major pathways: (1) the PI3K/AKT signaling cascade regulates transcription 
of mitotic inhibitors such as CDKN1a, CDKN1b and cyclin D1, and enhances the 
translational factor eIF4E; (2) the MAPK pathway regulates factors involved in pluripotency 
such as NANOG and SOX2, and in proliferation (Mithraprabhu & Loveland, 2009). By 
acting on TRP53 activity, KIT/KITLG pathway controls apoptosis of PGCs by regulating the 
BCL2 components (i.e. BAX, BAK, BCL2) and their cofactors (i.e. PUMA, NOXA) (Pesce et 
al., 1993; Carson et al., 1994), explaining why ectopic PGCs that lose KIT/KITLG interaction 
in 129 wild-type mice are eliminated by apoptosis.  
Loss of KIT (KitW and KitWv) or KITLG (KitlgSl, KitlgSlJ and KitlgSlgb) leads to massive PGC 
loss, resulting from high levels of apoptosis beginning on or before E9 (Stevens, 1967; 
McCoshen & McCallion, 1975; Nocka et al., 1990; Heaney et al., 2008). In these Kit and Kitlg 
heterozygous mutants, the wild-type allele is sufficient to rescue PGC viability at E13.5 and 
fertility in adult males. Loss of only membrane-bound KITLG in the KitlgSld deletion leads to 
a mild phenotype characterized by partial PGC deficiency because of a proliferation defect 
(Fig. 1) (Flanagan et al., 1991; Tajima et al., 1991). At later stages, this mutation adversely 
affects PGC differentiation resulting in sterility. In KitlgSl17H mutants, the membrane-bound 
form is not functional due to absence of its cytoplasmic tail (Brannan et al., 1992). These 
mutants present a slight phenotype apparent after birth with anomalies in spermatogenesis, 
leading to sterility (Fig. 1). Surprisingly, KitlgSld and KitlgSl17H mutants have normal 
apoptosis when mice lacking KIT or KITLG have a high apoptotic rate, suggesting that 
soluble KITLG alone is sufficient to re-establishing normal apoptosis (Flanagan et al., 1991; 
Brannan et al., 1992). Nonetheless, neither KitlgSld nor KitlgSl17H mutants are fertile, 
suggesting that membrane-bound KITLG is necessary for complete PGC development 
(proliferation and differentiation). Thus, the KIT/KITLG pathway controls the migration, 
proliferation and survival of PGCs during embryogenesis, and the proliferation, 
differentiation and the radial development of germ cells after birth. 
Although loss of KIT and KITLG have similar effects on PGC development, only KitlgSl, 
KitlgSlJ and KitlgSlgb heterozygotes have 2-fold increase in occurrence of TGCT-affected males 
(Fig. 1) (Stevens, 1967; Heaney et al., 2008), suggesting that KIT is haplosufficient to promote 
TGCT formation. Interestingly, KitlgSld allele has no effect on TGCT susceptibility (Heaney et 
al., 2008), suggesting that soluble KITLG is sufficient to suppress TGCT formation. The 
presence of EC clusters and the frequency of testicular abnormalities in KitlgSl and KitW 
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heterozygous males remain to be evaluated. However, given that EC clusters are probably 
the origin of TGCTs and that some clusters have been described in mice lacking the PI3K 
binding site on KIT (Kissel et al., 2000), we expect to find EC clusters at least in KitlgSl, KitlgSlJ 
and KitlgSlgb heterozygous males. Determining whether soluble KITLG in KitlgSld mutants 
reduces the frequency of these clusters, or whether KitW mutants also carry EC clusters 
without transformation into tumors, could highlight the molecular pathway involved in 
transformation of benign EC masses into malignant tumors. 
3.2 Pten 
Pten encodes a phosphatase that antagonizes both PI3K/AKT and MAPK signaling cascades 
through its dual phosphatase activities (Myers et al., 1997). Thus, PTEN is a key element of 
the KIT/KITLG pathway. Interestingly, PTEN regulates its own expression by stabilizing its 
transcriptional activator TRP53 (Tang & Eng, 2006).  
In the testis, PTEN is expressed in PGCs, but not in Sertoli cells (Kimura et al., 2003). Loss of 
PTEN leads to embryonic death, and heterozygotes have a high tumor incidence (Di 
Cristofano et al., 1998). PGCs lacking PTEN have defects in mitotic arrest and slow 
pluripotency loss after E13.5 (Fig. 1), and form EC clusters (Kimura et al., 2003). A high 
apoptotic rate is observed in the testis after E13.5 but remains insufficient to counterbalance 
abnormal proliferation. All mutant males develop bilateral TGCTs (Kimura et al., 2003). Pten 
transcript levels are reduced at least 2-fold in E13.5 gonads in MOLF males compared with 129 
males (R. Zhu et al., 2007), suggesting that Pten is one of the genes on chromosome 19 that 
contribute to the high TGCT frequency. Furthermore, Pten is the only genetic variant that 
increases TGCT susceptibility to 100% in a mixed genetic background (Kimura et al., 2003).  
Adenosine triphosphate-binding domains on PTEN regulate its subcellular localization 
(Lobo et al., 2009). Defect in these domains results in a predominantly nuclear localization, a 
DNA repair defect, and an inappropriate regulation of G1/S progression associated with a 
reduced apoptotic rate (He et al., 2011). PTEN mislocalization also leads to a reduced 
nuclear TRP53 level and transcriptional activity (He et al., 2011). Thus, PTEN plays an 
important role in cell growth and tumorigenesis, by regulating apoptosis, pluripotency, 
chromosome stability, DNA repair and cell cycle arrest (Kimura et al., 2003; Shen et al., 2007; 
Saal et al., 2008; He et al., 2011). Whether PTEN localization affects TGCT susceptibility is an 
open question. 
3.3 Trp53 
The Trp53 gene encodes a tumor suppressor expressed in both PGCs and pre-Sertoli cells 
during embryogenesis, down-regulated after the birth in spermatogonia, and re-expressed 
in primary spermatocytes at pachytene, suggesting a role for TRP53 in control of meiosis 
(Almon et al., 1993; Schwartz et al., 1993). TRP53 activity is under the control of the 
PI3K/AKT pathway and depends of TRP53 phosphorylation (Xu, 2003). TRP53 regulates 
expression of several genes encoding mitotic regulators (i.e. CDKN1a, cyclin G1), the tumor 
suppressor PTEN, the pluripotent factor NANOG, and several apoptotic regulators (i.e. 
BAX, NOXA, PUMA) (Lin et al., 2005; Michalak et al., 2005; Tang & Eng, 2006). TRP53 also 
activates PUMA, which controls activity of BCL2 components and induces a mitochondria-
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dependent apoptosis (Chipuk et al., 2004; D. Liu et al., 2010). Thus, TRP53 controls many 
key cellular pathways including apoptosis, pluripotency, G1/S cell cycle arrest, and meiosis.  
DNA damage leads to deficiency of both germ and Sertoli cells after γ-irradiation of fetal 
testis due to apoptosis and a proliferation defect (Lambrot et al., 2007). PGC deficiency is 
associated with increased TRP53 activity and induction of BAX, PUMA and CDKN1a 
expression (Lambrot et al., 2007). In mice, loss of TRP53 phosphorylation leads to 
constitutive activation of TRP53 and in turn too embryonic lethality (D. Liu et al., 2010). In 
contrast, Trp53 -/- mice have normal development but a significantly reduced lifespan due 
to high predisposition for spontaneous tumors, especially lymphomas (Donehower et al., 
1992; Jacks et al., 1994). Disruption of the Trp53 gene in a pure 129 background increases 
TGCT incidence to 35-50% (Fig. 1) (Rotter et al., 1993; Donehower et al., 1995). Homozygotes 
have a giant-cell degenerative syndrome characterized by abnormal primary spermatocytes 
that arrest meiosis at pachytene, and form clusters leading to germ cell deficiency but 
remain fertile (Rotter et al., 1993). Heterozygotes are fertile with a 2-fold increase of TGCT 
frequency in the 129 strain (Rotter et al., 1993; Donehower et al., 1995). In a 50/50 mixed 
background of C57BL/6 and 129, the TGCT incidence is reduced to ~20% (Jacks et al., 1994). 
On these backgrounds, heterozygotes exhibit apparently normal testicular morphology 
(Rotter et al., 1993; Jacks et al., 1994; Muller et al., 2000). Thus, the combination of the Trp53 
defect and the 129 genetic background results in a synergistic increase of giant-cell 
syndrome and TGCT penetrance.  
3.4 Dmrt1 
Dmrt1 encodes a male-specific transcriptional factor (Raymond et al., 1999). In the testis, 
DMRT1 is strongly expressed in pre-Sertoli cells and then in both Sertoli and 
undifferentiated germ cells from P1 onward (Raymond et al., 1999). DMRT1 disappears in 
germ cells that enter meiosis, suggesting that DMRT1 regulates initiation of either meiosis, 
mitotic arrest, or both, in a stage-dependent manner (Raymond et al., 2000; Fahrioglu et al., 
2007). During embryogenesis, DMRT1 controls transformation of PGCs into gonocytes by 
regulating expression of pluripotent factors such as SOX2 and NANOG, and their entrance 
into a quiescent state by controlling some cell cycle inhibitors such as CDKN2d (Krentz et 
al., 2009; Murphy et al., 2010). After birth, the DMRT1 control of cell cycle kinases allows 
mitotic reactivation of male gonocytes. DMRT1 also plays a role in radial migration 
(Fahrioglu et al., 2007). Finally, DMRT1 acts as a transcriptional gatekeeper that controls the 
switch from mitosis to meiosis in the undifferentiated spermatogonia (Matson et al., 2010).  
Interestingly, DMRT1 also has an indirect control of critical developmental steps by 
regulating expression of the retinaldehyde dehydrogenases ALDH1A1 and ADH4 (Matson 
et al., 2010). These enzymes are expressed in Sertoli cells and convert vitamin A-derived 
retinal into retinoic acid. Retinoic acid regulates cell proliferation, migration and 
differentiation (Bowles et al., 2006; Koubova et al., 2006). Catabolism of retinoic acid is 
facilitated by cytochrome P450 enzymes such as CYP26B1, which is highly expressed until 
E13.5 by mitochondria in Sertoli cells (Li et al., 2009). Moreover, retinoic acid signaling is 
under the control of NANOS2, which is an RNA binding protein located in P-bodies, and is 
essential for male PGC development (Tsuda et al., 2003; A. Suzuki & Saga, 2008). PGCs 
lacking CYP26B1 enter meiosis at E13.5 and have a high apoptotic rate (MacLean et al., 
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2007). Similarly, NANOS2 loss affects gonocytes that re-enter in the proliferative phase at 
E15, immediately initiate meiosis, and finally are completely depleted at E18.5 (Tsuda et al., 
2003; A. Suzuki & Saga, 2008). DMRT1 loss in the 129 strain increases 10-fold the numbers of 
PGCs that escape mitotic arrest at E16.5 and return into pluripotent state to form EC clusters 
but without re-entry into meiosis as observed in Nanos2 -/- and Cyp26b1 -/- mutants 
(Raymond et al., 2000; Krentz et al., 2009). Thus, NANOS2, CYP26B1 and consequently 
retinoic acid are required in PGCs for quiescence, meiosis and survival, whereas DMRT1 is 
only required for quiescence and differentiation despite its role on retinoic acid pathway. 
Furthermore, Dmrt1-/- males are sterile and 90% of those develop TGCTs (Fig. 1) (Krentz et 
al., 2009). Interestingly, heterozygotes are fertile and the incidence of TGCTs is similar to 
that in 129 wild-type mice, suggesting that DMRT1 is haplo-insufficient for TGCTs.  
3.5 Ay and Eif2s2 
The Agouti-yellow (Ay), which is a ~170 kb deletion on chromosome 2 in mice includes the 
entire coding region of both Eif2s2 and Raly genes as well as a part of the Agouti gene 
(Michaud et al., 1994). Eif2s2 gene encodes the beta subunit of translation initiation factor 
eIF2 (Sarre, 1989). Raly encodes an RNA-binding protein that acts in pre-mRNA processing. 
Agouti encodes a signaling protein involved in the pigment synthesis in melanocytes 
(Michaud et al., 1994). Interestingly, the Ay deletion places the coding region of Agouti under 
the control of the Raly promoter, resulting in ectopic expression of Agouti (Duhl et al., 1994). 
As a result, Agouti is expressed in both PGCs and Sertoli cells, while RALY and eIF2s2 are 
lost in embryonic testes of Ay mice (Heaney et al., 2009). Homozygosity for Ay results in a 
pre-implantation lethality, whereas heterozygous Ay mice develop obesity, diabetes, yellow 
coat color traits, and have an increase of the propensity to develop a variety of spontaneous 
tumors (Duhl et al., 1994). Surprisingly, the Ay allele is the only genetic modifier known to 
suppress TGCT susceptibility in 129 mice and this phenotype results from loss of Eif2s2 
(Lam et al., 2004; Heaney et al., 2009). Indeed, loss of one Eif2s2 allele decreases at least 2-
fold (less for Ay allele) the high TGCT susceptibility observed in the 129-M19/M19 males 
(Fig. 1) (Lam et al., 2004; Heaney et al., 2009). This protective effect is due to a rescue of the 
G1/S mitotic arrest from E16.5 onward, but without effect on apoptosis, suggesting that 
Eif2s2 deficiency affects only the mitotic activity but not the survival of PGCs (Heaney et al., 
2009). In addition, spermatogenesis is normal in the mutant adult testis although the weight 
of testes is significantly reduced compared with their control 129-M19/M19 males, 
suggesting that reduced Eif2s2 impedes but does not repress adult germ cell maturation 
(Heaney et al., 2009).  
By using genetic targeting in mice, several genes have been identified that play a crucial role 
in PGC development and transformation into TGCTs. These genes act in distinct pathways 
and understanding their interrelation is a challenge for future research. 
4. From mouse models to humans: Molecular basis of TGCT development 
In this section, we compare results for genetic studies of TGCT susceptibility in humans and 
in mice (Table 1), with an emphasis on gene functions and protein pathways that control 
development of the PGC stem cell lineage and that modulate susceptibility to TGCTs. 
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dependent apoptosis (Chipuk et al., 2004; D. Liu et al., 2010). Thus, TRP53 controls many 
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mitotic arrest, or both, in a stage-dependent manner (Raymond et al., 2000; Fahrioglu et al., 
2007). During embryogenesis, DMRT1 controls transformation of PGCs into gonocytes by 
regulating expression of pluripotent factors such as SOX2 and NANOG, and their entrance 
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essential for male PGC development (Tsuda et al., 2003; A. Suzuki & Saga, 2008). PGCs 
lacking CYP26B1 enter meiosis at E13.5 and have a high apoptotic rate (MacLean et al., 
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that in 129 wild-type mice, suggesting that DMRT1 is haplo-insufficient for TGCTs.  
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(Michaud et al., 1994). Eif2s2 gene encodes the beta subunit of translation initiation factor 
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(Michaud et al., 1994). Interestingly, the Ay deletion places the coding region of Agouti under 
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As a result, Agouti is expressed in both PGCs and Sertoli cells, while RALY and eIF2s2 are 
lost in embryonic testes of Ay mice (Heaney et al., 2009). Homozygosity for Ay results in a 
pre-implantation lethality, whereas heterozygous Ay mice develop obesity, diabetes, yellow 
coat color traits, and have an increase of the propensity to develop a variety of spontaneous 
tumors (Duhl et al., 1994). Surprisingly, the Ay allele is the only genetic modifier known to 
suppress TGCT susceptibility in 129 mice and this phenotype results from loss of Eif2s2 
(Lam et al., 2004; Heaney et al., 2009). Indeed, loss of one Eif2s2 allele decreases at least 2-
fold (less for Ay allele) the high TGCT susceptibility observed in the 129-M19/M19 males 
(Fig. 1) (Lam et al., 2004; Heaney et al., 2009). This protective effect is due to a rescue of the 
G1/S mitotic arrest from E16.5 onward, but without effect on apoptosis, suggesting that 
Eif2s2 deficiency affects only the mitotic activity but not the survival of PGCs (Heaney et al., 
2009). In addition, spermatogenesis is normal in the mutant adult testis although the weight 
of testes is significantly reduced compared with their control 129-M19/M19 males, 
suggesting that reduced Eif2s2 impedes but does not repress adult germ cell maturation 
(Heaney et al., 2009).  
By using genetic targeting in mice, several genes have been identified that play a crucial role 
in PGC development and transformation into TGCTs. These genes act in distinct pathways 
and understanding their interrelation is a challenge for future research. 
4. From mouse models to humans: Molecular basis of TGCT development 
In this section, we compare results for genetic studies of TGCT susceptibility in humans and 
in mice (Table 1), with an emphasis on gene functions and protein pathways that control 
development of the PGC stem cell lineage and that modulate susceptibility to TGCTs. 
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4.1 The KIT/KITLG pathway  
The KIT/KITLG pathway controls migration, proliferation, survival and differentiation of 
PGCs during embryogenesis and spermatogenesis. Although both Kit and Kitlg mutations 
affect development of several stem cell lineages including PGCs, only specific mutations 
in the Kitlg gene affect TGCT risk in mice (Heaney et al., 2008). In humans, four different 
GWAS identified allelic variations at the KITLG locus in individuals with TGCTs (Rapley 
et al., 2009; Turnbull et al., 2010; Kanetsky et al., 2009, 2011). Somatic mutations of KIT are 
also reported in men with TGCTs (Looijenga et al., 2003). In addition, deregulated 
expression of KITLG and KIT was found in TGCT biopsies (Murty et al., 1992). Thus, the 
KIT/KITLG pathway appears to be crucial for TGCT development both in humans and 
mice.  
Similar evidence supports the hypothesis that the PI3K/AKT and MAPK signaling cascades 
modulate PGC transformation into TGCTs in humans and in mice:  
 The SPROUTY 4 (SPRY4) gene encodes an inhibitor of MAPK signaling by inhibiting 
RAS activation (Leeksma et al., 2002). SPRY4 is associated with TGCT susceptibility in 
humans (Rapley et al., 2009; Turnbull et al., 2010; Kanetsky et al., 2009, 2011). 
 TRP53 deficiency is a potent but unusual modifier of TGCT susceptibility in both 
humans and mice. Although common in many cancers in humans (K. Suzuki & 
Matsubara, 2011), somatic TRP53 mutations are exceptionally rare in TGCTs in humans 
(Murty et al., 1994; Peng et al., 1995); somatic Trp53 mutations do not appear to have 
been surveyed in mice. By contrast, germline TRP53 mutations are the molecular basis 
for Li-Fraumeni syndrome, which increases susceptibility to various cancers including 
TGCTs (Malkin et al., 1990), and germline Trp53 mutations also increase susceptibility 
to many cancers including TGCTs in mice (Rotter et al., 1993; Donehower et al., 1995). 
Together these observations suggest that TRP53 mutations act in the soma, rather than 
in the germline, to promote transformation of PGCs. 
Various elements of TRP53-mediated apoptosis have been implicated in TGCT 
development. Indeed, variation within the BAK1 gene is associated with TGCT cases in 
humans (Rapley et al., 2009; Turnbull et al., 2010). In addition, expression of Cox15, which 
encodes the mitochondrial cytochrome C oxidase assembly protein that is essential for the 
cell death program, is altered in testes of 129-M19 mice, which have a dramatically elevated 
TGCT risk (R. Zhu et al., 2007). 
Interestingly, double homozygosity for the KITLG and DMRT1 risk haplotypes increases 
risk 14-fold in humans (Kanetsky et al., 2011), suggesting that these haplotypes affect TGCTs 
in a non-additive manner. These interactions could arise either through pathways 
downstream of KIT that regulate DMRT1 activity, or through membrane-bound KITLG 
activating an intrinsic pathway in Sertoli cells that modulate the DMRT1 or the retinoic acid 
pathways. Pre-Sertoli cells are depleted in KitlgSl mutants (Tajima et al., 1991) and their 
development is altered in Dmrt1 -/- mice (Raymond et al., 2000; Krentz et al., 2009), 
suggesting that DMRT1 and KITLG are essential to Sertoli cell development and that pre-
Sertoli cells might be involved in tumorigenesis, reinforcing the hypothesis of functional 
relations between KIT/KITLG and DMRT1. Finally, it is possible that at least one element of 
the KIT/KITLG pathway is a target gene of the transcriptional regulator DMRT1.  
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Table 1. Candidate modifiers of TGCTs in humans and their orthologues in mice.  
 
Germ Cell Tumor 84
4.1 The KIT/KITLG pathway  
The KIT/KITLG pathway controls migration, proliferation, survival and differentiation of 
PGCs during embryogenesis and spermatogenesis. Although both Kit and Kitlg mutations 
affect development of several stem cell lineages including PGCs, only specific mutations 
in the Kitlg gene affect TGCT risk in mice (Heaney et al., 2008). In humans, four different 
GWAS identified allelic variations at the KITLG locus in individuals with TGCTs (Rapley 
et al., 2009; Turnbull et al., 2010; Kanetsky et al., 2009, 2011). Somatic mutations of KIT are 
also reported in men with TGCTs (Looijenga et al., 2003). In addition, deregulated 
expression of KITLG and KIT was found in TGCT biopsies (Murty et al., 1992). Thus, the 
KIT/KITLG pathway appears to be crucial for TGCT development both in humans and 
mice.  
Similar evidence supports the hypothesis that the PI3K/AKT and MAPK signaling cascades 
modulate PGC transformation into TGCTs in humans and in mice:  
 The SPROUTY 4 (SPRY4) gene encodes an inhibitor of MAPK signaling by inhibiting 
RAS activation (Leeksma et al., 2002). SPRY4 is associated with TGCT susceptibility in 
humans (Rapley et al., 2009; Turnbull et al., 2010; Kanetsky et al., 2009, 2011). 
 TRP53 deficiency is a potent but unusual modifier of TGCT susceptibility in both 
humans and mice. Although common in many cancers in humans (K. Suzuki & 
Matsubara, 2011), somatic TRP53 mutations are exceptionally rare in TGCTs in humans 
(Murty et al., 1994; Peng et al., 1995); somatic Trp53 mutations do not appear to have 
been surveyed in mice. By contrast, germline TRP53 mutations are the molecular basis 
for Li-Fraumeni syndrome, which increases susceptibility to various cancers including 
TGCTs (Malkin et al., 1990), and germline Trp53 mutations also increase susceptibility 
to many cancers including TGCTs in mice (Rotter et al., 1993; Donehower et al., 1995). 
Together these observations suggest that TRP53 mutations act in the soma, rather than 
in the germline, to promote transformation of PGCs. 
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in a non-additive manner. These interactions could arise either through pathways 
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Other tyrosine kinase receptors that are expressed in PGCs may also contribute to TGCT 
development. A strong candidate is RET, which is activated by the growth factor GDNF 
receptor GFRA1. Gfra1 gene is located at 19D3 in mice, within a locus that was proposed as 
candidate TGCT modifier (Matin et al., 1999; Youngren et al., 2003). Furthermore, Ret is a 
known proto-oncogene (Grieco et al., 1990) and its expression is indirectly under the control 
of the TGCT modifier DMRT1 (Krentz et al., 2009). Allelic variations were identified at 
18q21 in TGCTs in humans (Murty et al., 1994; Crockford et al., 2006). This locus contains 
the Docking protein 6 (DOK6) gene that plays a role in RET signaling cascade (Crowder et al., 
2004). Interestingly, Dok6 gene is located on chromosome 18 in mice, reinforcing the 
hypothesis of the role of other tyrosine kinase receptors such as GDNF receptors on TGCT 
development (Anderson et al., 2009a). 
4.2 Telomerase and TGCTs 
By extending the TTAGGG telomeric nucleotide repeats, telomerase counterbalances loss of 
telomere length that usually occurs during cell division, and thus preserves chromosomal 
integrity (Venteicher et al., 2009). The active telomerase complex involves TERT (telomerase 
inverse transcriptase), the RNA component TERC, the ribonucleoprotein dyskerin (encoded 
by the X-linked DCK1 gene) and several other cofactors (Venteicher et al., 2009). Telomerase 
is activated by the telomerase Cajal body protein-1 (TCAB1) which is encoded by the 
WRAP53 gene (Jady et al., 2004).  
Mutations in TERT (Marrone et al., 2007), TERC (Vulliamy et al., 2001), DKC1 (Heiss et al., 
1998) and more recently WRAP53 (Zhong et al., 2011), which all lead to absence or 
dysfunction of telomerase, are found in congenital dyskeratosis, a human genetic deficiency 
characterized by abnormal skin pigmentation, bone marrow failure, and an elevated tumor 
frequency. Telomere defects are also associated with segmental progeria syndrome, which is 
characterized by accelerated ageing and is associated with a severe deficiency of adult stem 
cells in brain, bone marrow and testis (Burtner & Kennedy, 2010). Furthermore, telomerase 
dysfunction enhances tumor incidence in mice (Blasco et al., 1997). Thus, telomerase seems 
to play an essential role in stem cell development and cancer formation.  
Specific markers of TGCT susceptibility have been recently identified in humans at 12p13, 
which contains the gene encoding ATF7IP, an enhancer of TERT and TERC transcription, 
and at 5p15 within TERT (Turnbull et al., 2010). Furthermore, a marker of familial TGCT risk 
was located 50kb downstream of TERC (Crockford et al., 2006), and amplification of human 
Xq28 containing DCK1 was found in TGCTs (Skotheim et al., 2001). In mice, the primordial 
germ cell tumor 1 locus (pgct1), that contains Tert on chromosome 13, has been identified as 
an enhancer of TGCT susceptibility (Muller et al., 2000). Furthermore, loss of Tert in mice 
leads to PGC deficiency which increases accross generations, due to both reduced 
proliferation and increased apoptosis (Lee et al., 1998). This phenotype is more severe in 
males where PGC deficiency is complete at the sixth generation (Lee et al., 1998). Taking 
together, these observations highlight the involvement of telomerase and telomere biology 
in TGCT development. 
Interestingly, pgct1 locus interacts with TRP53 to modulate TGCT susceptibility in mice 
(Muller et al., 2000), and Wrap53 is a natural antisense transcript of Trp53 and regulates the 
levels of TRP53 in response to DNA damage (Mahmoudi et al., 2009). Furthermore, 
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telomerase dysfunction activates TRP53-dependent apoptosis (Chin et al., 1999). By contrast, 
progeria-like syndromes have been associated with alterations in TRP53-dependent 
apoptosis (D. Liu et al., 2010). Given these results and that both congenital dyskeratosis and 
segmental progeria affect similar stem cell lineages as KIT/KITLG defect (melanogenesis, 
gametogenesis and hematopoiesis), we propose an interrelation between KIT/KITLG 
pathway, via TRP53, and telomerase, via TERT and WRAP53, during embryogenesis that 
contributes to tumorigenesis. 
4.3 Sex chromosomes and TGCTs  
Males with Klinefelter’s syndrome (also known as XXY syndrome) have 50-fold greater 
TGCT risk (Gustavson et al., 1975). Secondly, gain of X chromosomes has been described in 
TGCTs in humans (Peltomaki et al., 1990; Skotheim et al., 2001). Third, chromosome X from 
the C57BL/6 strain reduces tumor incidence in 129-Ter/Ter mice (Hammond et al., 2007), 
suggesting that genes linked to chromosome X both in mice and humans modulate TGCT 
incidence. In addition to DCK1 at Xq28 in humans, other interesting genes are Sperm protein 
associated with the nucleus mapped to the X chromosome (SpanX) clusters at Xq27, a locus named 
Tgct1, which has been linked with bilateral TGCTs and undescended testicular syndrome in 
humans (Rapley et al., 2000; Kouprina et al., 2004; Crockford et al., 2006). Although the 
function of SPANX proteins is unknown, evidence is accumulating that suggests their 
involvement in tumorigenesis. For example, SPANX genes are deregulated in Down’s 
syndrome subjects who have undescended testis and an increased risk of TGCTs (Satge et 
al., 1997), further suggesting interaction of genes located on chromosome X and 
chromosome 21 for TGCT susceptibility. SPANX genes have a testis-specific expression that 
is conserved in rodents and humans, and was also detected in EC clusters and TGCTs 
(Westbrook et al., 2004; Salemi et al., 2006).  
Similarly, a complete loss of chromosome Y in humans (45 XO karyotype) reduces TGCT 
susceptibility (Soh et al., 1992). Furthermore, the rare gr/gr deletion of the Y chromosome 
that removes part of the AZFc region (Yq11) is found in men with infertility and low-
penetrance for TGCT susceptibility (Nathanson et al., 2005). This deletion affects DAZ 
(deleted in azoospermia), BPY2 (Basic protein, Y-linked) and CDY1 (chromodomain protein, 
Y-linked 1). DAZ encodes an RNA-binding protein that interacts with the P-body 
component PUM2 in PGCs (Moore et al., 2003). The functions of CDY1 and BPY2 remain 
unknown. Moreover, aberrant expression of testis-specific protein on Y (TSPY) at Yp11 in 
humans may contribute to predisposition for TGCTs (Y.F. Lau, 1999), revealing a differential 
effect of the Y chromosome on TGCT risk. In mice, neither the MOLF-derived nor the 
C57BL/6-derived chromosome Y significantly affects susceptibility in 129 mice (Hammond 
et al., 2007). However, by using a sex-reversed mouse model, TGCTs were not found in the 
absence of the Y chromosome (Anderson et al., 2009b). Furthermore, a possible interaction, 
which suppress TGCT susceptibility in mice, was described between the Y-linked genes, 
which have a low-penetrance for TGCTs, and either the Dnd1 gene (chromosome 18) or the 
genes located on chromosome 19 (perhaps Dmrt1 given its role in sex differentiation and in 
TGCT susceptibility) (Anderson et al., 2009b). This hypothesis is supported by the fact that 
Dnd1 has sex-dependent effects on PGC survival and tumor susceptibility. Indeed, Dnd1 is 
differentially expressed in XX (down-regulation) and XY (up-regulation) gonads (Youngren 
et al., 2005). Loss of Dnd1 leads to PGC deficiency that increases with age in males, but not 
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Other tyrosine kinase receptors that are expressed in PGCs may also contribute to TGCT 
development. A strong candidate is RET, which is activated by the growth factor GDNF 
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known proto-oncogene (Grieco et al., 1990) and its expression is indirectly under the control 
of the TGCT modifier DMRT1 (Krentz et al., 2009). Allelic variations were identified at 
18q21 in TGCTs in humans (Murty et al., 1994; Crockford et al., 2006). This locus contains 
the Docking protein 6 (DOK6) gene that plays a role in RET signaling cascade (Crowder et al., 
2004). Interestingly, Dok6 gene is located on chromosome 18 in mice, reinforcing the 
hypothesis of the role of other tyrosine kinase receptors such as GDNF receptors on TGCT 
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telomere length that usually occurs during cell division, and thus preserves chromosomal 
integrity (Venteicher et al., 2009). The active telomerase complex involves TERT (telomerase 
inverse transcriptase), the RNA component TERC, the ribonucleoprotein dyskerin (encoded 
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dysfunction enhances tumor incidence in mice (Blasco et al., 1997). Thus, telomerase seems 
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Specific markers of TGCT susceptibility have been recently identified in humans at 12p13, 
which contains the gene encoding ATF7IP, an enhancer of TERT and TERC transcription, 
and at 5p15 within TERT (Turnbull et al., 2010). Furthermore, a marker of familial TGCT risk 
was located 50kb downstream of TERC (Crockford et al., 2006), and amplification of human 
Xq28 containing DCK1 was found in TGCTs (Skotheim et al., 2001). In mice, the primordial 
germ cell tumor 1 locus (pgct1), that contains Tert on chromosome 13, has been identified as 
an enhancer of TGCT susceptibility (Muller et al., 2000). Furthermore, loss of Tert in mice 
leads to PGC deficiency which increases accross generations, due to both reduced 
proliferation and increased apoptosis (Lee et al., 1998). This phenotype is more severe in 
males where PGC deficiency is complete at the sixth generation (Lee et al., 1998). Taking 
together, these observations highlight the involvement of telomerase and telomere biology 
in TGCT development. 
Interestingly, pgct1 locus interacts with TRP53 to modulate TGCT susceptibility in mice 
(Muller et al., 2000), and Wrap53 is a natural antisense transcript of Trp53 and regulates the 
levels of TRP53 in response to DNA damage (Mahmoudi et al., 2009). Furthermore, 
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telomerase dysfunction activates TRP53-dependent apoptosis (Chin et al., 1999). By contrast, 
progeria-like syndromes have been associated with alterations in TRP53-dependent 
apoptosis (D. Liu et al., 2010). Given these results and that both congenital dyskeratosis and 
segmental progeria affect similar stem cell lineages as KIT/KITLG defect (melanogenesis, 
gametogenesis and hematopoiesis), we propose an interrelation between KIT/KITLG 
pathway, via TRP53, and telomerase, via TERT and WRAP53, during embryogenesis that 
contributes to tumorigenesis. 
4.3 Sex chromosomes and TGCTs  
Males with Klinefelter’s syndrome (also known as XXY syndrome) have 50-fold greater 
TGCT risk (Gustavson et al., 1975). Secondly, gain of X chromosomes has been described in 
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humans may contribute to predisposition for TGCTs (Y.F. Lau, 1999), revealing a differential 
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C57BL/6-derived chromosome Y significantly affects susceptibility in 129 mice (Hammond 
et al., 2007). However, by using a sex-reversed mouse model, TGCTs were not found in the 
absence of the Y chromosome (Anderson et al., 2009b). Furthermore, a possible interaction, 
which suppress TGCT susceptibility in mice, was described between the Y-linked genes, 
which have a low-penetrance for TGCTs, and either the Dnd1 gene (chromosome 18) or the 
genes located on chromosome 19 (perhaps Dmrt1 given its role in sex differentiation and in 
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et al., 2005). Loss of Dnd1 leads to PGC deficiency that increases with age in males, but not 
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in females (T. Noguchi & M. Noguchi, 1985). Furthermore, the few mutant germ cells that 
successfully migrate to the gonad give rise to mature oocytes in females, while in testes, they 
give rise to TGCTs in 95% of cases (Cook et al., 2009).  
Thus, sex chromosomes seem to play a crucial role in TGCT susceptibility. Identification of 
the candidate genes and of their interrelation remains to be elucidated. 
4.4 RNA biology, epigenetic regulation and TGCTs  
The translational complex eIF2 is composed of the alpha (eIF2s1), beta (eIF2s2) and gamma 
(eIF2s3) subunits (Sarre, 1989). Eif2s2 is a TGCT modifier in mice (Heaney et al., 2009), but 
remains to be confirmed in humans. Eif2s3 is located on both Y (Eif2s3y) and X (Eif2s3x) 
chromosomes in mice (in humans, no Y homologues have been found) (Ehrmann et al., 
1998). Given the role of sex chromosomes discussed above, Eif2s3 should be considered as a 
candidate for TGCT susceptibility. EIF4E is another translational factor which acts 
downstream of PI3K/AKT pathway. Interestingly, eIF4E is a potent oncogene (Wendel et 
al., 2004), regulated by the poly(A)-binding protein and its cofactor PAIP2 (Yanagiya et al., 
2010). Paip2 is located on mouse chromosome 18 near the Ter locus (Asada et al., 1994). 
Finally, Eif3a encodes another translational factor located on chromosome 19 in mice within 
a region involved in TGCT susceptibility (Matin et al., 1999; Youngren et al., 2003), but its 
direct role in TGCTs remains to be tested in mice and humans.  
Translation is under the control of P-bodies, which regulate many mRNA processes (i.e. 
post-transcriptional regulation, degradation, storage, transport, and stabilization) in cells 
under normal physiological conditions or in response to stress (Seydoux & Braun, 2006; 
Parker & Sheth, 2007). P-bodies are essential for male PGC development and probably also 
for tumorigenesis given the involvement of its major components (Hayashi et al., 2008; K.M. 
Nelson & Weiss, 2008). DDX3, which encodes a helicase of P-body, is located on both Y 
(DDX3y) and X (DDX3x) chromosomes in mice and humans, and has been identified as a 
tumor suppressor (Chao et al., 2006). Given the role of sex chromosomes and the close 
location of Ddx3y and Eif2s3y in mice, DDX3 should also be considered as a candidate for 
TGCT susceptibility. Interestingly, another DDX gene (DDX23) is located at 12q13 in 
humans, a locus which has been associated with TGCTs (Crockford et al., 2006). In addition, 
PGCs lacking DICER1, another helicase, are depleted around E13.5 in mice (Hayashi et al., 
2008), suggesting an essential role of Dicer1 in PGC development. Dicer1 has been also 
identified as a potential tumor suppressor in mice and probably also in humans (Su et al., 
2010). Nanos1, which encodes an RNA binding protein, is located on chromosome 19 in 
mice, within a region involved in TGCT susceptibility (Matin et al., 1999; Youngren et al., 
2003). Finally, allelic variations within the X-fragile mental retardation (FMR) genes (FMR1, 
FMR1nb and FMR2) at Xq27 in humans have been identified in TGCTs (Crockford et al., 
2006). These genes encode RNA binding proteins that are involved in translation regulation 
through an interaction with the DICER and Argonaute proteins (Jin et al., 2004). The number 
of CGG trinucleotide repeats in the 5’-untranslated region of FMR1 and their DNA 
methylation pattern determine the severity of FMR-related pathogenicity (Fu et al., 1991; 
McConkie-Rosell et al., 1993). Furthermore, loss of Fmr1 alters both proliferation and 
differentiation of several stem cell lineages including PGCs (Castren et al., 2005), suggesting 
a role of FMR1 in TGCT susceptibility.  
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Additional evidence shows an association between DNA methylation and TGCT 
susceptibility. First, DNA methylation in male PGCs is largely erased at E10.5-E11.5 and 
partially reestablished at E13-E14 (Sasaki & Matsui, 2008). This epigenetic reprogramming 
completely overlaps the critical period for TGCT formation (E11.5-E13.5) (Stevens & Little, 
1954; Stevens, 1967). Secondly, the DNA methyltransferase DNMT3L has been recently 
identified as a novel marker of TGCTs in humans (Minami et al., 2010), in accordance with 
the fact that TGCTs have a distinct epigenetic profile from other cancers (Ushida et al., 2011). 
Third, other genetic markers for TGCTs have been identified: (1) in humans, at 2p23 which 
contains DNMT3A, and at 12q13 which contains gene encoding the histone deacetylase 
HDAC7 (Crockford et al., 2006); (2) in mice, on a region of chromosome 18 that contains 
genes encoding two methyl-binding proteins MBD1 and MBD2 (Anderson et al., 2009a), and 
on chromosome 19 at a region that contains the remodeling chromatin factor Smarca2 (Matin 
et al., 1999; Youngren et al., 2003). Other studies correlate up-regulation of DNMT3A with 
demethylation of specific loci in TGCTs in humans (Ishii et al., 2007), and inhibition of both 
DNMTs and HDACs with prevention of cancer formation (W.G. Zhu & Otterson, 2003). 
Another TGCT marker has been identified at 4q24 in humans near the CENP-E gene that 
encodes a centromeric-associated protein required for establishing and maintaining of the 
mitotic checkpoint (Abrieu et al., 2000; Rapley et al., 2009). CENP-E is described in mice as 
tumor-suppressing or -promoting factor depending on the context (Weaver et al., 2007). 
Interestingly, TRP53 has been associated with DNA demethylation (Ashur-Fabian et al., 
2010) and several TRP53-target genes show aberrant methylation pattern in TGCTs in 
humans (Christoph et al., 2007). 
5. Transgenerational genetic effects on TGCT susceptibility 
Growing evidence suggests an alternative molecular basis of inheritance that complements 
conventional Mendelian inheritance with a similar strength, frequency and persistence 
across multiple generations (V.R. Nelson & Nadeau, 2010). These alternatives could involve 
four different forms: (1) environmental factors that create an epigenetic state that persists 
across generations (transgenerational environmental effects); (2) ancestral genetic factors 
that are sufficient to initiate epigenetic inheritance (transgenerational genetic effects); (3) 
environmental factors that have an epigenetic effect only in genetically predisposed 
individuals (transgenerational gene-environmental interactions); and (4) genetic variants in 
parents and others in offspring that interact to create an epigenetic state in offspring 
(transgenerational gene-gene interactions) (V.R. Nelson & Nadeau, 2010). The evidence for 
transgenerational genetic effects, as well as the implication inheritance of TGCT 
susceptibility will be discussed in this section.  
5.1 Environmental effects  
Pesticides and insecticides were intensively used in agricultural industries during previous 
decades. These chemicals, which are now found in foods and water, contain endocrine 
disruptors that act primarily through nuclear hormone receptors such as estrogen and 
androgen receptors (Danchin et al., 2011). In utero, perinatal or neonatal exposures affect 
male reproduction leading to infertility with an increase of testicular abnormalities and 
germ cell cancers in humans (A. Giwercman & Y.L. Giwercman, 2011). These effects can be 
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in females (T. Noguchi & M. Noguchi, 1985). Furthermore, the few mutant germ cells that 
successfully migrate to the gonad give rise to mature oocytes in females, while in testes, they 
give rise to TGCTs in 95% of cases (Cook et al., 2009).  
Thus, sex chromosomes seem to play a crucial role in TGCT susceptibility. Identification of 
the candidate genes and of their interrelation remains to be elucidated. 
4.4 RNA biology, epigenetic regulation and TGCTs  
The translational complex eIF2 is composed of the alpha (eIF2s1), beta (eIF2s2) and gamma 
(eIF2s3) subunits (Sarre, 1989). Eif2s2 is a TGCT modifier in mice (Heaney et al., 2009), but 
remains to be confirmed in humans. Eif2s3 is located on both Y (Eif2s3y) and X (Eif2s3x) 
chromosomes in mice (in humans, no Y homologues have been found) (Ehrmann et al., 
1998). Given the role of sex chromosomes discussed above, Eif2s3 should be considered as a 
candidate for TGCT susceptibility. EIF4E is another translational factor which acts 
downstream of PI3K/AKT pathway. Interestingly, eIF4E is a potent oncogene (Wendel et 
al., 2004), regulated by the poly(A)-binding protein and its cofactor PAIP2 (Yanagiya et al., 
2010). Paip2 is located on mouse chromosome 18 near the Ter locus (Asada et al., 1994). 
Finally, Eif3a encodes another translational factor located on chromosome 19 in mice within 
a region involved in TGCT susceptibility (Matin et al., 1999; Youngren et al., 2003), but its 
direct role in TGCTs remains to be tested in mice and humans.  
Translation is under the control of P-bodies, which regulate many mRNA processes (i.e. 
post-transcriptional regulation, degradation, storage, transport, and stabilization) in cells 
under normal physiological conditions or in response to stress (Seydoux & Braun, 2006; 
Parker & Sheth, 2007). P-bodies are essential for male PGC development and probably also 
for tumorigenesis given the involvement of its major components (Hayashi et al., 2008; K.M. 
Nelson & Weiss, 2008). DDX3, which encodes a helicase of P-body, is located on both Y 
(DDX3y) and X (DDX3x) chromosomes in mice and humans, and has been identified as a 
tumor suppressor (Chao et al., 2006). Given the role of sex chromosomes and the close 
location of Ddx3y and Eif2s3y in mice, DDX3 should also be considered as a candidate for 
TGCT susceptibility. Interestingly, another DDX gene (DDX23) is located at 12q13 in 
humans, a locus which has been associated with TGCTs (Crockford et al., 2006). In addition, 
PGCs lacking DICER1, another helicase, are depleted around E13.5 in mice (Hayashi et al., 
2008), suggesting an essential role of Dicer1 in PGC development. Dicer1 has been also 
identified as a potential tumor suppressor in mice and probably also in humans (Su et al., 
2010). Nanos1, which encodes an RNA binding protein, is located on chromosome 19 in 
mice, within a region involved in TGCT susceptibility (Matin et al., 1999; Youngren et al., 
2003). Finally, allelic variations within the X-fragile mental retardation (FMR) genes (FMR1, 
FMR1nb and FMR2) at Xq27 in humans have been identified in TGCTs (Crockford et al., 
2006). These genes encode RNA binding proteins that are involved in translation regulation 
through an interaction with the DICER and Argonaute proteins (Jin et al., 2004). The number 
of CGG trinucleotide repeats in the 5’-untranslated region of FMR1 and their DNA 
methylation pattern determine the severity of FMR-related pathogenicity (Fu et al., 1991; 
McConkie-Rosell et al., 1993). Furthermore, loss of Fmr1 alters both proliferation and 
differentiation of several stem cell lineages including PGCs (Castren et al., 2005), suggesting 
a role of FMR1 in TGCT susceptibility.  
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Additional evidence shows an association between DNA methylation and TGCT 
susceptibility. First, DNA methylation in male PGCs is largely erased at E10.5-E11.5 and 
partially reestablished at E13-E14 (Sasaki & Matsui, 2008). This epigenetic reprogramming 
completely overlaps the critical period for TGCT formation (E11.5-E13.5) (Stevens & Little, 
1954; Stevens, 1967). Secondly, the DNA methyltransferase DNMT3L has been recently 
identified as a novel marker of TGCTs in humans (Minami et al., 2010), in accordance with 
the fact that TGCTs have a distinct epigenetic profile from other cancers (Ushida et al., 2011). 
Third, other genetic markers for TGCTs have been identified: (1) in humans, at 2p23 which 
contains DNMT3A, and at 12q13 which contains gene encoding the histone deacetylase 
HDAC7 (Crockford et al., 2006); (2) in mice, on a region of chromosome 18 that contains 
genes encoding two methyl-binding proteins MBD1 and MBD2 (Anderson et al., 2009a), and 
on chromosome 19 at a region that contains the remodeling chromatin factor Smarca2 (Matin 
et al., 1999; Youngren et al., 2003). Other studies correlate up-regulation of DNMT3A with 
demethylation of specific loci in TGCTs in humans (Ishii et al., 2007), and inhibition of both 
DNMTs and HDACs with prevention of cancer formation (W.G. Zhu & Otterson, 2003). 
Another TGCT marker has been identified at 4q24 in humans near the CENP-E gene that 
encodes a centromeric-associated protein required for establishing and maintaining of the 
mitotic checkpoint (Abrieu et al., 2000; Rapley et al., 2009). CENP-E is described in mice as 
tumor-suppressing or -promoting factor depending on the context (Weaver et al., 2007). 
Interestingly, TRP53 has been associated with DNA demethylation (Ashur-Fabian et al., 
2010) and several TRP53-target genes show aberrant methylation pattern in TGCTs in 
humans (Christoph et al., 2007). 
5. Transgenerational genetic effects on TGCT susceptibility 
Growing evidence suggests an alternative molecular basis of inheritance that complements 
conventional Mendelian inheritance with a similar strength, frequency and persistence 
across multiple generations (V.R. Nelson & Nadeau, 2010). These alternatives could involve 
four different forms: (1) environmental factors that create an epigenetic state that persists 
across generations (transgenerational environmental effects); (2) ancestral genetic factors 
that are sufficient to initiate epigenetic inheritance (transgenerational genetic effects); (3) 
environmental factors that have an epigenetic effect only in genetically predisposed 
individuals (transgenerational gene-environmental interactions); and (4) genetic variants in 
parents and others in offspring that interact to create an epigenetic state in offspring 
(transgenerational gene-gene interactions) (V.R. Nelson & Nadeau, 2010). The evidence for 
transgenerational genetic effects, as well as the implication inheritance of TGCT 
susceptibility will be discussed in this section.  
5.1 Environmental effects  
Pesticides and insecticides were intensively used in agricultural industries during previous 
decades. These chemicals, which are now found in foods and water, contain endocrine 
disruptors that act primarily through nuclear hormone receptors such as estrogen and 
androgen receptors (Danchin et al., 2011). In utero, perinatal or neonatal exposures affect 
male reproduction leading to infertility with an increase of testicular abnormalities and 
germ cell cancers in humans (A. Giwercman & Y.L. Giwercman, 2011). These effects can be 
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reversible, permanent or even transgenerational, and involve alterations of DNA 
methylation (Anway et al., 2005; Danchin et al., 2011; Kalfa et al., 2011).  
Other natural nutrients could also modulate predisposition to disease such as TGCTs. As 
discussed above, vitamin A plays an essential role in PGC development and might also 
influence TGCT susceptibility. Similarly, folate which is a methyl-donor nutrient affects 
DNA methylation and is essential for PGC development (Danchin et al., 2011). Determining 
the effects of folate and vitamins on TGCT susceptibility, and whether supply of these 
nutrients can reverse TGCT development is a challenge for future research both in rodents 
and humans. A related challenge is understanding relation between genetic modifiers and 
environmental factors on TGCT susceptibility. 
5.2 Parent-of-origin effects  
While environmental factors could affect reproductive health across generations in a parent-
of-origin manner (Anway et al., 2005; Kalfa et al., 2011), two examples reveal similar 
parental-dependent transgenerational effect of TGCT modifier genes in mice.  
Loss of KITLG (KitlgSl, KitlgSlJ and KitlgSlgb) in mice causes 2-fold increase of TGCT 
susceptibility in the 129 strain (Stevens, 1967; Heaney et al., 2008). Surprisingly, among the 
progeny of the KitlgSlgb/+ males, wild-type sons never develop TGCTs (5% expected), 
whereas wild-type sons of the reciprocal crosses (maternal KitlgSlgb allele) are affected at the 
expected rate (Fig. 2) (Heaney et al., 2008). Thus, absence of one Kitlg allele in the male 
germline leads to an epigenetic change that affects TGCT susceptibility in the predisposed 
129 strain. Whether this protective effect persists across generations is currently being tested 
(E. Leung & J.H. Nadeau). Determining the molecular basis of this epigenetic modification, 
and whether other Kitlg mutant males (i.e. KitlgSl and KitlgSlJ) have similar effects remain to 
be determined. 
 
Fig. 2. Example of parental transgenerational effects in a mouse model for TGCTs. 
Similarly, wild-type sons of females with the Ay allele, which acts as a TGCT suppressor due to 
the deletion of Eif2s2, have a 65% of risk being affected (80% expected) (Heaney et al., 2009; 
J.D. Heaney & J.H. Nadeau, unpublished), revealing another example of a transgenerational 
effect on TGCTs transmitted in this case through the maternal germ-lineage.  
5.3 Gene-gene interactions  
The intercross of Trp53 -/+ and KitWv -/+ mice yields {KitWv -/+; Trp53 -/+} double 
heterozygotes which are intercrossed to generate double homozygotes (Jordan et al., 1999). 
Surprisingly, {KitWv -/-; Trp53 -/-} males are fertile due to a rescue of PGCs at E13.5 (Jordan et 
al., 1999), confirming that the high rate of apoptosis observed in KitWv -/- embryonic gonads 
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depends on KIT/KITLG-TRP53 interactions. Loss of both TRP53 alleles is necessary to 
rescue fertility because both {KitWv -/-; Trp53 +/+} and {KitWv -/-; Trp53 -/+} males are sterile 
(Jordan et al., 1999). Interestingly, only 10% of normal {KitWv -/-; Trp53 -/-} germ cells are 
present in the adult testes, compared to 34% after birth. This deficiency in the adult testes 
correlates with presence of testicular abnormalities (germ cell radial migratory defect, 
meiotic failure and apoptosis). As discussed above, these testicular abnormalities could be 
the origin of TGCTs. Unfortunately, this study was conducted on a mixed background and 
the TGCT susceptibility of these offspring remains to be investigated in the 129 strain. 
However, intercrosses of Trp53 -/+ and KitlgSlJ -/+ mice give the double heterozygous {KitlgSlJ 
-/+; Trp53 -/+} males that have a surprising 4-fold reduced TGCT frequency (7%; 26% 
expected) (Lam et al., 2004), suggesting that Kitlg and Trp53 genes can interact to 
counterbalance their effects on TGCT susceptibility. The effect of this gene interaction on 
PGC development remains to be investigated. 
KitlgSlJ allele interacts also with the MOLF-derived chromosome 19. Indeed, the double 
heterozygotes {KitlgSlJ -/+; M19/+} have a significantly increased TGCT susceptibility (57%; 
45% expected) due to an increase in the number of bilateral cases (Lam et al., 2004). These 
results suggest that KitlgSlJ hemizygosity potentiates the effect of M19 on TGCT susceptibility.  
The intercross of C57BL/6-Bax -/- and 129-Ter/Ter mice yields double homozygotes {Ter/Ter; 
Bax -/-} that show at least 50% of PGCs rescued at E13.5 (Cook et al., 2009), demonstrating 
that the PGC deficiency in 129-Ter/Ter males is due to BAX-mediated apoptosis. However, 
rescued PGCs are completely lost in adult, suggesting that mechanisms affecting PGC 
development after E13 are BAX-independent in 129-Ter/Ter mice. This hypothesis is 
supported by the observation that loss of BAX does not affect the TGCT frequency, which 
remains elevated (91%; 94% expected) (Cook et al., 2009). Surprisingly, the {Ter/Ter; Bax -/+} 
males have a 2-fold decrease of tumor risk and {Ter/Ter; Bax +/+} males do not develop 
TGCTs (Cook et al., 2009). This protective phenotype is interesting but we cannot determine 
whether it results from a genetic background effect (C57BL/6 vs 129) or from a genetic 
interaction (Bax vs Dnd1). Backcrosses of the double homozygotes {Ter/Ter; Bax -/-} to pure 
C57BL/6 background mice suppress the TGCT susceptibility (Cook et al., 2011), favoring a 
background effect on TGCT susceptibility.  
The double {Ter/Ter; Sf1 -/+} mutants in the 129 strain have a 2-fold reduction in risk due to a 
reduced frequency of bilateral tumors (R. Zhu et al., 2010). Despite this protective effect on 
TGCT formation, all mutant males are sterile due to a complete germ cell deficiency (R. Zhu 
et al., 2010). This phenotype is similar as those observed in the {Ter/Ter; Bax -/+} males 
suggesting a common pathway involving both SF1 and BAX on PGC deficiency in 129-
Ter/Ter mice.  
The interaction of Ter allele with the four risk alleles KitlgSlJ, mutated Trp53, M19 and Ay in 
the respective double heterozygous males increased TGCT susceptibility at least 2-fold in 
the 129 strain by enhancing the frequency of bilateral tumors (Lam et al., 2007). Surprisingly, 
all {Ter/+; +/+} males of these four intercrosses also have a 2-fold increase in TGCT 
frequency, suggesting transgenerational epistasis that acts only in the presence of the Ter 
allele in the offspring generation. The mechanism underlying interactions with the Ter allele 
remains elusive, although the new role of DND1 in the micro-RNA biology (Kedde et al., 
2007) may be one ways by which this transgenerational effect acts.  
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reversible, permanent or even transgenerational, and involve alterations of DNA 
methylation (Anway et al., 2005; Danchin et al., 2011; Kalfa et al., 2011).  
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influence TGCT susceptibility. Similarly, folate which is a methyl-donor nutrient affects 
DNA methylation and is essential for PGC development (Danchin et al., 2011). Determining 
the effects of folate and vitamins on TGCT susceptibility, and whether supply of these 
nutrients can reverse TGCT development is a challenge for future research both in rodents 
and humans. A related challenge is understanding relation between genetic modifiers and 
environmental factors on TGCT susceptibility. 
5.2 Parent-of-origin effects  
While environmental factors could affect reproductive health across generations in a parent-
of-origin manner (Anway et al., 2005; Kalfa et al., 2011), two examples reveal similar 
parental-dependent transgenerational effect of TGCT modifier genes in mice.  
Loss of KITLG (KitlgSl, KitlgSlJ and KitlgSlgb) in mice causes 2-fold increase of TGCT 
susceptibility in the 129 strain (Stevens, 1967; Heaney et al., 2008). Surprisingly, among the 
progeny of the KitlgSlgb/+ males, wild-type sons never develop TGCTs (5% expected), 
whereas wild-type sons of the reciprocal crosses (maternal KitlgSlgb allele) are affected at the 
expected rate (Fig. 2) (Heaney et al., 2008). Thus, absence of one Kitlg allele in the male 
germline leads to an epigenetic change that affects TGCT susceptibility in the predisposed 
129 strain. Whether this protective effect persists across generations is currently being tested 
(E. Leung & J.H. Nadeau). Determining the molecular basis of this epigenetic modification, 
and whether other Kitlg mutant males (i.e. KitlgSl and KitlgSlJ) have similar effects remain to 
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the deletion of Eif2s2, have a 65% of risk being affected (80% expected) (Heaney et al., 2009; 
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effect on TGCTs transmitted in this case through the maternal germ-lineage.  
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depends on KIT/KITLG-TRP53 interactions. Loss of both TRP53 alleles is necessary to 
rescue fertility because both {KitWv -/-; Trp53 +/+} and {KitWv -/-; Trp53 -/+} males are sterile 
(Jordan et al., 1999). Interestingly, only 10% of normal {KitWv -/-; Trp53 -/-} germ cells are 
present in the adult testes, compared to 34% after birth. This deficiency in the adult testes 
correlates with presence of testicular abnormalities (germ cell radial migratory defect, 
meiotic failure and apoptosis). As discussed above, these testicular abnormalities could be 
the origin of TGCTs. Unfortunately, this study was conducted on a mixed background and 
the TGCT susceptibility of these offspring remains to be investigated in the 129 strain. 
However, intercrosses of Trp53 -/+ and KitlgSlJ -/+ mice give the double heterozygous {KitlgSlJ 
-/+; Trp53 -/+} males that have a surprising 4-fold reduced TGCT frequency (7%; 26% 
expected) (Lam et al., 2004), suggesting that Kitlg and Trp53 genes can interact to 
counterbalance their effects on TGCT susceptibility. The effect of this gene interaction on 
PGC development remains to be investigated. 
KitlgSlJ allele interacts also with the MOLF-derived chromosome 19. Indeed, the double 
heterozygotes {KitlgSlJ -/+; M19/+} have a significantly increased TGCT susceptibility (57%; 
45% expected) due to an increase in the number of bilateral cases (Lam et al., 2004). These 
results suggest that KitlgSlJ hemizygosity potentiates the effect of M19 on TGCT susceptibility.  
The intercross of C57BL/6-Bax -/- and 129-Ter/Ter mice yields double homozygotes {Ter/Ter; 
Bax -/-} that show at least 50% of PGCs rescued at E13.5 (Cook et al., 2009), demonstrating 
that the PGC deficiency in 129-Ter/Ter males is due to BAX-mediated apoptosis. However, 
rescued PGCs are completely lost in adult, suggesting that mechanisms affecting PGC 
development after E13 are BAX-independent in 129-Ter/Ter mice. This hypothesis is 
supported by the observation that loss of BAX does not affect the TGCT frequency, which 
remains elevated (91%; 94% expected) (Cook et al., 2009). Surprisingly, the {Ter/Ter; Bax -/+} 
males have a 2-fold decrease of tumor risk and {Ter/Ter; Bax +/+} males do not develop 
TGCTs (Cook et al., 2009). This protective phenotype is interesting but we cannot determine 
whether it results from a genetic background effect (C57BL/6 vs 129) or from a genetic 
interaction (Bax vs Dnd1). Backcrosses of the double homozygotes {Ter/Ter; Bax -/-} to pure 
C57BL/6 background mice suppress the TGCT susceptibility (Cook et al., 2011), favoring a 
background effect on TGCT susceptibility.  
The double {Ter/Ter; Sf1 -/+} mutants in the 129 strain have a 2-fold reduction in risk due to a 
reduced frequency of bilateral tumors (R. Zhu et al., 2010). Despite this protective effect on 
TGCT formation, all mutant males are sterile due to a complete germ cell deficiency (R. Zhu 
et al., 2010). This phenotype is similar as those observed in the {Ter/Ter; Bax -/+} males 
suggesting a common pathway involving both SF1 and BAX on PGC deficiency in 129-
Ter/Ter mice.  
The interaction of Ter allele with the four risk alleles KitlgSlJ, mutated Trp53, M19 and Ay in 
the respective double heterozygous males increased TGCT susceptibility at least 2-fold in 
the 129 strain by enhancing the frequency of bilateral tumors (Lam et al., 2007). Surprisingly, 
all {Ter/+; +/+} males of these four intercrosses also have a 2-fold increase in TGCT 
frequency, suggesting transgenerational epistasis that acts only in the presence of the Ter 
allele in the offspring generation. The mechanism underlying interactions with the Ter allele 
remains elusive, although the new role of DND1 in the micro-RNA biology (Kedde et al., 
2007) may be one ways by which this transgenerational effect acts.  
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6. Conclusions 
Mouse models of TGCTs have made major contributions to stem cell biology, 
developmental biology of the PGC lineage, and genetic and epigenetic studies of TGCT 
susceptibility.  
The germ cell lineage, which has been termed the ‘mother of all stem cells’, carries DNA and 
other molecular features that together constitute our genetic and epigenetic heritage 
(Donovan, 1998). Controlling differentiation and proliferation of PGCs, which belong to the 
only lineage of cells that naturally show totipotency is therefore essential for maintaining 
their integrity. Many factors have been shown to affect molecular mechanisms regulating 
pluripotency versus differentiation, proliferation versus death, and migration versus stasis 
during normal PGC development (Pesce et al., 1993; Lin et al., 2005; Shen et al., 2007; 
Heaney et al., 2009; Murphy et al., 2010; Cook et al., 2011). In parallel, insights are beginning 
to emerge about the ways in which anomalies in these factors and processes lead to 
transformation (Rotter et al., 1993; Kimura et al., 2003; Youngren et al., 2005; Heaney et al., 
2008; Krentz et al., 2009). Despite their fundamental relevance to understanding important 
aspects of human biology, these studies are obviously difficult to conduct in humans. Thus, 
studies of PGCs and their transformed derivatives in mice will likely remain relevant to our 
understanding of the genetics and developmental origins of TGCTs in humans. 
Despite being a common cancer in young men (Buetow, 1995), with heritable TGCT risk 
among the highest of all cancers (Gilbert et al., 2011), the genetic control of inherited 
susceptibility has proven to be remarkably elusive. However, with the availability of 
complete panels of genetic markers, high-throughput assays, and increasingly rigorous 
analytical methods, both linkage analysis and GWAS have begun to yield results. The first 
breakthrough involved the gr/gr deletion on the X chromosome (Nathanson et al., 2005), 
followed more recently with GWAS evidence for KITLG, SPRY4, DMRT1, TERT, BAK1 
and ATF7IP as strong candidate susceptibility genes (Rapley et al., 2009; Turnbull et al., 
2010; Kanetsky et al., 2009, 2011). The recent evidence for involvement of KITLG in 
humans was anticipated by corresponding evidence in mice involving mutations in the 
Kitlg gene (Heaney et al., 2008). The fact that some but not all Kitlg mutants affect 
susceptibility implies that allele-specific tests and structure-function studies will both be 
important to understand the ways in which KITLG variants affect TGCT susceptibility in 
humans.  
More recently, heritable epigenetic changes have been shown to strongly influence TGCT 
risk in mouse models. In particular, TGCT modifier genes in the parental generation were 
shown to interact with the Dnd1 modifier to increase both the number of affected males and 
the proportion of bilateral cases (Lam et al., 2007). Similar evidence for transgenerational 
genetic effects has also been reported for Kitlg mutants (Heaney et al., 2008). These and 
related discoveries suggest that heritable epigenetic changes might be as important as 
conventional genetic effects in controlling inherited TGCT risk, and might account for the 
substantial difference in risk between sons and brothers of cases (Hutter et al., 1967). 
Identifying the nature of these epigenetic factors, characterizing their molecular 
mechanisms, and testing their contribution to TGCT susceptibility in humans and in mice 
remain major challenges. 
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1. Introduction 
Over the past decade, accumulating evidence has implicated the phenomenon of epigenetic 
dysregulation in a variety of cancers (Biermann and Steger, 2007). Defined as the heritable 
changes in gene function that are not attributable to changes in DNA sequence, epigenetics 
involve biochemical modifications to DNA regulatory elements as well as to the tail regions 
of histone proteins (Maekawa and Watanabe, 2007). Lysine and arginine residues may be 
acetylated and methylated, with their effect being to activate or repress gene expression in 
the vicinity of that specific histone modification. Promoter regions of DNA are modified 
through the methylation of cytosine in CpG dinucleotides, resulting in the downregulation 
of those genes. Recent data suggest that these epigenetic modifications play a role in the 
development and progression of testicular germ cell tumors (TGCTs). This chapter will 
focus predominantly on adult TGCTs, along with their precursor carcinoma in situ (CIS), and 
will largely exclude the distinctive pediatric/prepubertal TGCTs. Many excellent reviews 
describing the classification of adult TGCTs exist (see Bahrami et al., 2007), and their content 
will not be duplicated here. Suffice it to say that the two main categories of TGCTs will be 
addressed in this chapter: the relatively undifferentiated seminomas, and the more 
differentiated non-seminomas (ranging from the less differentiated embryonal carcinomas 
to the highly differentiated yolk sac tumors, teratomas, and choriocarcinomas). Examination 
of histone modifications, histone modifying enzymes, genes exhibiting promoter DNA 
hypermethylation, and DNA methyltransferases in the context of CIS, seminomas, and non-
seminomas should increase our understanding of TGCT biology and potentially generate 
new clinical applications. 
2. Histone modifications and modifying enzymes 
Histone modifications greatly influence the transcription status of nearby genes in a highly 
specific manner. Lysine and arginine residues on the tails of histones H3 and H4 may be 
methylated to generate signatures that associate with active chromatin, such as the 
trimethylation of H3 lysine 4 (H3K4me3), or with repressed chromatin, such as the 
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dimethylation and trimethylation of histone H3 lysine 9 (H3K9me2 and H3K9me3). 
Histones may also be acetylated and deacetylated through histone acetyltransferases and 
histone deacetylases (HDACs), which correspond to active and repressed chromatin, 
respectively. Histone modifying enzymes that transfer methyl groups to target residues 
include EZH2, SUV39H1/2, and G9a, while enzymes that remove methyl groups include 
JMJD3 and UTX. 
2.1 H3K9 methylation 
Dimethylation and trimethylation of histone H3 lysine 9 (H3K9me2 and H3K9me3) are 
associated with transcriptional repression. These marks are established by the histone 
methyltransferases SUV39H1/2 and G9a, which are critical to establish and maintain 
regions of heterochromatin (Peters et al., 2001; Tachibana et al., 2007). When global H3K9 
methyl marks were examined in human CIS, Almstrup and colleagues found their presence 
to be very weak, revealing patterns similar to those in 20-40 week old normal fetal gonocytes 
(Almstrup et al., 2010). Interestingly, these marks were absent from the undifferentiated 
components of adult non-seminomatous embryonal carcinomas, but strongly detected in the 
undifferentiated seminomas (Almstrup et al., 2010). Godmann et al. reported the abundance 
of H3K9 methyl marks in both non-seminomas and seminomas, though they did not specify 
which nonseminomatous TGCTs they examined, nor their extent of differentiation 
(Godmann et al., 2009). In normal juvenile and adult mouse spermatogonia, the H3K9me2 
mark is notably absent from the undifferentiated cells that exhibit stem cell activity; its 
presence coincides with the lineage commitment to differentiation (Payne and Braun, 2006). 
H3K9me3, meanwhile, exhibits a distinct perinuclear distribution in the undifferentiated 
germ cells that shifts and broadens to abundant punctate foci in the differentiating Type A 
spermatogonia, localizing to heterochromatin-rich regions (Payne and Braun, 2006). While 
these patterns have not been extensively evaluated in human seminiferous tubules, it is 
tempting to speculate that the transformation from normal primordial germ 
cells/gonocytes to CIS, and then subsequently to seminomas, involves the progressive 
upregulation of histone methyltransferase activity that results in more abundant 
H3K9me2 and H3K9me3 marks.  
2.2 H3K27 methylation 
Trimethylation of histone H3 lysine 27 (H3K27me3) is associated with transcriptional 
repression; this mark is established by the histone methyltransferase EZH2, a member of the 
Polycomb group protein family (Cao and Zhang, 2004). Similar to H3K9 methyl marks, 
H3K27me3 distribution is weak in CIS and abundant in seminomas (Almstrup et al., 2010). 
Surprisingly, EZH2 is strongly detected in the cytoplasm of CIS. Given that this enzyme 
normally functions in the nucleus to methylate histones, its cytoplasmic accumulation likely 
reflects misregulation in CIS. EZH2 is absent from embryonal carcinomas, as is H3K27me3 
(Almstrup et al., 2010). 
2.3 H3K4 methylation 
Methylation of histone H3 lysine 4 (H3K4me1, H3K4me2, H3K4me3) is associated with 
transcriptional activation; H3K4me3 is established by the histone methyltransferase 
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Meisetz/PRDM9 (Hayashi et al., 2005). In contrast to the H3K9 and H3K27 methyl marks, 
H3K4me1 and H3K4me2/3 are abundant in CIS (Almstrup et al., 2010). Interestingly, the 
marks show opposing patterns in seminomas and non-seminomas (embryonal carcinomas), 
with H3K4me1 abundant in the former and weakly distributed in the latter, and H3K4me2/3 
exhibiting the reverse. The significance of this observation is not clear. H3K4me2/3 appears 
more broadly distributed than H3K4me1 in normal human adult spermatogenic cells 
(Almstrup et al., 2010). As with H3K9 methyl marks, Godmann and colleagues observe 
H3K4me3 in both non-seminomas and seminomas (Godmann et al., 2009). 
2.4 H4/H2AR3 methylation 
Symmetrical dimethylation of histones H4 and H2A at arginine 3 (H4R3me2 and 
H2AR3me2) is associated with transcriptional repression, and is established by the 
complex of BLIMP1 and PRMT5 (Ancelin et al., 2006). BLIMP1 is a transcriptional 
repressor with an N-terminal PR-SET domain, a C-terminal acidic domain, and five zinc-
finger domains; PRMT5 is a member of the protein arginine methyltransferase family. In 
normal fetal male germ cells of both mice and humans, H4R3me2 and H2AR3me2 marks 
are abundant in migratory primordial germ cells and gradually lost upon the transition to 
post-migratory gonocytes (Ancelin et al., 2006; Eckert, et al., 2008). In normal human adult 
testis, both marks are present in Type A spermatogonia, as well as round spermatids 
(Eckert et al., 2008). In CIS and seminomas, H4R3me2 and H2AR3me2 marks are 
abundant, with stronger signals detected in the seminomas. Heterogeneous, weak 
distribution of both marks is observed in some nonseminomatous TGCTs (embryonal 
carcinomas and teratomas). Dimethylation of H4R3 and H2AR3 is absent from 
choriocarcinomas. 
2.5 EZH2 
Enhancer of Zeste homolog 2 (EZH2) is a member of the Polycomb group protein family, 
functioning as a histone methyltransferase and adding methyl groups to H3K27 to 
generate H3K27me3. It is also considered to be an oncogene, shown to play a critical role 
in the development of breast cancer, prostate cancer, and malignant melanomas 
(Varambally et al., 2002; Bachmann et al., 2006). When examined in four cases of CIS, 64 
seminomas, and 36 non-seminomas (9 embryonal carcinomas, 3 teratocarcinomas, and 24 
mixed/combined TGCTs), EZH2 expression showed significant downregulation when 
compared to normal testicular tissue (~80 vs. ~18 in CIS/TGCTs, relative normalized 
units), as measured by quantitative real-time RT-PCR (Hinz et al., 2009). Surprisingly,  
this assessment of EZH2 mRNA conflicts with several observations of Almstrup  
and colleagues, who found a strong cytoplasmic distribution of EZH2 protein in CIS  
and abundant H3K27me3 marks in seminomas (Almstrup et al., 2010). These 
discrepancies could be due to the different methodologies used by the two groups (RT-
PCR with oligo primers vs. immunohistochemistry with antibodies), including the 
processing of the specimens. As EZH2 has previously been shown to be frequently 
expressed in TGCTs (Bracken et al., 2003), additional studies combining both quantitative 
RNA and protein analysis are warranted to clarify the role of EZH2 in CIS and 
seminomatous/nonseminomatous TGCTs. 
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Meisetz/PRDM9 (Hayashi et al., 2005). In contrast to the H3K9 and H3K27 methyl marks, 
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discrepancies could be due to the different methodologies used by the two groups (RT-
PCR with oligo primers vs. immunohistochemistry with antibodies), including the 
processing of the specimens. As EZH2 has previously been shown to be frequently 
expressed in TGCTs (Bracken et al., 2003), additional studies combining both quantitative 
RNA and protein analysis are warranted to clarify the role of EZH2 in CIS and 
seminomatous/nonseminomatous TGCTs. 
 




Protein arginine methyltransferase 5 forms a complex with the BLIMP1 transcriptional 
repressor to symmetrically dimethylate H4R3 and H2AR3. As with the histone methyl 
marks it generates, PRMT5 is abundant in migratory primordial germ cells and is 
downregulated after the cells transition to post-migratory gonocytes (Ancelin et al., 2006; 
Eckert, et al., 2008). In normal human adult testis, PRMT5 is present in pachytene 
spermatocytes and round spermatids (Eckert et al., 2008). In CIS and seminomas, PRMT5 is 
strongly detected in the cytoplasm and nucleus, respectively. This enzyme is also observed 
in the cytoplasm of embryonal carcinomas and teratomas, but is absent from 
choriocarcinomas. The cytoplasmic localization of PRMT5 in many of the CIS and TGCT 
samples, compared to the nuclear distribution seen in normal fetal germ cells, might 
indicate misregulation occurring as a result of the oncogenic transformation events. 
2.7 JMJD3 and UTX 
Jumonji domain containing 3 (JMJD3; KDM6B) and ubiquitously transcribed tetratricopeptide 
repeat, X chromosome (UTX; KDM6A) are histone demethylase enzymes that remove 
methyl groups from H3K27me2 and H3K27me3. These proteins therefore functionally 
oppose EZH2. In normal human adult testis, JMJD3 is weakly detected in spermatogonia 
and round spermatids, with stronger distribution observed in spermatocytes (Almstrup et 
al., 2010). UTX exhibits a similar overall pattern, with less intensity seen at each germ cell 
stage. In CIS, neither JMJD3 nor UTX are observed, which is concordant with high levels of 
EZH2 detected in these samples (Almstrup et al., 2010). In seminomatous and 
nonseminomatous TGCTs, JMJD3 and UTX both exhibit weak distribution at levels similar 
to EZH2. 
2.8 HDAC1 
Histone deacetylase 1 removes acetyl groups from lysine residues that are localized at the 
N-terminal end of histones. HDAC1, as with other members of the HDAC family, induces 
transcriptional repression (De Ruijter et al., 2003). In normal human adult testis, HDAC1 
protein is observed in the nuclei of spermatogonia and Sertoli cells (Omisanjo et al., 2007). In 
both seminomatous and nonseminomatous TGCTs (embryonal carcinomas and teratomas), 
HDAC1 is consistently detected. 
2.9 Histone modifications in Sertoli cells 
HDAC1 and H3K9me3, as well as other histone modifying enzymes and modified tail 
residues, are present in normal human and mouse Sertoli cells (Omisanjo et al., 2007; Payne 
and Braun, 2006). Because Sertoli cells must maintain constant physical contact with germ 
cells at all stages inside each seminiferous tubule, the influence they have upon 
spermatogenesis is profound. Two essential growth factors that ensure the survival and 
maintenance of spermatogenic cells, and which are expressed by Sertoli cells, are Steel 
(KITL) and glial cell line-derived neurotrophic factor (GDNF). Steel activates the kit receptor 
(KIT) on differentiating spermatogonia in the postnatal testis, while GDNF activates 
associated receptors in undifferentiated spermatogonia: GDNF family receptor alpha 1 
(GFRA1) and ret tyrosine kinase (RET; Sette et al., 2000; Jing et al., 1996; Viglietto et al., 
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2000). Loss-of-function mutations of Steel and Gdnf in Sertoli cells deleteriously affect germ 
cell fate (Tajima et al., 1994; Meng et al., 2000). The loss of spermatogenic cells due to 
infertility or TGCTs also alters the epigenetic state of Sertoli cells, resulting in an increase in 
global histone H4 acetylation within the Sertoli cell nuclei of these human testes (Faure et 
al., 2003). In patients with seminomas and Sertoli cell-only syndrome, hyperacetylated 
histone H4 is observed in 70% of Sertoli cells. When Sertoli cell-specific gene targeting in 
mice inactivates Sin3a, which normally encodes an HDAC1-interacting protein, mutant 
testes exhibit the following: a significant reduction in spermatogonial stem cells, a 
progressive loss of differentiating spermatogonia, and a block in spermatid elongation, 
followed by extensive germ cell degeneration (Payne et al., 2010). Additionally, fewer 
teratomas are formed in a mouse tumor induction assay when donor germ cells from fetal 
Sin3a-mutant testes are transplanted into recipient adult testes (Payne et al, 2010). These 
results suggest that the epigenome in normal Sertoli cells supports a niche for 
spermatogonial stem cell activity, and provides a permissive microenvironment for the 
formation of adult TGCTs from fetal CIS. Further investigation on how Sertoli cells 
contribute to the development of TGCTs should increase our understanding of extrinsic 
factors that influence tumorigenesis. 
3. Genes exhibiting promoter DNA hypermethylation 
Numerous studies have shown that repetitive DNA within the human genome, consisting of 
Small Interspersed Nuclear Elements (SINEs), Long Interspersed Nuclear Elements (LINEs), 
and Long Terminal Repeats (LTRs), is globally hypomethylated in tumors (Ehrlich and 
Wang, 1981; Gama-Sosa et al., 1983; Dunn, 2003; Rodriguez et al., 2006). These repetitive 
elements are enriched in m5C relative to the whole genome within non-tumorigenic cells, 
but exhibit reduced methylation relative to the genome in many cancers, including those of 
the breast and ovary (Narayan et al., 1998; Qu et al., 1999). One interpretation of these 
findings is that the loss of methylation in repetitive DNA promotes genomic instability, 
resulting in deletions, translocations, and chromosomal rearrangements (Eden et al., 2003; 
Esteller, 2008). Hypomethylated centromeric regions, for example, can contribute to 
aneuploidy, and the reduced methylation of satellite sequences can lead to inappropriate 
recombination (Hatziapostolou and Iliopoulos, 2011). Active LINEs and microsatellite DNA 
instability have both been discovered in TGCTs (Bratthauer and Fanning, 1992; Huddart et 
al., 1995). Interestingly, a recent study found that while seminomatous tumors contain both 
LINE1 and Alu repeats (SINE family members) in a hypomethylated state, 
nonseminomatous tumors exhibit hypomethylated LINE1, but methylated Alu repeats 
(Ushida et al., 2011). 
In contrast, single-copy DNA regulatory elements of specific categories of genes undergo 
hypermethylation in many tumors (Estécio and Issa, 2011). CpG islands within promoter 
regions are usually unmethylated in non-tumorigenic cells, permitting gene transcription 
under the appropriate conditions (Suzuki and Bird, 2008). De novo methylation of CpG 
islands induces transcriptional silencing, often repressing tumor suppressor gene activity 
that creates optimal conditions for the onset and progression of most cancers. One of the 
first genes discovered to exhibit promoter DNA hypermethylation in tumor cells was RB, 
retinoblastoma (Sakai et al., 1991). To date, many genes identified as being susceptible to 
hypermethylation are known to suppress epithelial cancers, including those of the testis, 
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2000). Loss-of-function mutations of Steel and Gdnf in Sertoli cells deleteriously affect germ 
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prostate, lung, and colon, as well as leukemias and lymphomas (Lind et al., 2007; Wali, 
2010). It is important to note that in the majority of TGCTs examined for hypermethylated 
gene promoters, CpG islands of most selected genes are methylated in non-seminomas, but 
are not appreciably methylated in seminomatous tumors (Koul et al., 2002; Honorio et al., 
2003, Lind et al., 2006). In support of this finding, global detection of m5C in CpG islands 
using a monoclonal antibody and immunohistochemistry revealed that the more 
differentiated TGCT histologies of non-seminomas (yolk sac tumors, teratomas, 
choriocarcinomas) exhibit hypermethylation, while the undifferentiated histology of 
seminomas do not show methylation (Wermann et al., 2010). Thus, it appears that in 
seminomas, both the repetitive DNA elements and the single-copy regulatory elements of 
genes are in an unmethylated state, highlighting a unique characteristic of these specific 
tumors. While many of the genes silenced by methylation are involved in DNA repair and 
the cell cycle checkpoint, others encode transcription factors, proteolytic enzymes, cell 
adhesion molecules, and proteins involved in various processes. Key genes that fall into 
each of these categories, identified to exhibit promoter DNA hypermethylation in TGCTs, 
will now be discussed in detail. 
3.1 DNA repair/cell cycle checkpoint genes 
RASSF1A 
This gene encodes the Ras association domain family 1 isoform A (RASSF1A). It is one of the 
most prevalent hypermethylated genes across all human cancers studied (Gordon and 
Baksh, 2011). In addition to TGCTs, RASSF1A is hypermethylated in the cancers of the 
breast, cervix, esophagus, brain, kidney, bladder, ovary, lung and skin (Pfeifer et al., 2002; 
Lusher et al., 2002; Koul et al., 2002; Honorio et al., 2003; Kuroki et al., 2003; Spugnardi et al., 
2003; Lind et al., 2006). RASSF1A tumor suppressor activity is important for DNA damage 
repair of double strand breaks and for pro-apoptotic mechanisms (Hamilton et al., 2009; 
Avruch et al., 2009). Four major studies detecting hypermethylated RASSF1A in untreated 
TGCTs have been published to date, with conflicting results for seminomas. Koul and 
colleagues reported that of the seminomatous and nonseminomatous TGCTs they 
examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~100% in yolk sac tumors, ~45% in embryonal carcinomas, ~22% in 
teratomas, and ~9% in mixed/combined tumors); only 1 of 29 seminomas exhibited 
hypermethylated RASSF1A (Koul et al., 2002). In their examination of TGCTs, Honorio et al. 
found hypermethylated CpG islands in 15 of 18 (83%) non-seminomas, with frequencies of 
80% (4/5) in yolk sac tumors, 60% (3/5) in embryonal carcinomas, 100% (5/5) in teratomas, 
and 100% in two choriocarcinomas and one mixed tumor; 4 of 10 (40%) seminomas 
exhibited RASSF1A hypermethylation, distinguishing these results from the previous study 
(Honorio et al., 2003). Lind and colleagues, meanwhile, observed elevated methylation in 10 
of 35 (28.6%) nonseminomatous TGCTs and in 0 of 19 seminomas (Lind et al., 2006). The 
frequencies in the non-seminomas were: 50% (3/6) in yolk sac tumors, 37.5% (6/16) in 
embryonal carcinomas, 77.8% (7/9) in teratomas, and 100% in one choriocarcinoma. In 
contrast, Tian et al. recently reported that both seminomatous and nonseminomatous 
tumors contained equivalent frequencies of hypermethylated RASSF1A CpG islands 
(~78.6%), with an average of 13/16 CpG sites in a methylated state as measured by sodium 
bisulfite sequencing (Tian et al., 2011). In an earlier study, Kawakami and colleagues did not 
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detect the hypermethylation of RASSF1A, or any other gene they examined, in any of the 
TGCTs under investigation (Kawakami et al., 2003). Thus, from all of these studies it 
appears that RASSF1A is hypermethylated at a frequency of up to 100% in yolk sac tumors, 
teratomas, choriocarcinomas, and up to 60% in embryonal carcinomas, but exhibits 
divergent methylation patterns in seminomas. Further characterization of RASSF1A in 
seminomas is needed to address these discrepancies. Interestingly, when Koul and 
colleagues examined 39 cisplatin-resistant and 31 cisplatin-sensitive non-seminomas, 
RASSF1A exhibited a much higher frequency of methylation in the cisplatin-resistant group 
(52%) than in the cisplatin-sensitive group (28%), though the sample size was too small for 
statistical significance (Koul et al., 2004). The methylation status of the RASSF1A promoter 
might therefore be a useful prognostic indicator of nonseminomatous tumor sensitivity to 
cisplatin, and could allow for the adjustment of chemotherapy treatment strategy 
accordingly. Finally, it has been shown that hypermethylated RASSF1A CpG islands are 
detected in the cell-free circulating serum DNA of TGCT patients at a frequency of ~47% 
(Ellinger et al., 2009). This method of detection could provide an additional benefit to 
existing parameters in the clinic. 
MGMT 
This gene encodes O-6-methylguanine-DNA methyltransferase (MGMT), which provides 
defense against the mutagenic effects of O-6-methylguanine (alkylation adduct) in DNA and 
potential G-to-A transition mutations. MGMT repairs the O-6 position of guanine in DNA 
by transferring the alkyl group from this position to a cysteine residue within the structure 
of the protein (Mitra, 2007). The MGMT promoter is hypermethylated in glioblastomas, 
hepatocellular carcinomas, colorectal, esophageal, and lung cancers, as well as in TGCTs 
(Cao et al., 2009; Zhang et al., 2003; Ahlquist et al., 2008; Baumann et al., 2006; Wolf et al., 
2001; Smith-Sørensen et al., 2002; Koul et al., 2002; Honorio et al., 2003; Koul et al., 2004). 
Smith-Sørensen and colleagues identified hypermethylated CpG islands in both 
seminomatous tumors (24%, 8/33) and nonseminomatous tumors (69%, 24/35), while the 
groups of Koul and Honorio found MGMT hypermethylation only in non-seminomas 
(frequencies of ~25% in yolk sac tumors, ~45% in embryonal carcinomas, ~30% in teratomas, 
and ~9% in mixed/combined tumors for Koul et al.); 44% of non-seminomas exhibited 
hypermethylated MGMT for Honorio and colleagues (Smith-Sørensen et al., 2002; Koul et 
al., 2002; Honorio et al., 2003). In contrast to RASSF1A, Koul et al. found that MGMT was 
hypermethylated more often in cisplatin-sensitive non-seminomas (31%) than in cisplatin-
resistant tumors (13%), though the P-value was not significant (Koul et al., 2004). Compared 
to the hypermethylation of RASSF1A and all other genes examined in TGCTs, MGMT 
exhibited the highest frequency of hypermethylation in seminomas (11%, 8 of 72 combined 
from all three studies). Given the overall small sample sizes and discrepancies reported 
among the groups, it would be worth conducting a larger study examining RASSF1A and 
MGMT hypermethylation in seminomas to more accurately conclude whether the CpG 
islands of these genes might be the exception to the overall trend of unmethylated cytosine 
in seminoma DNA. 
BRCA1 
Breast cancer 1 encodes a multi-faceted protein involved in numerous cellular functions: 
DNA damage repair, cell cycle checkpoint, centrosome duplication, transcriptional 
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examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~100% in yolk sac tumors, ~45% in embryonal carcinomas, ~22% in 
teratomas, and ~9% in mixed/combined tumors); only 1 of 29 seminomas exhibited 
hypermethylated RASSF1A (Koul et al., 2002). In their examination of TGCTs, Honorio et al. 
found hypermethylated CpG islands in 15 of 18 (83%) non-seminomas, with frequencies of 
80% (4/5) in yolk sac tumors, 60% (3/5) in embryonal carcinomas, 100% (5/5) in teratomas, 
and 100% in two choriocarcinomas and one mixed tumor; 4 of 10 (40%) seminomas 
exhibited RASSF1A hypermethylation, distinguishing these results from the previous study 
(Honorio et al., 2003). Lind and colleagues, meanwhile, observed elevated methylation in 10 
of 35 (28.6%) nonseminomatous TGCTs and in 0 of 19 seminomas (Lind et al., 2006). The 
frequencies in the non-seminomas were: 50% (3/6) in yolk sac tumors, 37.5% (6/16) in 
embryonal carcinomas, 77.8% (7/9) in teratomas, and 100% in one choriocarcinoma. In 
contrast, Tian et al. recently reported that both seminomatous and nonseminomatous 
tumors contained equivalent frequencies of hypermethylated RASSF1A CpG islands 
(~78.6%), with an average of 13/16 CpG sites in a methylated state as measured by sodium 
bisulfite sequencing (Tian et al., 2011). In an earlier study, Kawakami and colleagues did not 
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detect the hypermethylation of RASSF1A, or any other gene they examined, in any of the 
TGCTs under investigation (Kawakami et al., 2003). Thus, from all of these studies it 
appears that RASSF1A is hypermethylated at a frequency of up to 100% in yolk sac tumors, 
teratomas, choriocarcinomas, and up to 60% in embryonal carcinomas, but exhibits 
divergent methylation patterns in seminomas. Further characterization of RASSF1A in 
seminomas is needed to address these discrepancies. Interestingly, when Koul and 
colleagues examined 39 cisplatin-resistant and 31 cisplatin-sensitive non-seminomas, 
RASSF1A exhibited a much higher frequency of methylation in the cisplatin-resistant group 
(52%) than in the cisplatin-sensitive group (28%), though the sample size was too small for 
statistical significance (Koul et al., 2004). The methylation status of the RASSF1A promoter 
might therefore be a useful prognostic indicator of nonseminomatous tumor sensitivity to 
cisplatin, and could allow for the adjustment of chemotherapy treatment strategy 
accordingly. Finally, it has been shown that hypermethylated RASSF1A CpG islands are 
detected in the cell-free circulating serum DNA of TGCT patients at a frequency of ~47% 
(Ellinger et al., 2009). This method of detection could provide an additional benefit to 
existing parameters in the clinic. 
MGMT 
This gene encodes O-6-methylguanine-DNA methyltransferase (MGMT), which provides 
defense against the mutagenic effects of O-6-methylguanine (alkylation adduct) in DNA and 
potential G-to-A transition mutations. MGMT repairs the O-6 position of guanine in DNA 
by transferring the alkyl group from this position to a cysteine residue within the structure 
of the protein (Mitra, 2007). The MGMT promoter is hypermethylated in glioblastomas, 
hepatocellular carcinomas, colorectal, esophageal, and lung cancers, as well as in TGCTs 
(Cao et al., 2009; Zhang et al., 2003; Ahlquist et al., 2008; Baumann et al., 2006; Wolf et al., 
2001; Smith-Sørensen et al., 2002; Koul et al., 2002; Honorio et al., 2003; Koul et al., 2004). 
Smith-Sørensen and colleagues identified hypermethylated CpG islands in both 
seminomatous tumors (24%, 8/33) and nonseminomatous tumors (69%, 24/35), while the 
groups of Koul and Honorio found MGMT hypermethylation only in non-seminomas 
(frequencies of ~25% in yolk sac tumors, ~45% in embryonal carcinomas, ~30% in teratomas, 
and ~9% in mixed/combined tumors for Koul et al.); 44% of non-seminomas exhibited 
hypermethylated MGMT for Honorio and colleagues (Smith-Sørensen et al., 2002; Koul et 
al., 2002; Honorio et al., 2003). In contrast to RASSF1A, Koul et al. found that MGMT was 
hypermethylated more often in cisplatin-sensitive non-seminomas (31%) than in cisplatin-
resistant tumors (13%), though the P-value was not significant (Koul et al., 2004). Compared 
to the hypermethylation of RASSF1A and all other genes examined in TGCTs, MGMT 
exhibited the highest frequency of hypermethylation in seminomas (11%, 8 of 72 combined 
from all three studies). Given the overall small sample sizes and discrepancies reported 
among the groups, it would be worth conducting a larger study examining RASSF1A and 
MGMT hypermethylation in seminomas to more accurately conclude whether the CpG 
islands of these genes might be the exception to the overall trend of unmethylated cytosine 
in seminoma DNA. 
BRCA1 
Breast cancer 1 encodes a multi-faceted protein involved in numerous cellular functions: 
DNA damage repair, cell cycle checkpoint, centrosome duplication, transcriptional 
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regulation, and many others (Deng and Brodie, 2000). Hypermethylated BRCA1 is observed 
in a variety of cancers, including breast, ovary, bladder, lung, and testis (Rice et al., 2000; 
Bianco et al., 2000; Cabello et al., 2011; Wang et al., 2008; Koul et al., 2002). Koul and 
colleagues reported that of the seminomatous and nonseminomatous TGCTs they 
examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~49% in yolk sac tumors, and equivalent percentages in embryonal 
carcinomas, teratomas, and mixed/combined tumors, 20-24%); only 1 of 29 seminomas 
exhibited hypermethylated BRCA1 (Koul et al., 2002). No differences were observed 
between cisplatin-sensitive (31%) and –resistant (30%) non-seminomas with respect to CpG 
island methylation (Koul et al., 2004). 
FANCF 
Fanconi anemia, complementation group F encodes a DNA repair protein that supports post-
replication repair, cell cycle checkpoint function, and maintenance of normal chromosome 
stability (Léveillé et al., 2004). FANCF is hypermethylated in cervical and ovarian cancers, as 
well as TGCTs (Narayan et al., 2004; Taniguchi et al., 2003; Koul et al., 2004). Koul and 
colleagues examined CpG island methylation only in nonseminomatous tumors, and found 
the overall frequency to be 5.7%. No differences were observed between cisplatin-sensitive 
(7%) and –resistant (6%) non-seminomas with respect to hypermethylated FANCF (Koul et 
al., 2004). 
XPA 
Xeroderma pigmentosum, complementation group A encodes a zinc finger protein that 
participates in the initial step of DNA excision repair (de Vries and van Steeg, 1996). XPA 
guards against the harmful effects of UV-B radiation and chemical compounds that would 
otherwise impair DNA replication and RNA transcription. While XPA expression is 
diminished in some colorectal cancers, CpG methylation has only been observed in one 
nonseminomatous TGCT (Yu et al., 2006; Lind et al., 2006). Lind and colleagues found that 
one of 6 yolk sac tumors exhibited hypermethylated XPA; no methylation was detected in 
any of 16 embryonal carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined 
tumors, and 20 seminomas (Lind et al., 2006). Thus, it appears that XPA is not appreciably 
methylated in either seminomas or non-seminomas. 
MLH1 
mutL homolog 1 (a homolog of the E. coli DNA mismatch repair gene mutL) encodes a protein 
that forms a component of the post-replicative DNA mismatch repair system. MLH1 is 
involved in DNA damage signaling, inducing cell cycle arrest and apoptosis under certain 
conditions (Buermeyer et al., 1999). The MLH1 promoter is hypermethylated in numerous 
cancers, including colorectal, gastric, and endometrial carcinomas, and tumors of the breast, 
ovary, and testis (Herman et al., 1998; Leung et al., 1999; Esteller et al., 1998; Murata et al., 
2002; Strathdee et al., 1999; Koul et al., 2002; Olasz et al., 2005). Koul and colleagues reported 
that of the seminomatous and nonseminomatous TGCTs they examined, nearly all of the 
hypermethylated CpG islands were observed in non-seminomas (no methylation detected 
in yolk sac tumors or teratomas, and frequencies of <10% in embryonal carcinomas and 
mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated MLH1 (Koul 
et al., 2002). Olasz et al. found an overall methylation frequency of 21.6% in the TGCTs they 
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examined, yet only 1 in 15 samples from refractory tumors showed CpG hypermethylation 
(Olasz et al., 2005). Unlike what has been observed in familiar colorectal cancer, no 
correlation exists between MLH1 methylation status and microsatellite instability in TGCTs 
(Herman et al., 1998; Olasz et al., 2005). No relationship is seen between the clinical outcome 
of TGCTs and MLH1 hypermethylation, dampening its prospect as a potential biomarker. 
APC 
adenomatous polyposis coli encodes a tumor suppressor protein that antagonizes Wnt 
signaling. APC is also critical for cell migration and adhesion, transcriptional activation, 
DNA repair, and apoptosis (Senda et al., 2007). Hypermethylated APC is observed in many 
cancers, including colorectal, esophageal, breast, lung, prostate, and testis (Hiltunen et al., 
1997; Kawakami et al., 2000; Virmani et al., 2001; Yegnasubramanian et al., 2004; Koul et al., 
2002; Honorio et al., 2003). Koul and colleagues found an overall CpG methylation 
frequency of 9.8% in the nonseminomatous TGCTs they examined (~100% in yolk sac 
tumors, ~12% in teratomas, and ~3% in mixed/combined tumors; no methylation seen in 
embryonal carcinomas or seminomas), while Honorio et al. detected APC hypermethylation 
in 29% of non-seminomas (Koul et al., 2002; Honorio et al., 2003). No differences were 
observed between cisplatin-sensitive (24%) and –resistant (29%) non-seminomas with 
respect to hypermethylated APC (Koul et al., 2004). It was also recently shown that 
hypermethylated CpG islands of APC are detected in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~58% (Ellinger et al., 2009). 
FHIT 
fragile histidine triad gene encodes an enzyme, diadenosine 5',5'''-P1,P3-triphosphate 
hydrolase, that is involved in purine metabolism. It also promotes genomic integrity 
through DNA damage response and DNA repair mechanisms (Saldivar et al., 2010). FHIT is 
one of the most frequent targets of allele deletion in tumors, and is hypermethylated in 
cancers of the lung, cervix, liver, and testis (Hsu et al., 2007; Ki et al., 2008; Iyer et al., 2010; 
Koul et al., 2002; Honorio et al., 2003). Koul and colleagues observed FHIT 
hypermethylation at an overall frequency of 6.5% in non-seminomas (~49% in yolk sac 
tumors, ~8% in embryonal carcinomas, ~2% in teratomas, and ~3% in mixed/combined 
tumors), while Honorio et al. detected CpG methylation in 29% of nonseminomatous 
tumors (Koul et al., 2002; Honorio et al., 2003). No differences were observed between 
cisplatin-sensitive (7%) and –resistant (6%) non-seminomas with respect to hypermethylated 
FHIT (Koul et al., 2004). 
CDKN2A 
cyclin-dependent kinase inhibitor 2A generates multiple transcript variants that differ in their 
first exons. One of the transcripts contains an alternate open reading frame (ARF), yielding a 
protein that stabilizes tumor suppressor p53 through the sequestration of MDM2 (Gjerset, 
2006). CDKN2A can also induce cell cycle arrest in G1 and G2, and promote apoptosis. 
CDKN2A hypermethylation in the forms of p14(ARF) and p16(INK) has been detected in 
numerous cancers, including those of the colon, stomach, kidney, uterus, ovary, and testis 
(Esteller et al., 2001; Chaubert et al., 1997). Variable results have been shown for TGCTs. 
Chaubert and colleagues reported the presence of hypermethylated CDKN2A in 13 of 26 
(50%) TGCTs using the method of PCR amplification after HpaII enzyme digestion 
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regulation, and many others (Deng and Brodie, 2000). Hypermethylated BRCA1 is observed 
in a variety of cancers, including breast, ovary, bladder, lung, and testis (Rice et al., 2000; 
Bianco et al., 2000; Cabello et al., 2011; Wang et al., 2008; Koul et al., 2002). Koul and 
colleagues reported that of the seminomatous and nonseminomatous TGCTs they 
examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~49% in yolk sac tumors, and equivalent percentages in embryonal 
carcinomas, teratomas, and mixed/combined tumors, 20-24%); only 1 of 29 seminomas 
exhibited hypermethylated BRCA1 (Koul et al., 2002). No differences were observed 
between cisplatin-sensitive (31%) and –resistant (30%) non-seminomas with respect to CpG 
island methylation (Koul et al., 2004). 
FANCF 
Fanconi anemia, complementation group F encodes a DNA repair protein that supports post-
replication repair, cell cycle checkpoint function, and maintenance of normal chromosome 
stability (Léveillé et al., 2004). FANCF is hypermethylated in cervical and ovarian cancers, as 
well as TGCTs (Narayan et al., 2004; Taniguchi et al., 2003; Koul et al., 2004). Koul and 
colleagues examined CpG island methylation only in nonseminomatous tumors, and found 
the overall frequency to be 5.7%. No differences were observed between cisplatin-sensitive 
(7%) and –resistant (6%) non-seminomas with respect to hypermethylated FANCF (Koul et 
al., 2004). 
XPA 
Xeroderma pigmentosum, complementation group A encodes a zinc finger protein that 
participates in the initial step of DNA excision repair (de Vries and van Steeg, 1996). XPA 
guards against the harmful effects of UV-B radiation and chemical compounds that would 
otherwise impair DNA replication and RNA transcription. While XPA expression is 
diminished in some colorectal cancers, CpG methylation has only been observed in one 
nonseminomatous TGCT (Yu et al., 2006; Lind et al., 2006). Lind and colleagues found that 
one of 6 yolk sac tumors exhibited hypermethylated XPA; no methylation was detected in 
any of 16 embryonal carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined 
tumors, and 20 seminomas (Lind et al., 2006). Thus, it appears that XPA is not appreciably 
methylated in either seminomas or non-seminomas. 
MLH1 
mutL homolog 1 (a homolog of the E. coli DNA mismatch repair gene mutL) encodes a protein 
that forms a component of the post-replicative DNA mismatch repair system. MLH1 is 
involved in DNA damage signaling, inducing cell cycle arrest and apoptosis under certain 
conditions (Buermeyer et al., 1999). The MLH1 promoter is hypermethylated in numerous 
cancers, including colorectal, gastric, and endometrial carcinomas, and tumors of the breast, 
ovary, and testis (Herman et al., 1998; Leung et al., 1999; Esteller et al., 1998; Murata et al., 
2002; Strathdee et al., 1999; Koul et al., 2002; Olasz et al., 2005). Koul and colleagues reported 
that of the seminomatous and nonseminomatous TGCTs they examined, nearly all of the 
hypermethylated CpG islands were observed in non-seminomas (no methylation detected 
in yolk sac tumors or teratomas, and frequencies of <10% in embryonal carcinomas and 
mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated MLH1 (Koul 
et al., 2002). Olasz et al. found an overall methylation frequency of 21.6% in the TGCTs they 
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examined, yet only 1 in 15 samples from refractory tumors showed CpG hypermethylation 
(Olasz et al., 2005). Unlike what has been observed in familiar colorectal cancer, no 
correlation exists between MLH1 methylation status and microsatellite instability in TGCTs 
(Herman et al., 1998; Olasz et al., 2005). No relationship is seen between the clinical outcome 
of TGCTs and MLH1 hypermethylation, dampening its prospect as a potential biomarker. 
APC 
adenomatous polyposis coli encodes a tumor suppressor protein that antagonizes Wnt 
signaling. APC is also critical for cell migration and adhesion, transcriptional activation, 
DNA repair, and apoptosis (Senda et al., 2007). Hypermethylated APC is observed in many 
cancers, including colorectal, esophageal, breast, lung, prostate, and testis (Hiltunen et al., 
1997; Kawakami et al., 2000; Virmani et al., 2001; Yegnasubramanian et al., 2004; Koul et al., 
2002; Honorio et al., 2003). Koul and colleagues found an overall CpG methylation 
frequency of 9.8% in the nonseminomatous TGCTs they examined (~100% in yolk sac 
tumors, ~12% in teratomas, and ~3% in mixed/combined tumors; no methylation seen in 
embryonal carcinomas or seminomas), while Honorio et al. detected APC hypermethylation 
in 29% of non-seminomas (Koul et al., 2002; Honorio et al., 2003). No differences were 
observed between cisplatin-sensitive (24%) and –resistant (29%) non-seminomas with 
respect to hypermethylated APC (Koul et al., 2004). It was also recently shown that 
hypermethylated CpG islands of APC are detected in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~58% (Ellinger et al., 2009). 
FHIT 
fragile histidine triad gene encodes an enzyme, diadenosine 5',5'''-P1,P3-triphosphate 
hydrolase, that is involved in purine metabolism. It also promotes genomic integrity 
through DNA damage response and DNA repair mechanisms (Saldivar et al., 2010). FHIT is 
one of the most frequent targets of allele deletion in tumors, and is hypermethylated in 
cancers of the lung, cervix, liver, and testis (Hsu et al., 2007; Ki et al., 2008; Iyer et al., 2010; 
Koul et al., 2002; Honorio et al., 2003). Koul and colleagues observed FHIT 
hypermethylation at an overall frequency of 6.5% in non-seminomas (~49% in yolk sac 
tumors, ~8% in embryonal carcinomas, ~2% in teratomas, and ~3% in mixed/combined 
tumors), while Honorio et al. detected CpG methylation in 29% of nonseminomatous 
tumors (Koul et al., 2002; Honorio et al., 2003). No differences were observed between 
cisplatin-sensitive (7%) and –resistant (6%) non-seminomas with respect to hypermethylated 
FHIT (Koul et al., 2004). 
CDKN2A 
cyclin-dependent kinase inhibitor 2A generates multiple transcript variants that differ in their 
first exons. One of the transcripts contains an alternate open reading frame (ARF), yielding a 
protein that stabilizes tumor suppressor p53 through the sequestration of MDM2 (Gjerset, 
2006). CDKN2A can also induce cell cycle arrest in G1 and G2, and promote apoptosis. 
CDKN2A hypermethylation in the forms of p14(ARF) and p16(INK) has been detected in 
numerous cancers, including those of the colon, stomach, kidney, uterus, ovary, and testis 
(Esteller et al., 2001; Chaubert et al., 1997). Variable results have been shown for TGCTs. 
Chaubert and colleagues reported the presence of hypermethylated CDKN2A in 13 of 26 
(50%) TGCTs using the method of PCR amplification after HpaII enzyme digestion 
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(Chaubert et al., 1997). The groups of Smith-Sørensen, Honorio, and Kawakami, in contrast, 
were not able to detect methylated CpG islands of CDKN2A when examined by 
methylation-specific PCR (Smith-Sørensen et al., 2002; Honorio et al., 2003; Kawakami et al., 
2003). Differing experimental strategies might explain this discrepancy. Hypermethylation 
of p14(ARF) and p16(INK) was recently observed in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~53% (Ellinger et al., 2009). 
3.2 Transcription factor genes 
NANOG 
This gene encodes an important regulator of pluripotency maintenance in the inner cell 
mass of blastocyst-stage embryos and in undifferentiated embryonic stem cells. NANOG 
prevents differentiation into mesoderm by interacting with SMAD1 and blocking the 
recruitment of co-activators in that signaling pathway (Suzuki et al., 2006). Migratory 
primordial germ cells express NANOG, but upon the differentiation of male germ cells into 
fetal gonocytes and neonatal spermatogonia, NANOG is downregulated (Gaskell et al., 
2004). Thus, normal juvenile and adult male germ cells do not express NANOG. 
Interestingly, Nettersheim et al. detected hypomethylated NANOG, and corresponding 
protein, in all seminomas and embryonal carcinomas (undifferentiated non-seminomas) 
they obtained from TGCT patients (Nettersheim et al., 2011). In contrast, all differentiated 
non-seminomas (yolk sac tumors, teratomas, and choriocarcinomas) exhibited CpG 
hypermethylation and an absence of NANOG protein. Similarly, normal adult 
spermatogonia contain hypermethylated NANOG, supporting the prevailing hypothesis 
that seminomas are derived from gonocyte precursors in the fetal gonad (Nettersheim et al., 
2011). Thus, differences within the state of TGCT differentiation correlate with the extent of 
NANOG hypermethylation. 
HIC1 
hypermethylated in cancer 1 encodes a transcriptional repressor protein that functionally 
interacts with p53 to suppress the development of cancer throughout aging (Chen et al., 
2005). The HIC1 promoter is hypermethylated in many cancers, including those of the 
breast, cervix, and testis (Fujii et al., 1998; Dong et al., 2001; Koul et al., 2002). Koul and 
colleagues observed HIC1 hypermethylation only in non-seminomas (frequencies of ~100% 
in yolk sac tumors, ~35% in embryonal carcinomas, ~21% in teratomas, and ~9% in 
mixed/combined tumors). None of 29 seminomas exhibited hypermethylated HIC1 (Koul et 
al., 2002). HIC1 also exhibited a much higher frequency of methylation in the cisplatin-
resistant group (47%) than in the cisplatin-sensitive group (24%), though the sample size 
was too small for statistical significance (Koul et al., 2004). Like RASSF1A, the methylation 
status of the HIC1 promoter could be a useful prognostic indicator of nonseminomatous 
tumor sensitivity to cisplatin. 
HOXA9 
homeobox A9 encodes a transcription factor that regulates differentiation and morphogenesis, 
and is important for hematopoiesis (Lawrence et al., 1997). Hypermethylated HOXA9 has 
been reported for ovarian carcinomas, oral squamous cell carcinomas, lung cancer, liver 
cancer, and TGCTs (Wu et al., 2007; Guerrero-Preston et al., 2011; Hwang et al., 2011; Feng et 
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al., 2010; Lind et al., 2006). Lind and colleagues observed HOXA9 hypermethylation only in 
nonseminomatous tumors, in 9 of 35 samples (detected in yolk sac tumors, teratomas, and 
one choriocarcinoma; Lind et al., 2006). 
HOXB5 
homeobox B5 encodes a transcription factor involved in lung and gut development, 
regulating differentiation and morphogenesis, and providing specific positional identities 
on the anterior-posterior axis (Volpe et al., 1997; Fu et al., 2003). Hypermethylated HOXB5 
has been reported for ovarian carcinomas and TGCTs (Wu et al., 2007; Lind et al., 2006). 
Lind and colleagues observed HOXB5 hypermethylation only in nonseminomatous tumors, 
in 5 of 35 samples (detected exclusively in teratomas; Lind et al., 2006). 
RARB 
retinoic acid receptor, beta encodes a nuclear receptor that binds to retinoic acid, 
heterodimerizing with the retinoid x receptor and regulating transcriptional activity though 
retinoic acid response elements located in target genes (Dollé, 2009). RARB 
hypermethylation has been detected in numerous cancers, including those of the cervix, 
prostate, lung, bladder, and testis (Narayan et al., 2003; Singal et al., 2004; Feng et al., 2008; 
Cabello et al., 2011; Koul et al., 2002; Honorio et al., 2003). The groups of Koul and Honorio 
found RARB hypermethylation only in non-seminomas (frequencies of ~49% in yolk sac 
tumors, ~15% in embryonal carcinomas, and ~5% in teratomas for Koul et al.); only 5% of 
non-seminomas exhibited hypermethylated RARB for Honorio and colleagues (Koul et al., 
2002; Honorio et al., 2003). Koul et al. also found that RARB was hypermethylated more 
often in cisplatin-sensitive non-seminomas (14%) than in cisplatin-resistant tumors (0%), 
with a P-value of 0.05 (Koul et al., 2004). 
EMX2 
empty spiracles homeobox 2 encodes a transcription factor that regulates neuroblast 
proliferation, migration and differentiation, patterns the forebrain, and defines cortical 
territories (Cecchi, 2002). In the urogenital system, EMX2 is expressed in epithelial cells and 
is negatively regulated by HOXA10 (Troy et al., 2003). Hypermethylated EMX2 has been 
reported for lung cancer and TGCTs (Okamoto et al., 2010; Lind et al., 2006). Lind and 
colleagues found that one of 6 yolk sac tumors exhibited hypermethylated EMX2; no 
methylation was detected in any of 16 embryonal carcinomas, 9 teratomas, 1 
choriocarcinoma, 3 mixed/combined tumors, and 20 seminomas (Lind et al., 2006). Thus, it 
appears that EMX2 is not appreciably methylated in either seminomas or non-seminomas. 
MSX1 
msh homeobox 1 encodes a member of the muscle segment homeobox gene family. 
Functioning as a transcriptional repressor, MSX1 influences limb pattern formation and 
craniofacial development (Alappat et al., 2003). Hypermethylated MSX1 has been reported 
for acute lymphoblastic leukemia, and cancers of the breast, lung, colon, prostate, and testis 
(Dunwell et al., 2009; Shames et al., 2006; Lind et al., 2006). Lind and colleagues found that 
one of 6 yolk sac tumors exhibited hypermethylated MSX1; no methylation was detected in 
any of 16 embryonal carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined 
tumors, and 20 seminomas (Lind et al., 2006). Thus, it appears that MSX1 is not appreciably 
methylated in either seminomas or non-seminomas. 
 
Germ Cell Tumor 
 
116 
(Chaubert et al., 1997). The groups of Smith-Sørensen, Honorio, and Kawakami, in contrast, 
were not able to detect methylated CpG islands of CDKN2A when examined by 
methylation-specific PCR (Smith-Sørensen et al., 2002; Honorio et al., 2003; Kawakami et al., 
2003). Differing experimental strategies might explain this discrepancy. Hypermethylation 
of p14(ARF) and p16(INK) was recently observed in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~53% (Ellinger et al., 2009). 
3.2 Transcription factor genes 
NANOG 
This gene encodes an important regulator of pluripotency maintenance in the inner cell 
mass of blastocyst-stage embryos and in undifferentiated embryonic stem cells. NANOG 
prevents differentiation into mesoderm by interacting with SMAD1 and blocking the 
recruitment of co-activators in that signaling pathway (Suzuki et al., 2006). Migratory 
primordial germ cells express NANOG, but upon the differentiation of male germ cells into 
fetal gonocytes and neonatal spermatogonia, NANOG is downregulated (Gaskell et al., 
2004). Thus, normal juvenile and adult male germ cells do not express NANOG. 
Interestingly, Nettersheim et al. detected hypomethylated NANOG, and corresponding 
protein, in all seminomas and embryonal carcinomas (undifferentiated non-seminomas) 
they obtained from TGCT patients (Nettersheim et al., 2011). In contrast, all differentiated 
non-seminomas (yolk sac tumors, teratomas, and choriocarcinomas) exhibited CpG 
hypermethylation and an absence of NANOG protein. Similarly, normal adult 
spermatogonia contain hypermethylated NANOG, supporting the prevailing hypothesis 
that seminomas are derived from gonocyte precursors in the fetal gonad (Nettersheim et al., 
2011). Thus, differences within the state of TGCT differentiation correlate with the extent of 
NANOG hypermethylation. 
HIC1 
hypermethylated in cancer 1 encodes a transcriptional repressor protein that functionally 
interacts with p53 to suppress the development of cancer throughout aging (Chen et al., 
2005). The HIC1 promoter is hypermethylated in many cancers, including those of the 
breast, cervix, and testis (Fujii et al., 1998; Dong et al., 2001; Koul et al., 2002). Koul and 
colleagues observed HIC1 hypermethylation only in non-seminomas (frequencies of ~100% 
in yolk sac tumors, ~35% in embryonal carcinomas, ~21% in teratomas, and ~9% in 
mixed/combined tumors). None of 29 seminomas exhibited hypermethylated HIC1 (Koul et 
al., 2002). HIC1 also exhibited a much higher frequency of methylation in the cisplatin-
resistant group (47%) than in the cisplatin-sensitive group (24%), though the sample size 
was too small for statistical significance (Koul et al., 2004). Like RASSF1A, the methylation 
status of the HIC1 promoter could be a useful prognostic indicator of nonseminomatous 
tumor sensitivity to cisplatin. 
HOXA9 
homeobox A9 encodes a transcription factor that regulates differentiation and morphogenesis, 
and is important for hematopoiesis (Lawrence et al., 1997). Hypermethylated HOXA9 has 
been reported for ovarian carcinomas, oral squamous cell carcinomas, lung cancer, liver 
cancer, and TGCTs (Wu et al., 2007; Guerrero-Preston et al., 2011; Hwang et al., 2011; Feng et 
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al., 2010; Lind et al., 2006). Lind and colleagues observed HOXA9 hypermethylation only in 
nonseminomatous tumors, in 9 of 35 samples (detected in yolk sac tumors, teratomas, and 
one choriocarcinoma; Lind et al., 2006). 
HOXB5 
homeobox B5 encodes a transcription factor involved in lung and gut development, 
regulating differentiation and morphogenesis, and providing specific positional identities 
on the anterior-posterior axis (Volpe et al., 1997; Fu et al., 2003). Hypermethylated HOXB5 
has been reported for ovarian carcinomas and TGCTs (Wu et al., 2007; Lind et al., 2006). 
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runt-related transcription factor 3 encodes a member of the runt domain-containing family of 
transcription factors that binds to core sequences found in a number of enhancers and 
promoters (Otto et al., 2003). The RUNX3 promoter is hypermethylated in many cancers, 
including those of the lung, liver, colon, bladder, breast, and testis (Li et al., 2004; Xiao and 
Liu, 2004; Goel et al., 2004; Kim et al., 2005; Hwang et al., 2007; Kato et al., 2003; Lind et al., 
2006). Interestingly, Kato and colleagues reported that while 8 of 10 infantile yolk sac 
tumors exhibited RUNX3 hypermethylation (specimens obtained from pediatric patients), 0 
of 12 adult nonseminomatous TGCTs contained methylated RUNX3, despite 7 of the 11 
mixed/combined TGCTs containing yolk sac tumors (Kato et al., 2003). Similarly, Lind et al. 
found that only one of 6 adult yolk sac tumors exhibited hypermethylated RUNX3, and no 
methylation was detected in any of 49 other adult non-seminomas (16 embryonal 
carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined tumors, and 20 seminomas; 
Lind et al., 2006). These observations strongly suggest that distinct epigenetic dysregulatory 
mechanisms occur in pediatric, but not adult yolk sac tumors, and that RUNX3 is not 
appreciably methylated in either seminomatous or nonseminomatous adult TGCTs. 
3.3 Proteolysis genes 
PRSS21 
protease, serine, 21 encodes a member of the trypsin family of serine proteases that uses the 
hydroxyl group of serine to cleave target peptide bonds involving the carboxyl group of 
lysine or arginine (Rawlings and Barrett, 1994). PRSS21 is thought to regulate proteolytic 
events associated with male germ cell maturation, as it is expressed highly only in normal 
testis, and its hypermethylation and transcriptional repression have been observed in 
TGCTs (Manton et al., 2005; Kempkensteffen et al., 2006). Manton and colleagues reported 
that the majority of CpG islands were methylated in both seminomatous (86%, 3 samples) 
and nonseminomatous (87%, 5 samples) tumors (Manton et al., 2005). While 
Kempkensteffen et al. found the overall level of hypermethylation lower in seminomas than 
in non-seminomas, the levels were still significantly higher when compared to normal 
testicular tissue (Kempkensteffen et al., 2006). Thus, PRSS21 appears to show the most 
extensive hypermethylation of any gene examined to date in seminomas, and might 
therefore be a useful biomarker for early detection of these tumors in the clinic, especially if 
detected in the cell-free circulating serum DNA. 
TIMP3 
tissue inhibitor of metalloproteinase 3 encodes a protein that inhibits matrix metalloproteinases, 
enzymes that degrade components of the extracellular matrix (Apte et al., 1995). TIMP3 
hypermethylation has been detected in numerous cancers, including those of the kidney, 
colon, breast, brain, lung, and testis (Esteller et al., 2001; Koul et al., 2002). Koul and 
colleagues, however, observed an overall frequency of hypermethylation of just 3.3% in 
non-seminomas, with detection of methylated CpG islands limited to embryonal carcinomas 
and mixed/combined tumors (Koul et al., 2002). No hypermethylation was seen in 
seminomas. Therefore, compared to other genes, TIMP3 does not appear to be as extensively 
hypermethylated in non-seminomas. 
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3.4 Cell adhesion genes 
CDH1 
cadherin 1 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
epithelial tissues, E-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, and a highly conserved cytoplasmic tail. Mutations in CDH1 that 
disrupt the adhesive properties of E-cadherin occur in some breast and gastric carcinomas 
(Hirohashi, 1998). CDH1 hypermethylation is also detected in many cancers, including 
leukemia and those of the esophagus, breast, prostate, and testis (Esteller et al., 2001; Koul et 
al., 2002; Honorio et al., 2003). Koul and colleagues reported that of the seminomatous and 
nonseminomatous TGCTs they examined, the majority of hypermethylated CpG islands 
were observed in non-seminomas (frequencies of <10% in embryonal carcinomas, teratomas, 
and mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated CDH1 
(Koul et al., 2002). Honorio et al. detected an overall methylation frequency of 11% in non-
seminomas (Honorio et al., 2003). No differences were observed between cisplatin-sensitive 
(3%) and –resistant (6%) non-seminomas with respect to hypermethylated CDH1 (Koul et 
al., 2004). 
CDH13 
cadherin 13 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
heart tissues, H-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, but unlike other cadherins, lacks the highly conserved cytoplasmic 
tail. The CDH13 promoter is hypermethylated in numerous cancers, including chronic 
myeloid leukemia and those of the breast, lung, bladder, and testis (Roman-Gomez et al., 
2003; Toyooka et al., 2001; Maruyama et al., 2001; Honorio et al., 2003; Lind et al., 2006). 
Honorio and colleagues reported an overall frequency of hypermethylated CDH13 in 12% of 
non-seminomas, while Lind et al. detected hypermethylation in 9% of nonseminomatous (2 
of 16 embryonal carcinomas; 0 of 9 teratomas) and 6% (1/17) of seminomatous TGCTs 
(Honorio et al., 2003; Lind et al., 2006). Despite the small sample size, CDH13 
hypermethylation was observed in the more undifferentiated TGCTs and not in the more 
highly differentiated non-seminomas, distinguishing this gene from most others that have 
been described here. 
3.5 Genes involved in other processes 
SCGB3A1 (extracellular/cytokine) 
secretoglobin, family 3A, member 1 encodes a secreted protein, formerly called high in normal 1 
(HIN1), which has tumor suppressor activity, although the exact function of the protein is 
unknown. SCGB3A1 is highly expressed in the lung and trachea of humans and mice, with 
additional expression in a species-dependent manner (Tomita and Kimura, 2008). 
Hypermethylated SCGB3A1 has been reported for cancers of the nasopharynx, breast, lung, 
prostate, pancreas, stomach, and testis, among others (Wong et al., 2003; Fackler et al., 2003; 
Krop et al., 2004; Gong et al., 2011; Lind et al., 2006). Lind and colleagues observed SCGB3A1 
hypermethylation in 19 of 35 non-seminomas (frequencies of ~100% in choriocarcinomas, 
~75% in teratomas, ~47% in yolk sac tumors, and ~35% in embryonal carcinomas); no 
methylation was detected in seminomas (Lind et al., 2006). 
 




runt-related transcription factor 3 encodes a member of the runt domain-containing family of 
transcription factors that binds to core sequences found in a number of enhancers and 
promoters (Otto et al., 2003). The RUNX3 promoter is hypermethylated in many cancers, 
including those of the lung, liver, colon, bladder, breast, and testis (Li et al., 2004; Xiao and 
Liu, 2004; Goel et al., 2004; Kim et al., 2005; Hwang et al., 2007; Kato et al., 2003; Lind et al., 
2006). Interestingly, Kato and colleagues reported that while 8 of 10 infantile yolk sac 
tumors exhibited RUNX3 hypermethylation (specimens obtained from pediatric patients), 0 
of 12 adult nonseminomatous TGCTs contained methylated RUNX3, despite 7 of the 11 
mixed/combined TGCTs containing yolk sac tumors (Kato et al., 2003). Similarly, Lind et al. 
found that only one of 6 adult yolk sac tumors exhibited hypermethylated RUNX3, and no 
methylation was detected in any of 49 other adult non-seminomas (16 embryonal 
carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined tumors, and 20 seminomas; 
Lind et al., 2006). These observations strongly suggest that distinct epigenetic dysregulatory 
mechanisms occur in pediatric, but not adult yolk sac tumors, and that RUNX3 is not 
appreciably methylated in either seminomatous or nonseminomatous adult TGCTs. 
3.3 Proteolysis genes 
PRSS21 
protease, serine, 21 encodes a member of the trypsin family of serine proteases that uses the 
hydroxyl group of serine to cleave target peptide bonds involving the carboxyl group of 
lysine or arginine (Rawlings and Barrett, 1994). PRSS21 is thought to regulate proteolytic 
events associated with male germ cell maturation, as it is expressed highly only in normal 
testis, and its hypermethylation and transcriptional repression have been observed in 
TGCTs (Manton et al., 2005; Kempkensteffen et al., 2006). Manton and colleagues reported 
that the majority of CpG islands were methylated in both seminomatous (86%, 3 samples) 
and nonseminomatous (87%, 5 samples) tumors (Manton et al., 2005). While 
Kempkensteffen et al. found the overall level of hypermethylation lower in seminomas than 
in non-seminomas, the levels were still significantly higher when compared to normal 
testicular tissue (Kempkensteffen et al., 2006). Thus, PRSS21 appears to show the most 
extensive hypermethylation of any gene examined to date in seminomas, and might 
therefore be a useful biomarker for early detection of these tumors in the clinic, especially if 
detected in the cell-free circulating serum DNA. 
TIMP3 
tissue inhibitor of metalloproteinase 3 encodes a protein that inhibits matrix metalloproteinases, 
enzymes that degrade components of the extracellular matrix (Apte et al., 1995). TIMP3 
hypermethylation has been detected in numerous cancers, including those of the kidney, 
colon, breast, brain, lung, and testis (Esteller et al., 2001; Koul et al., 2002). Koul and 
colleagues, however, observed an overall frequency of hypermethylation of just 3.3% in 
non-seminomas, with detection of methylated CpG islands limited to embryonal carcinomas 
and mixed/combined tumors (Koul et al., 2002). No hypermethylation was seen in 
seminomas. Therefore, compared to other genes, TIMP3 does not appear to be as extensively 
hypermethylated in non-seminomas. 
 
Epigenetic Modifications in Testicular Germ Cell Tumors 
 
119 
3.4 Cell adhesion genes 
CDH1 
cadherin 1 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
epithelial tissues, E-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, and a highly conserved cytoplasmic tail. Mutations in CDH1 that 
disrupt the adhesive properties of E-cadherin occur in some breast and gastric carcinomas 
(Hirohashi, 1998). CDH1 hypermethylation is also detected in many cancers, including 
leukemia and those of the esophagus, breast, prostate, and testis (Esteller et al., 2001; Koul et 
al., 2002; Honorio et al., 2003). Koul and colleagues reported that of the seminomatous and 
nonseminomatous TGCTs they examined, the majority of hypermethylated CpG islands 
were observed in non-seminomas (frequencies of <10% in embryonal carcinomas, teratomas, 
and mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated CDH1 
(Koul et al., 2002). Honorio et al. detected an overall methylation frequency of 11% in non-
seminomas (Honorio et al., 2003). No differences were observed between cisplatin-sensitive 
(3%) and –resistant (6%) non-seminomas with respect to hypermethylated CDH1 (Koul et 
al., 2004). 
CDH13 
cadherin 13 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
heart tissues, H-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, but unlike other cadherins, lacks the highly conserved cytoplasmic 
tail. The CDH13 promoter is hypermethylated in numerous cancers, including chronic 
myeloid leukemia and those of the breast, lung, bladder, and testis (Roman-Gomez et al., 
2003; Toyooka et al., 2001; Maruyama et al., 2001; Honorio et al., 2003; Lind et al., 2006). 
Honorio and colleagues reported an overall frequency of hypermethylated CDH13 in 12% of 
non-seminomas, while Lind et al. detected hypermethylation in 9% of nonseminomatous (2 
of 16 embryonal carcinomas; 0 of 9 teratomas) and 6% (1/17) of seminomatous TGCTs 
(Honorio et al., 2003; Lind et al., 2006). Despite the small sample size, CDH13 
hypermethylation was observed in the more undifferentiated TGCTs and not in the more 
highly differentiated non-seminomas, distinguishing this gene from most others that have 
been described here. 
3.5 Genes involved in other processes 
SCGB3A1 (extracellular/cytokine) 
secretoglobin, family 3A, member 1 encodes a secreted protein, formerly called high in normal 1 
(HIN1), which has tumor suppressor activity, although the exact function of the protein is 
unknown. SCGB3A1 is highly expressed in the lung and trachea of humans and mice, with 
additional expression in a species-dependent manner (Tomita and Kimura, 2008). 
Hypermethylated SCGB3A1 has been reported for cancers of the nasopharynx, breast, lung, 
prostate, pancreas, stomach, and testis, among others (Wong et al., 2003; Fackler et al., 2003; 
Krop et al., 2004; Gong et al., 2011; Lind et al., 2006). Lind and colleagues observed SCGB3A1 
hypermethylation in 19 of 35 non-seminomas (frequencies of ~100% in choriocarcinomas, 
~75% in teratomas, ~47% in yolk sac tumors, and ~35% in embryonal carcinomas); no 
methylation was detected in seminomas (Lind et al., 2006). 
 
Germ Cell Tumor 
 
120 
SORBS1 (glucose transport) 
sorbin and SH3 domain containing 1 encodes a protein involved in tyrosine phosphorylation of 
c-Abl, via an interaction with the insulin receptor, and is required for insulin-stimulated 
glucose transport (Lin et al., 2001). Lind and colleagues reported SORBS1 hypermethylation 
in 1 of 20 seminomatous TGCTs examined, with no detection in non-seminomas (0/35; Lind 
et al., 2006). Given the sample size, additional studies will be necessary to conclusively 
determine whether this gene is a useful biomarker for TGCTs.  
GSTP1 (metabolic process) 
glutathione S-transferase, pi 1 encodes an enzyme important for detoxification by catalyzing 
the conjugation of hydrophobic and electrophilic compounds with reduced glutathione 
(Strange et al., 2001). The GST family is categorized into four classes: alpha, mu, pi, and 
theta. GSTP1 hypermethylation is observed in many cancers, including those of the liver, 
kidney, breast, lung, esophagus, brain, and colon (Esteller et al., 2001). The groups of 
Kawakami and Honorio did not find hypermethylated GSTP1 in any of their seminomatous 
or nonseminomatous TGCT samples, but Koul et al. reported GSTP1 hypermethylation in 1 
of 29 seminomas (none in non-seminomas) and Ellinger et al. detected CpG island 
methylation in the cell-free circulating serum DNA of TGCT patients at a frequency of ~25% 
(Koul et al., 2002; Kawakami et al., 2003; Honorio et al., 2003; Ellinger et al., 2009). The TGCT 
patients had seminomas (N=36) as well as non-seminomas (N=37), and the hypermethylation 
frequency observed by Ellinger and colleagues was equivalent between the two groups 
(Ellinger et al., 2009). Clearly, additional studies will be necessary to determine why 
discrepancies exist between not observing GSTP1 hypermethylation in the majority of TGCT 
samples and frequently observing it in the cell-free serum DNA of TGCT patients. 
PTGS2 (oxidation-reduction) 
prostaglandin-endoperoxidase synthase 2 encodes a key enzyme in prostaglandin biosynthesis, 
also known as COX2, which acts as both a dioxygenase and a peroxidase. Two isozymes of 
PTGS exist, the constitutive PTGS1 and the inducible PTGS2, which differ in their regulation 
of expression and tissue distribution. This gene encodes the inducible isozyme, and is 
misregulated in many cancers (Rizzo, 2011). Hypermethylated PTGS2 has been reported for 
gliomas, gastric carcinomas, prostate cancer, and breast cancer, among others (Uhlmann et 
al., 2003; Yu et al., 2003; Yegnasubramanian et al., 2004; Chow et al., 2005). Ellinger and 
colleagues detected PTGS2 CpG island hypermethylation in the cell-free circulating serum 
DNA of TGCT patients at a frequency of ~45%; no differences were observed between 
patients with seminomas and those with non-seminomas (Ellinger et al., 2009). It remains to 
be seen whether a similar frequency of hypermethylation is observed directly in TGCT 
specimens. Currently, the cell-free serum-based detection of hypermethylated PTGS2, like 
RASSF1A, APC, CDKN2A and GSTP1, could provide additional benefits to existing 
parameters in the clinic. 
NME2 (phosphorylation) 
non-metastatic cells 2, protein (NM23B) expressed in (official gene name) encodes a protein 
that, together with the product of NME1, forms the hexamer nucleoside diphosphate 
kinase (Postel et al., 2002). Koul and colleagues reported NME2 CpG hypermethylation in 
one embryonal carcinoma sample (Koul et al., 2002), but no other known observations in 
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TGCTs or other cancers have been published, raising the uncertainty over the significance 
of this discovery. 
4. DNA methyltransferases 
DNA methylation is established by the coordinated activity of enzymes known as DNA 
methyltransferases (DNMTs). The mammalian DNMT family consists of DNMT1, 
DNMT3A, DNMT3B, and DNMT3L, and is responsible for the generation, acquisition, and 
maintenance of methylated cytosines residing in CpG dinucleotides (Jurkowska et al., 2010). 
DNMT3A and DNMT3B are de novo methyltransferases, while DNMT1 is a maintenance 
methyltransferase, required to preserve the methylated status of the DNA. Levels of DNMTs 
are increased in numerous cancers, accounting for the hypermethylation of CpG islands 
observed in the promoters of many genes. Thus, DNMTs are promising targets for the 
design of new anti-cancer therapeutics. 
4.1 DNMT1 
DNA methyltransferase 1 is responsible for the maintenance of the DNA methylation status 
in CpG dinucleotides (Bestor et al., 1988). Hypermethylation of CpG islands in gene 
promoters, as Section 3 in this chapter extensively describes, is associated with the 
transcriptional silencing of tumor suppressors and other genes in many cancers, including 
TGCTs. Omisanjo and colleagues examined the expression of DNMT1 mRNA and protein in 
TGCTs to determine whether DNMT1 is upregulated. In normal human adult testis, DNMT1 
mRNA is expressed in spermatogonia, pachytene spermatocytes, and round spermatids, as 
measured by in situ hybridization; the protein is nuclear in spermatogonia, cytoplasmic in 
round spermatids, and interestingly, is not detected in pachytene spermatocytes (Omisanjo 
et al., 2007). In non-seminomas (8 embryonal carcinomas and 8 teratomas), both mRNA and 
protein are detected, with a stronger signal observed in the embryonal carcinomas. Neither 
mRNA nor protein are detected in seminomas (0/16; Omisanjo et al., 2007). These 
differential TGCT expression patterns of DNMT1 were also found using RNA microarray 
analysis and quantitative real-time RT-PCR, showing significantly upregulated transcript 
levels in embryonal carcinomas, but low levels in seminomas (Biermann et al., 2007). In 
contrast, semi-quantitative RT-PCR analysis performed by Ishii and colleagues showed no 
difference in DNMT1 expression between control tissue and either seminomatous or 
nonseminomatous TGCTs (Ishii et al., 2007). DNA methyltransferase inhibitors, such as 5-
aza-2’-deoxycytidine, have been shown to reactivate silenced tumor suppressor genes in 
treated cancer cells, implying that DNMTs are both necessary and sufficient to maintain 
hypermethylated CpG islands in many tumors. 
4.2 DNMT3A 
DNA methyltransferase 3A is responsible for the de novo transfer of methyl groups to CpG 
dinucleotides. DNMT3A catalyzes the transfer of a methyl group from S-adenosyl-
methionine to the 5’ position of cytosine in DNA (Okano et al., 1999). Studies in mice have 
shown that DNMT3A is essential for imprinting, as well as for spermatogenesis (Kaneda et 
al., 2004). Ishii and colleagues recently examined the expression of DNMT3A mRNA and 
protein in TGCTs, known to exhibit hypermethylated CpG islands in numerous genes, to 
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determine whether DNMT3A is upregulated. Semi-quantitative RT-PCR analysis revealed 
that DNMT3A and its isoform, DNMT3A2, are significantly overexpressed in seminomas as 
well as non-seminomas (embryonal carcinomas, teratomas, choriocarcinomas, yolk sac 
tumors; Ishii et al., 2007). Protein analysis by immunoblot revealed that the DNMT3A2 
isoform is exhibited several times higher than control levels in both seminomatous and 
nonseminomatous TGCTs (Ishii et al., 2007). Thus, the upregulation of DNMT3A2 appears 
to generate higher amounts of protein, and seems to be tumor cell-specific. Ishii et al. then 
examined the methylation levels of CpG-rich regions in the DNMT3A gene, and found more 
unmethylated DNMT3A CpG dinucleotides in seminomas than in adjacent non-tumor tissue 
(Ishii et al., 2007). Overexpression of DNMT3A in TGCTs therefore appears to result from 
the hypomethylation of CpG islands in key regulatory regions, allowing inappropriate 
transcription to occur. 
4.3 DNMT3B 
DNA methyltransferase 3B is responsible for the de novo transfer of methyl groups to CpG 
dinucleotides. DNMT3B catalyzes the transfer of a methyl group from S-adenosyl-
methionine to the 5’ position of cytosine in DNA (Okano et al., 1999). Beyrouthy and 
colleagues recently examined the protein expression of DNMT3B in embryonal carcinoma 
cell lines to determine whether they exhibit higher protein levels than in normal tissues or 
somatic tumors. Western blot analysis revealed that DNMT3B is significantly overexpressed 
in embryonal carcinoma cell lines when compared to all other cell types (Beyrouthy et al., 
2009). Three earlier microarray studies reported upregulated DNMT3B mRNA in non-
seminomas (primarily embryonal carcinomas), but not in seminomas when compared to 
non-cancerous controls (Almstrup et al., 2005; Korkola et al., 2005; Skotheim et al., 2005). In 
contrast, Ishii et al. found no significant difference in DNMT3B expression between control 
tissue and either seminomatous or nonseminomatous TGCTs, which were mostly teratomas, 
choriocarcinomas, and yolk sac tumors (Ishii et al., 2007). This difference in TGCT sample 
type could explain the discrepancy in the results; clearly DNMT3B appears to be 
overexpressed in embryonal carcinomas. Furthermore, knockdown of DNMT3B reverses 5-
aza-2’-deoxycytidine hypersensitivity in both cisplatin-sensitive and cisplatin-resistant 
embryonal carcinoma cells (Beyrouthy et al., 2009). While cisplatin sensitivity itself is not 
affected by DNMT3B expression, 5-aza-2’-deoxycytidine hypersensitivity in embryonal 
carcinoma cells appears to be dependent on DNMT3B expression, regardless of whether the 
cells are sensitive or resistant to cisplatin. 
5. Clinical applications 
When compared to many other cancers, a remarkable aspect in the majority of TGCTs is the 
high curability rate using cisplatin-based chemotherapy in combination with radiation 
therapy. However, up to 30% of metastatic germ cell tumors of the testis are refractory to 
cisplatin treatment and can lead to mortality. As discussed earlier, hypermethylation of CpG 
islands in the promoters of two genes, RASSF1A and HIC1, has been observed in cisplatin-
resistant tumors at a frequency of approximately 50%, while promoter hypermethylation for 
MGMT and RARB has been detected at higher frequencies in cisplatin-sensitive vs. 
chemoresistant tumors (Koul et al., 2004). Recent investigation into the use of DNA 
demethylating agent 5-azacytidine in TCam-2 cells as a method to decrease cisplatin 
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resistance has shown promising results (Wermann et al., 2010). Drugs that target DNMTs are 
currently in use in clinical trials, such as 5-aza-2’-deoxycytidine for treating myelodysplastic 
syndromes (Müller-Thomas et al., 2009), and newer drugs are under development. 
6. Conclusion 
A greater understanding of the role of histone modifications, histone modifying enzymes, 
genes exhibiting promoter DNA hypermethylation, and DNA methyltransferases in adult 
TGCTs should yield potentially useful biomarkers to aid in early detection, as well as new 
methods of treatment to overcome chemotherapy-resistant tumors. The presence of 
hypermethylated RASSF1A, APC, CDKN2A, GSTP1, and PTGS2 in the cell-free serum DNA 
of TGCT patients raises the important question of how early in the tumorigenic process 
these markers could be detected at interpretable levels. Optimizing this strategy of 
identifying potential TGCTs before they develop to the extent of requiring aggressive 
chemotherapy and radiation treatment will be an important endeavor during the next 
decade. Because some metastatic TGCTs are refractory to cisplatin-based chemotherapy, 
searching for an alternative treatment regimen for these tumors is equally important. The 
potential use of 5-azacytidine, or similar DNMT inhibitors, in overcoming cisplatin 
resistance holds promise for such cases. Further investigation of epigenetic modifications in 
TGCTs at the bench and in the clinic will address these goals. 
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1. Introduction 
Tight junctions are cellular structures present in epithelial, endothelial and mesothelial cells 
(1, 2, 3). They are located at the apicolateral part of the cell membrane and regulate the 
paracellular permeability of cell layers which is called the gate function (4). They also have a 
fence function segregating the apical region of the cell membrane from the lateral parts 
preventing proteins of the apical area from mixing up with those of the lateral regions (1,4). 
Tight junctions also take part in determination of cellular polarity (1,4). They prevent 
pathogens from invading into the subepithelial tissues and thus can be considered to 
represent one part of the innate immune system (5).  
In freeze fraction electron microscopy tight junctions form a beltlike branching structure 
around the cell which varies from 0.27m to 0.37m in thickness which depends on the cell 
type (6). Tight junctions are composed of membrane proteins and scaffolding proteins.The 
former include claudins, occludin, tricellulin and junctional adhesion molecules (7). 
Claudins, occluding and tricellulin have four transmembrane domains while junctional 
adhesion molecules have only one (7). Scaffolding proteins mediate interactions between 
tight junctions and the interior compartments of the cells. They include ZO-1 (Zona 
occludens-1), ZO-2, ZO-3, MAGI-1 (membrane-associated guanylate kinase with inverted 
orientation-1), cingulin and MUPP1 (multi-PDZ domain protein 1) (1,7).  
2. Claudins 
Claudins are tight junction proteins responsible for the regulation of paracellular 
permeability in cell layers. There are 27 claudins known and the diversity of claudins is the 
basis for differences in the solute and electrical permeability in different cell layers (1,8) 
(Table 1). In kidney tubules different claudins are expressed in different areas of the 
nephron determining the solute and electrolytic permeability in different regions of the 
kidney tubule (9). A similar segmental distribution in claudin expression is observed in the 
gut (10). Claudins do not share structural resemblance to either occludin or tricellulin (11). 
Claudins are key components of tight junctions (1,4). They are 21-28kDa proteins containing 
an aminoterminal intracellular part, four transmembrane domains, two extracellular loops, 
an intracellular loop and an intracellular carboxyterminal end (1,4,5,7). The carboxyterminal  
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variants Other aspects 





Entry cofactor for hepatitis C 
virus, right-left patterning in 
embryogenesis, knockdown 
causes transdermal water loss 
CLD2 Xq22.3-q23 24.5 - 5 Knockdown prevents bile canalicular formation  
CLD3 7q11.23 23.3   Receptor for CPE 
CLD4 7q11.23 22.0   Receptor for CPE 
CLD5 22q11.21 23.1   
Present mainly in 
endothelium, heart 
development in Xenopus, 
knockdown causes 
disturbances in BBB function 
CLD6 16p13.3 23.3   Entry cofactor for hepatitis C virus 
CLD7 17 22.4  3 Knockdown decreases Cloride permeability 
CLD8 21.22.11 24.8    
CLD9 16p13.3 22.8   Entry cofactor for hepatitis C virus 
CLD10 13q31-34 24.2-24.5  6  





Knockdown causes nerve 
conduction disturbances, male 
sterility, deafness 
CLD12 7q21 27.1  3 D vitamin induced Ca abrorption from enterocytes 
CLD14 21q22.3 25.7 Sensoryneural deafness 5 
Reduced mineral bone density, 
kidney stones, 
knockout causes deafness 
CLD15 7q11.22 24.3  2 Megaintestine in knockout mice 
CLD16 3q28 33.8 Hypomagnesemia type 3   
CLD17 21q22.11 24.6   Intronless gene 
CLD18 3q22.3 27.7-27.9  2 Present in lung, gastrointestinal tract 
CLD19 1p34.2 22.0-23.2 
Hypomagnese
mia with ocular 
involvement 
2 Knockout affects nerve conduction 
CLD20 6q25 23.5    
CLD21 4q35.1 25.4    
CLD22 4q35.1 25.5   Intronless gene 
CLD23 8p23.1 31.9   Expressed in germinal center B cells, stomach, placenta 
CLD24 4q35.1 22.8    
CLD25 11q23.2     
Claudins 13, 26 and 27 are not found in humans 
Table 1. Some characteristics of different claudins present in humans 
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end contains the PDZ domains by which scaffolding proteins like ZO1 and ZO2 attach to 
claudins (1, 12). The larger of the extracellular loops (EL1) influences paracellular charge 
selectivity and contains the co-receptor site for Hepatitis C virus (HCV) (1,12). The smaller 
loop (EL2) mediates attachment of the claudin molecule to the corresponding one of the 
neighbouring cell and also contains the oligomerisation site and receptor site for clostridium 
perfringens enterotoxin (CPE) (1,12) (Figure 1). 
The larger loop (EL-1) regulates paracellular electrical and solute permeability. The smaller 
loop (EL-2) mediates attachment between claudins of different cells. Four transmembrane 
domains separate the ends of the loops from the intracellular sequences of the molecules. 
The intracellular carboxyterminal end contains attachment sites for the PDZ domains of ZO-
1, ZO-2 and ZO-3 molecules. It also contains phosphorylation sites which influence the 









Fig. 1. A schematic presentation of the general molecular structure of claudins. Claudins 
form a structure formed by two extracellular loops (EL-1 and EL-2) in the cell membrane. 
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Claudins may associate with each other as homodimers or heterodimers (1). 
Heterodimerisation occurs selectively between specific claudins, for example, Claudins 1 
can heterodimerise with 4 but not with 2 (1). In addition to such vertical association between 
neigbouring cells, claudins also bind to one another laterally on cell membranes to form the 
tight junctional strand (1). Claudin 2 expression in tight junctions generally leads to a leakier 
barrier function (1).Generally, claudins 2, 7, 10, 15 and 16 increase paracellular cation 
permeability by forming pores in the tight junctions whereas claudins 4, 5, 8, 11, 14 and 18 
have an opposite function (1). 
Claudins are widely expressed in epithelial cells but they are also found in endothelial and 
mesothelial cells, and in glial cells (2, 3, 13, 14). Several types of claudins are expressed in 
epithelial cells, but their distribution may vary according to the cell type and tissue site in 
question (2). Some claudins have a characteristic distribution. Claudin 5 is found in 
endothelial cells but it is also found in epithelium especially in neoplasia (1, 2). Claudin 11 is 
found in oligodendrocytes and in Sertoli cells but its expression has also been shown in 
endothelial cells of the corpus cavernosus (15, 16). 
2.1 Claudins in disease 
Claudin expression is modified in many diseases including both neoplastic and non-
neoplastic conditions (5, 17). In cancers derived from epithelial cells claudin expression may 
be increased or decreased (17).The expression of claudins varies in tumors at different sites 
(7) and is different in head and neck (18), pancreatic (19), colonic (20,21), ovarian (22), and 
breast cancers (23) as well as within the same site like in gastric cancer, where there is lower 
expression of claudins in diffuse carcinoma compared to the intestinal type (24). In breast 
cancer claudin 4 expression is increased and its expression is found in more aggressive types 
of tumors (25). Claudin 16 expression, on the other hand, is associated with a better 
prognosis (26). Moreover, claudin 7 is downregulated in many cancers, such as breast and 
colon carcinoma, where its diminished expression is also associated with a poor prognosis 
(21, 27).  
In non-epithelial cancers, claudin expression has been found in malignant mesotheliomas, 
tumors derived from cells lining serosal cavities (3). The expression of claudins is, however, 
lower than that found in epithelial tumors and the difference in claudin expression can be 
used in the differential diagnosis between mesotheliomas and adenocarcinomas metastatic 
to the lung (3). Such findings have been substantiated in many reports indicating that 
claudin 3 and 4 might be especially useful in this respect (3, 28). 
Claudins may also be useful in the differential diagnosis between soft tissue tumors and 
carcinomas, especially when such tumors are poorly differentiated and their origin is hard 
to substantiate based on morphology alone. Soft tissue tumors generally do not express 
claudins, exceptions are synovial sarcomas which also morphologically contain epithelial 
elements, and perineurinomas (29, 30). Furthermore, hemangiomas and angiosarcomas 
express claudin 5, by which expression they can be distinguished from other soft tissue 
tumors (2). 
In non-neoplastic diseases claudin expression may be deranged in diseases where the 
permeability of cell layers is disturbed. Such conditions include intestinal and kidney 
diseases, vascular diseases and lung diseases with a diminished or lost cellular permeability 
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leading to tissue edema. In various inflammations, claudin expression may be deranged. 
Examples of such are chronic colitis, like Crohn’s disease or colitis ulcerosa where 
expression of claudins have been changed (31,32). Many intestinal pathogens, such as 
aggressive strains of E coli, may lower the electrical and solute permeability of intestinal 
epithelia through displacement or downregulation of claudins and tight junctional 
scaffolding proteins leading to loss of fluid to the intestinal lumen (33,34). Claudins may 
also serve as receptors for bacterial toxins and viruses. Claudin 1 serves as a coreceptor for 
hepatitis virus 1, and several viruses may modify tight junctional permeability by 
downregulation or displacement of claudins from the tight junction (35, 36, 37, 38). Also 
bacterial toxins may use claudins as receptors. The toxin secreted by clostridium perfringens 
uses claudin 3 and 4 as receptors to open up paracellular spaces between cells (39). This also 
leads to cellular destruction and clostridium perfringens enterotoxins has been used in 
experimental models as a chemical to destroy ovarian and prostate cancer cells which have a 
high expression of claudins 3 and 4 (39). Additionally, modified clostridium perfringens 
enterotoxin (CPE) can be used in treatment of cancer to enable penetration of cytostatic 
drugs to cancer tissues (5, 39). 
In the kidney, claudins are differentially expressed along the tubular segments leading to a 
modulated anionic and solute permeability in different regions of the segments which is 
detrimental for the absorption functions of the kidney (9). Claudins 16 and 19, for instance, 
regulate Mg and Cl permeability of the kidney tubular cells and mutations in these claudins 
lead to disturbances of the permeability of these electrolytes (40). In lung diseases like 
ARDS, expression of claudin 4 is downregulated leading to increased permeability of the 
alveolar wall (41, 42). Counteracting claudin 4 downregulation could thus be one putative 
treatment for this often fatal lung disease. 
2.2 Claudins in gonadal structures 
In mRNA and array analysis indicate that claudins 1, 2, 3, 5, 7, 8, 10, 11, 12, and 23 are 
present in testicular tissue of rodents. Claudin 11 is found to be the highest (15). Such 
studies do not, however, indicate the location of claudin mRNA, and claudin 5 mRNA, for 
instance, may also partly be derived from endothelial cells. 
In human testicular tissues claudin 1, 6 and 7 protein expression has been found in 
seminiferous tubules (43). In rete testis epithelium, claudins 1 and 7 are strongly expressed 
while claudin 4 is weak and claudins 3, 5 and 6 are negative (43). Claudin 11 is present in 
Sertoli cells and takes part in formation of the blood testis barrier (44). In normal 
seminiferous epithelium claudin 11 is located at the basal compartment and the distribution 
is similar to ZO1 and ZO2 in this location (45). Claudin 1, 3 and 11 expression in Sertoli cells 
of mouse and rat testis appears to be regulated by androgens (46, 47, 48). Also 
gonadotropins regulate the expression of tight junctional proteins such as claudin 11 and 
occludin (49). 
Expression of claudins and other tight junction proteins have not been studied in ovaries to 
such an extent as in the testis. Trace amounts of claudin 1, 2 , 4, 5, 7, 10, 11, 12 have been 
detected in normal ovarian tissues (17). Ovarian surface epithelial cells express claudin 1, 
ZO1 and occludin (50). Ovarian HOSE (human ovarian surface epithelial) cells do not 
express claudins 3 or 4 (51). On the other hand, in array based analysis, ovarian serous 
 
Germ Cell Tumor 
 
138 
Claudins may associate with each other as homodimers or heterodimers (1). 
Heterodimerisation occurs selectively between specific claudins, for example, Claudins 1 
can heterodimerise with 4 but not with 2 (1). In addition to such vertical association between 
neigbouring cells, claudins also bind to one another laterally on cell membranes to form the 
tight junctional strand (1). Claudin 2 expression in tight junctions generally leads to a leakier 
barrier function (1).Generally, claudins 2, 7, 10, 15 and 16 increase paracellular cation 
permeability by forming pores in the tight junctions whereas claudins 4, 5, 8, 11, 14 and 18 
have an opposite function (1). 
Claudins are widely expressed in epithelial cells but they are also found in endothelial and 
mesothelial cells, and in glial cells (2, 3, 13, 14). Several types of claudins are expressed in 
epithelial cells, but their distribution may vary according to the cell type and tissue site in 
question (2). Some claudins have a characteristic distribution. Claudin 5 is found in 
endothelial cells but it is also found in epithelium especially in neoplasia (1, 2). Claudin 11 is 
found in oligodendrocytes and in Sertoli cells but its expression has also been shown in 
endothelial cells of the corpus cavernosus (15, 16). 
2.1 Claudins in disease 
Claudin expression is modified in many diseases including both neoplastic and non-
neoplastic conditions (5, 17). In cancers derived from epithelial cells claudin expression may 
be increased or decreased (17).The expression of claudins varies in tumors at different sites 
(7) and is different in head and neck (18), pancreatic (19), colonic (20,21), ovarian (22), and 
breast cancers (23) as well as within the same site like in gastric cancer, where there is lower 
expression of claudins in diffuse carcinoma compared to the intestinal type (24). In breast 
cancer claudin 4 expression is increased and its expression is found in more aggressive types 
of tumors (25). Claudin 16 expression, on the other hand, is associated with a better 
prognosis (26). Moreover, claudin 7 is downregulated in many cancers, such as breast and 
colon carcinoma, where its diminished expression is also associated with a poor prognosis 
(21, 27).  
In non-epithelial cancers, claudin expression has been found in malignant mesotheliomas, 
tumors derived from cells lining serosal cavities (3). The expression of claudins is, however, 
lower than that found in epithelial tumors and the difference in claudin expression can be 
used in the differential diagnosis between mesotheliomas and adenocarcinomas metastatic 
to the lung (3). Such findings have been substantiated in many reports indicating that 
claudin 3 and 4 might be especially useful in this respect (3, 28). 
Claudins may also be useful in the differential diagnosis between soft tissue tumors and 
carcinomas, especially when such tumors are poorly differentiated and their origin is hard 
to substantiate based on morphology alone. Soft tissue tumors generally do not express 
claudins, exceptions are synovial sarcomas which also morphologically contain epithelial 
elements, and perineurinomas (29, 30). Furthermore, hemangiomas and angiosarcomas 
express claudin 5, by which expression they can be distinguished from other soft tissue 
tumors (2). 
In non-neoplastic diseases claudin expression may be deranged in diseases where the 
permeability of cell layers is disturbed. Such conditions include intestinal and kidney 
diseases, vascular diseases and lung diseases with a diminished or lost cellular permeability 
 
Claudins and Germ Cell Tumors 
 
139 
leading to tissue edema. In various inflammations, claudin expression may be deranged. 
Examples of such are chronic colitis, like Crohn’s disease or colitis ulcerosa where 
expression of claudins have been changed (31,32). Many intestinal pathogens, such as 
aggressive strains of E coli, may lower the electrical and solute permeability of intestinal 
epithelia through displacement or downregulation of claudins and tight junctional 
scaffolding proteins leading to loss of fluid to the intestinal lumen (33,34). Claudins may 
also serve as receptors for bacterial toxins and viruses. Claudin 1 serves as a coreceptor for 
hepatitis virus 1, and several viruses may modify tight junctional permeability by 
downregulation or displacement of claudins from the tight junction (35, 36, 37, 38). Also 
bacterial toxins may use claudins as receptors. The toxin secreted by clostridium perfringens 
uses claudin 3 and 4 as receptors to open up paracellular spaces between cells (39). This also 
leads to cellular destruction and clostridium perfringens enterotoxins has been used in 
experimental models as a chemical to destroy ovarian and prostate cancer cells which have a 
high expression of claudins 3 and 4 (39). Additionally, modified clostridium perfringens 
enterotoxin (CPE) can be used in treatment of cancer to enable penetration of cytostatic 
drugs to cancer tissues (5, 39). 
In the kidney, claudins are differentially expressed along the tubular segments leading to a 
modulated anionic and solute permeability in different regions of the segments which is 
detrimental for the absorption functions of the kidney (9). Claudins 16 and 19, for instance, 
regulate Mg and Cl permeability of the kidney tubular cells and mutations in these claudins 
lead to disturbances of the permeability of these electrolytes (40). In lung diseases like 
ARDS, expression of claudin 4 is downregulated leading to increased permeability of the 
alveolar wall (41, 42). Counteracting claudin 4 downregulation could thus be one putative 
treatment for this often fatal lung disease. 
2.2 Claudins in gonadal structures 
In mRNA and array analysis indicate that claudins 1, 2, 3, 5, 7, 8, 10, 11, 12, and 23 are 
present in testicular tissue of rodents. Claudin 11 is found to be the highest (15). Such 
studies do not, however, indicate the location of claudin mRNA, and claudin 5 mRNA, for 
instance, may also partly be derived from endothelial cells. 
In human testicular tissues claudin 1, 6 and 7 protein expression has been found in 
seminiferous tubules (43). In rete testis epithelium, claudins 1 and 7 are strongly expressed 
while claudin 4 is weak and claudins 3, 5 and 6 are negative (43). Claudin 11 is present in 
Sertoli cells and takes part in formation of the blood testis barrier (44). In normal 
seminiferous epithelium claudin 11 is located at the basal compartment and the distribution 
is similar to ZO1 and ZO2 in this location (45). Claudin 1, 3 and 11 expression in Sertoli cells 
of mouse and rat testis appears to be regulated by androgens (46, 47, 48). Also 
gonadotropins regulate the expression of tight junctional proteins such as claudin 11 and 
occludin (49). 
Expression of claudins and other tight junction proteins have not been studied in ovaries to 
such an extent as in the testis. Trace amounts of claudin 1, 2 , 4, 5, 7, 10, 11, 12 have been 
detected in normal ovarian tissues (17). Ovarian surface epithelial cells express claudin 1, 
ZO1 and occludin (50). Ovarian HOSE (human ovarian surface epithelial) cells do not 
express claudins 3 or 4 (51). On the other hand, in array based analysis, ovarian serous 
 
Germ Cell Tumor 
 
140 
cancer cells displayed a strong mRNA expression of claudins 3, 4 and 7 compared  
to non-neoplastic cells (52).Claudin 3 and 4 expression appears to be nonexistent in surface 
ovarian cells but is increased in ovarian cysts (53).  
3. Germ cell tumors 
Germ cell tumors represent a tumor group derived from primordial germ cells of the body 
(54). They develop in testicular and ovarial tissues but are also found at extragonadal sites 
such as the mediastinum, and hypothalamic or suprasellar regions. Up to 95 % of testicular 
tumors are of germ cell derivation while in ovaries they make up only of 3-5 % of the tumor 
cases (55). Germ cell tumors of the testis develop from intratubular germ cell neoplasia 
(ITGCN) (except for spermatocytic seminoma and infantile germ cell tumors) and their 
development is linked to maturation arrest.The corresponding ovarian counterpart for 
ITGCN is gonadoblastoma (56). 
Germ cell tumors can be divided in pure and mixed form (54). Pure germ cell tumors are 
composed of only one tumor component while mixed tumors consist of two or more (54). 
Testicular mixed germ cell tumors represent 30 to 50 % of the tumors while in the ovaries 
they represent about 20 %. The commonest pure germ cell tumor is 
seminoma/dysgerminoma representing 50 % and 40 % of testicular and ovarian germ cell 
tumors, respectively. Embryonal carcinoma is composed of undifferentiated cells with an 
epithelial appearance and it is more common in testis than in ovaries (54,57). Yolk sac 
tumor, on the other hand, is relatively more common in the ovaries (57). There are many 
histologic patterns, such as microcystic, papillary, macrocystic, hepatoid, solid and 
glandular-alveolar patterns, often mixed with each other (54). The tumor recapitulates the 
structures of yolk sac, the allantoin membrane and extraembryonic mesenchyme (54). It 
contains hyaline globules and Schiller-Duval bodies (57). Choriocarcinoma is rare both in 
ovaries and testis (54). It is composed of neoplastic cytotrophoblastic and 
syncytiotrophoblastic cells intermixed with hemorrhagic and necrotic background (54). 
Examples of benign germ cell tumors are teratomas which display a mixture of mature 
endodermal, mesodermal or ectodermal components (54). In some teratomas one 
component may predominate. Such is the case in dermoid cysts which contain a 
predominant component of cutaneous tissue leading to a cystic tumor containing keratin 
and hair structures (58). In immature teratomas or teratomas with somite type malignancies 
one or more components of the cell layers is malignant (54). 
Immunohistochemical markers useful in the diagnosis of germ cell tumors include AFP and 
HCG which are positive in yolk sac tumor and choriocarcinoma, respectively (54,59). PLAP 
is invariably present in both but also in seminoma and embryonal carcinoma (54,59). They 
both express OCT3/4 which is not present in yolk sac tumor or choriocarcinoma (54,59). 
Embryonal carcinoma expresses SOX2 and CD30 which are not present in seminoma which, 
on the other hand, expresses SOX 17 (54,59). 
4. Claudins in germ cell tumors 
Germ cell tumors are neoplasms which are derived and may express several cell types of the 
ectoderm, endoderm or mesoderm. There are also many times a mixture of different cell 
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components in these tumors (54). Of benign germ cell tumors a good example is teratoma 
which contains full developed components of epithelial, mesodermal and/or neural 
elements (54,58). Claudin expression in these tumors is analogous to the expression found in 
tissues of the comparable non-neoplastic tissues in human body (43). Thus expression of 
claudins 1, 2, 3, 4, 5 and 7 is usually amply found but expression is different in squamous or 
glandular epithelia (43). Squamous epithelium expresses strongly claudin 1 and 4 but 
claudin 3 is weakly or negatively expressed (43). On the other hand, glandular epithelia 
express claudin 3 strongly in teratomas (43). Claudin 7 is strongly expressed in both of these 
epithelia, but claudin 5 and 6 are negative (43). The different expression of claudins 3 and 4 
is also reflected in malignant tumors derived from squamous or glandular epithelia. 
Adenocarcinomas of the oesophagus show a significantly higher expression of claudin 3 
than squamous cell carcinomas (60). A similar situation is found for between lung squamous 
cell and adenocarcinomas (61). Mesenchymal tissues are generally negative for claudins 
with the exception of claudin 5 which is expressed in endothelial cells (2). Blood vessels may 
also show expression of some other claudins, like claudins 2 and 3 (2). Tissues found in 
teratomas are, however, many and strong conclusions cannot be drawn based on materials 
consisting only of some cases. 
Teratocarcinomas express variable levels of claudins 1, 2, 3, 4 and 7 in carcinomatous 
elements but some cases display also positivity for claudins 5 and 6 (43). Claudin 5 which is 
mainly an endothelial marker and partly responsible for the function of blood brain or blood 
testis barrier (15, 62) is overexpressed in several carcinomas, like ovarian or lung carcinomas 
(61, 63, 64). The expression appears to be present in poorly differentiated tumors in serous 
ovarian carcinomas and is associated with a worse survival (64). Such expression may reflect 
a more primitive nature of the epithelial tumor cells but may also be an expression of 
vascular mimicry in tumors reflecting the capacity of neoplastic epithelial cells to attain 
endothelial features, a phenomenon described in melanomas, sarcomas and carcinomas 
(65,66). Whether expression of claudin 5 in teratocarcinomas influences behavior of these 
tumors is, however, unknown. 
In tumor biology, derivation of malignant tumors has been suggested, on one hand, to 
clonal evolution of malignant cells, on the other hand, tumors have been suggested to 
develop through stem cells (67, 68). In clonal evolution there is a constant development of 
varied population of malignant cells and the most apt ones having the best survival 
capabilities to survive and make up the bulk of the tumors and develop metastases (67,68). 
According to the stem cell theory, tumors contain a population of stem cells which are 
present in specific locations (niche) in tumors (68). These cells which produce cancer tissue 
through dysregulation of asymmetric division are the basic invasive and metastasizing 
elements of the tumor and the rest are a more differentiated bulk which have not a 
significant impact on the spread and survival of the cells (68). Primitive pluripotent stem 
cells do not usually express antigens. Organ specific stem cells already committed to a 
specific differentiation can, however, be characterized by specific antigens (69). Such 
antigens present in breast carcinomas are CD44 and CD25, for instance (69). Of claudins, 
claudin 6 has been suggested to be an early epithelial stem cell marker (70). In line with this 
claudin 6 was present in a proportion of epithelial elements of teratocarcinomas, and in 
embryonal carcinomas but also in yolk sac or choriocarcinomatous elements suggesting that 
such claudin 6 positive stem cell may also differentiate towards extraembryonic cells (43).  
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Generally, however, claudins are parts of an element which is a sign of differentiation in 
epithelia, and their presence on the cell membrane of epithelia speaks for the presence of 
functioning tight junctions (1,2). Thus, a feature expected for a stem cells could be a lack of 
claudin expression. Indeed, in breast carcinoma, a claudin low population of breast 
carcinomas, having a low expression of claudins 3, 4 and 7 has been characterized to 
represent a tumor with similar features to the triple negative breast tumors and having a 
significant overlap with them (71). Even though there is a diminished expression of claudin 
3 and 4 in embryonal carcinoma and claudin 3 in teratocarcinoma, both tumors express 
strongly claudin 7 and generally express claudins 1-7. The concept of stem cells cannot thus 
be addressed through diminished or absent claudin expression in germ cell tumors.  
Embryonal carcinomas are primitive tumors committed to the epithelial lineage. In line with 
this they express claudins 1-7 (43). There is only one study which has investigated claudin 
expression in these tumors, but work has also been carried out in embryonal carcinoma cell 
lines. In the studies of Sawada et al, the F9 embryonal carcinoma cell line expressed the 
studied claudins 6 and 7 and this expression was induced by hepatocyte nuclear factor 
alpha (72). It also induced the formation of tight junctions and a polarised morphology of 
these cells and retarded cellular proliferation by upregulation p21 (72). Differentiation of 
embryonal cells to embryoid bodies increase the mRNA of several claudins, such as claudins 
2, 6 and 7 and also occludin (73). 
Seminomas are primitive germ cell tumors which have a specific morphology consisting of 
nests of large round cells which are usually surrounded by an inflammatory infiltrate 
consisting of small lymphocytes (54). Seminomas express strongly claudin 7 but some cases 
express also claudin 5 (43). The specific expression of these claudins in seminomas with lack 
of claudins 3, 4 and 1 clearly distinguishes these tumors from other germ cell tumors (43). 
Seminomas also display a strong expression of twist suggesting that it might be one factor 
contributing to the lack of expression of these claudins (43). Twist expression is associated 
with a poor prognosis in some tumors, such as breast carcinoma, but generally the 
expression of twist is low in carcinomas (74). It, however, is supposed to contribute to 
epitheliomesenchymal transition (EMT) in organ specific tumors which is also in line with 
the association with this function (74). A high expression of twist in seminomas probably 
signifies an inherent character of these tumor cells to express this transcription factor and it 
probably has another function in such a non-epithelial neoplasm. There are, however, no 
clinical studies assessing the prognostic value of twist or claudins in seminoma or other 
germ cell tumors. 
Choriocarcinomas are aggressive tumors differentiating towards trophoblastic cells (54). 
Areas of choriocarcinoma are many times present in mixed germ cell tumors and pure 
choriocarcinomas are rare (54). They consist of large, neoplastic trophoblastic cells with 
areas of strong hemorrhage (54). Choriocarcinoma cells have an especially strong expression 
of claudin 4 (43). Claudin 4 is commonly present in epithelial neoplasms and in several 
tissues and it is considered to have a sealing function on paracellular membranes (1). In lung 
diseases, for instance, claudin 4 is downregulated in acute respiratory distress syndrome 
and lung inflammations contributing to the development of lung edema (41,42). Claudin 4 
also serves as a receptor for clostridium perfringens enterotoxin, and chemically modified 
enterotoxins have been used in cancer treatment to facilitate penetration of 
chemotherapeutics to claudin 4 positive tumors (39). The significance of the strong 
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expression of claudin 4 in choriocarcinoma cells is obscure but suggests that its expression 
may be important for the function of trophoblastic cells.  
Intratubular germ cell neoplasia is the precursor lesion of germ cell neoplasms of the testis 
(54). In studies on claudin 11 expression in these lesions, claudin 11 expression was 
increased but the increased did not take place in the neoplastic germ cells but in Sertoli cells 
where claudin 11 was displaced from the membrane (45). The relative protein expression of 
claudins 1-7 in testicular germ cell neoplasia and testicular tissue is presented in Table 2 (43). 
 
Germ cell tumor 
component claudin 1 claudin 3 claudin 4 claudin 5 claudin 6 claudin 7  
seminoma - - - ++ - ++  
embryonal carcinoma ++ + + ++ ++ +++  
teratocarcinoma +++ + +++ ++ ++ +++  
teratoma +++ ++ +++ ++ ++ +++  
chorioncarcinoma - - ++ + + +  
Testicular tissue        
seminiferous tubules + - - - + +  
Rete testis epithelium +++ - + - - +++  
-=negative; += weak, ++= moderate, +++= strong expression 
Table 2. Summary of the average protein expression of claudins 1, 3, 4, 5, 6 and 7 in germ 
cell tumors and testicular tissues 
5. Claudins in diagnosis and treatment of germ cell tumors 
Seminomas differ from other germ cell tumors by their expression of claudin 5 and 7 and 
lack of other claudins (43). Choriocarcinoma, on the other hand, expresses claudin 4 strongly 
(43). However, germ cell tumors have a specific histopathologic character and many times it 
is easy to distinguish seminoma or chorioncarcinoma from other germ cell tumors. In lymph 
node metastases, analysis of claudins might be of some help. Seminomas in lymphatic 
tissues in the mediastinum, for instance, may resemble the syncytial variant of nodular 
sclerosis Hodgkin’s disease which do not express claudins at all (2). Germ cell tumors, 
however, have already established markers and claudins may hardly will be of any 
additional help in their diagnosis (54). 
Claudins 3 and 4 have been found to function as receptors for clostridium perfringens 
enterotoxin (CPE) (39). In prostate and ovarian cancer cell lines expressing claudins 3 and 4 
clostridium perfringens enterotoxin is able to destroy such cells (75,76). Claudins 3 and 4 
are, however, expressed in many non-neoplastic cells so CPE cannot be used in treatment of 
cancer without side effects even though the cytotoxicity appears to be lower in non-
neoplastic cells (76). Chemically modified CPE has, however, been used to open up tight 
junctions in cancer treatment experiments to allow a better penetrance of chemotherapeutic 
drugs to reach cancer cells (77). Such treatments strategy might also be possible in 
intratubular germ cell neoplasia when the tumor cells are still enveloped by the blood testis 
barrier. The main claudin responsible for the tight junctional permeability in the blood testis 
barrier is claudin 11, although claudins 3 and 5 also play some role (15). Additionally, CPE 
treatment based on cytotoxicity might be theoretically possible in those cases of germ cell 
neoplasia expressing claudins 3 and 4, like chorioncarcinoma or embryonal carcinoma (43).  
 
Germ Cell Tumor 
 
142 
Generally, however, claudins are parts of an element which is a sign of differentiation in 
epithelia, and their presence on the cell membrane of epithelia speaks for the presence of 
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diseases, for instance, claudin 4 is downregulated in acute respiratory distress syndrome 
and lung inflammations contributing to the development of lung edema (41,42). Claudin 4 
also serves as a receptor for clostridium perfringens enterotoxin, and chemically modified 
enterotoxins have been used in cancer treatment to facilitate penetration of 
chemotherapeutics to claudin 4 positive tumors (39). The significance of the strong 
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5.1 Claudins in Sertoli cells 
The blood testis barrier is formed by tight junctions between adjacent Sertoli cells (15). Claudin 
11 is obligatory for the function and formation of tight junctional barrier in the testis (15). In 
claudin 11 knockout mice, Sertoli cells are detached from the seminiferous tubules and attain 
fibroblastoid features (78). In androgen receptor depleted mice the development of tight 
junctions of Sertoli cells is deranged with aberrations in the expression of several genes 
including occludin, claudin 11 and 3 (79, 80). Additionally, also claudin 5 mRNA has been 
detected in seminiferous epithelial cells and its expression is increased in mice at the time of 
blood testis barrier development (15). The expression of claudin 5 was dependent on ets 
variant gene 5 (ETV5) and germ cells (15). Interestingly, claudin 5 was not affected by ETV5 in 
vascular structures of the testis (15). The loss of claudin 5 expression in Sertoli cells resulted in 
an elevated solute permeability as detected by biotin tracer leakage (15). 
TGFbeta3 inhibits the expression of claudin 11, occludin and ZO1 by a MAP 38 kinase 
dependent mechanism in Sertoli cells (81). FSH and TNF alpha inhibits claudin 11 
expression in Sertoli cell culture (82). Testosterone increases claudin 11 mRNA expression in 
a dose dependent manner (47). The influence of antiandrogenic flutamide is complex (47). 
Fetally administered flutamide in mice resulted in prepubertal decrease of claudin 11 in 
Sertoli cells but the inhibition in adult testes was dose dependent, lower doses resulting in 
decreased expression (47). When given orally to 13 weeks’ old rats, flutamide induced a 
decrease in the mRNA expression of occludin but did not affect claudin 1 or 11 mRNA (83). 
Thus androgens and gonadotropins may theoretically influence the penetrance of the blood 
testis barrier by modifying claudin 11 expression but such treatment strategy may lead to 
intolerable side effects perhaps through breakage of self tolerance and development of 
autoimmune diseases or reactions induced by exposure of self antigens normally hidden by 
the blood testis barrier. 
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